Hemodynamic	O
correlates	O
of	O
transient	O
cognitive	O
impairment	O
after	O
transient	O
ischemic	O
attack	O
and	O
minor	O
stroke	O
:	O
A	O
transcranial	B-P
Doppler	I-P
study	I-P
.	O

Transient	O
cognitive	O
impairment	O
(	O
TCI	O
)	O
on	O
the	O
Mini	B-P
Mental	I-P
State	I-P
Evaluation	I-P
score	O
is	O
common	O
after	O
transient	O
ischemic	O
attack	O
/	O
minor	O
stroke	O
and	O
might	O
identify	O
patients	O
at	O
increased	O
risk	O
of	O
dementia	O
.	O

We	O
aimed	O
to	O
replicate	O
TCI	O
using	O
the	O
Montreal	O
Cognitive	O
Assessment	O
(	O
MoCA	O
)	O
,	O
compare	O
it	O
with	O
persistent	O
Mild	O
Cognitive	O
Impairment	O
(	O
PMCI	O
)	O
,	O
and	O
to	O
determine	O
whether	O
global	O
cerebral	O
hemodynamic	O
changes	O
could	O
explain	O
transient	O
impairment	O
.	O

Consecutive	O
patients	O
with	O
transient	O
ischemic	O
attack	O
/	O
minor	O
stroke	O
(	O
NIHSS	O
≤	O
3	O
)	O
were	O
assessed	O
with	O
the	O
MoCA	O
and	O
transcranial	B-P
Doppler	I-P
ultrasound	I-P
acutely	O
and	O
at	O
1	O
month	O
.	O

We	O
compared	O
patients	O
with	O
TCI	O
(	O
baseline	O
MoCA	O
<	O
26	O
with	O
≥	O
2	O
points	O
increase	O
at	O
1	O
month	O
)	O
,	O
PMCI	O
(	O
MoCA	O
<	O
26	O
with	O
<	O
2	O
points	O
increase	O
)	O
,	O
and	O
no	O
cognitive	O
impairment	O
(	O
NCI	O
;	O
MoCA	O
≥	O
26	O
)	O
.	O

Of	O
326	O
patients	O
,	O
46	O
(	O
14.1	O
%	O
)	O
had	O
PMCI	O
,	O
98	O
(	O
30.1	O
%	O
)	O
TCI	O
,	O
and	O
182	O
(	O
55.8	O
%	O
)	O
NCI	O
.	O

At	O
baseline	O
,	O
TCI	O
patients	O
had	O
higher	O
systolic	O
blood	O
pressure	O
(	O
150.95	O
±	O
21.52	O
vs	O
144.86	O
±	O
22.44	O
mmHg	O
,	O
p	O
=	O
0.02	O
)	O
and	O
lower	O
cerebral	O
blood	O
flow	O
velocities	O
,	O
particularly	O
end-diastolic	O
velocity	O
(	O
30.16	O
±	O
9.63	O
vs	O
35.02	O
±	O
9.01	O
cm/s	O
,	O
p	O
<	O
0.001	O
)	O
and	O
mean	O
flow	O
velocity	O
(	O
48.95	O
±	O
12.72	O
vs	O
54	O
±	O
12.46	O
cm/s	O
,	O
p	O
=	O
0.001	O
)	O
than	O
those	O
with	O
NCI	O
,	O
but	O
similar	O
clinical	O
and	O
hemodynamic	O
profiles	O
to	O
those	O
with	O
PMCI	O
.	O

Systolic	O
BP	O
fell	O
between	O
baseline	O
and	O
1	O
month	O
(	O
mean	O
reduction	O
=	O
14.01	O
±	O
21.26	O
mmHg	O
)	O
and	O
end-diastolic	O
velocity	O
and	O
mean	O
flow	O
velocity	O
increased	O
(	O
mean	O
increase	O
=	O
+	O
2.42	O
±	O
6.41	O
and	O
1.89	O
±	O
8.77	O
cm/s	O
,	O
respectively	O
)	O
,	O
but	O
these	O
changes	O
did	O
not	O
differ	O
between	O
patients	O
with	O
TCI	O
,	O
PMCI	O
,	O
and	O
NCI	O
.	O

TCI	O
is	O
detectable	O
with	O
the	O
MoCA	O
after	O
transient	O
ischemic	O
attack	O
and	O
minor	O
stroke	O
and	O
has	O
similar	O
clinical	O
and	O
hemodynamic	O
profile	O
to	O
PMCI	O
.	O

However	O
,	O
TCI	O
does	O
not	O
appear	O
to	O
be	O
due	O
to	O
exaggerated	O
acute	O
reversible	O
global	O
hemodynamic	O
changes	O
.	O

Unbiased	O
estimates	O
of	O
cerebrospinal	O
fluid	O
β-amyloid	O
1-42	O
cutoffs	O
in	O
a	O
large	O
memory	O
clinic	O
population	O
.	O

We	O
sought	O
to	O
define	O
a	O
cutoff	O
for	O
β-amyloid	O
1-42	O
in	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
,	O
a	O
key	O
marker	O
for	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
,	O
with	O
data-driven	O
Gaussian	O
mixture	O
modeling	O
in	O
a	O
memory	O
clinic	O
population	O
.	O

We	O
performed	O
a	O
combined	O
cross-sectional	O
and	O
prospective	O
cohort	O
study	O
.	O

We	O
selected	O
2462	O
subjects	O
with	O
subjective	O
cognitive	O
decline	O
,	O
mild	O
cognitive	O
impairment	O
,	O
AD	O
-type	O
dementia	O
,	O
and	O
dementia	O
other	O
than	O
AD	O
from	O
the	O
Amsterdam	O
Dementia	O
Cohort	O
.	O

We	O
defined	O
CSF	O
β-amyloid	O
1-42	O
cutoffs	O
by	O
data-driven	O
Gaussian	O
mixture	O
modeling	O
in	O
the	O
total	O
population	O
and	O
in	O
subgroups	O
based	O
on	O
clinical	B-P
diagnosis	I-P
,	O
age	O
,	O
and	O
apolipoprotein	O
E	O
(	O
APOE	O
)	O
genotype	O
.	O

We	O
investigated	O
whether	O
abnormal	O
β-amyloid	O
1-42	O
as	O
defined	O
by	O
the	O
data-driven	O
cutoff	O
could	O
better	O
predict	O
progression	O
to	O
AD	O
-type	O
dementia	O
than	O
abnormal	O
β-amyloid	O
1-42	O
defined	O
by	O
a	O
clinical	B-P
diagnosis	I-P
-based	O
cutoff	O
using	O
Cox	O
proportional	O
hazards	O
regression	O
.	O

In	O
the	O
total	O
group	O
of	O
patients	O
,	O
we	O
found	O
a	O
cutoff	O
for	O
abnormal	O
CSF	O
β-amyloid	O
1-42	O
of	O
680	O
pg/ml	O
(	O
95	O
%	O
CI	O
660-705	O
pg/ml	O
)	O
.	O

Similar	O
cutoffs	O
were	O
found	O
within	O
diagnostic	O
and	O
APOE	O
genotype	O
subgroups	O
.	O

The	O
cutoff	O
was	O
higher	O
in	O
elderly	O
subjects	O
than	O
in	O
younger	O
subjects	O
.	O

The	O
data-driven	O
cutoff	O
was	O
higher	O
than	O
our	O
clinical	B-P
diagnosis	I-P
-based	O
cutoff	O
and	O
had	O
a	O
better	O
predictive	O
accuracy	O
for	O
progression	O
to	O
AD	O
-type	O
dementia	O
in	O
nondemented	O
subjects	O
(	O
HR	O
7.6	O
versus	O
5.2	O
,	O
p	O
<	O
0.01	O
)	O
.	O

Mixture	O
modeling	O
is	O
a	O
robust	O
method	O
to	O
determine	O
cutoffs	O
for	O
CSF	O
β-amyloid	O
1-42	O
.	O

It	O
might	O
better	O
capture	O
biological	O
changes	O
that	O
are	O
related	O
to	O
AD	O
than	O
cutoffs	O
based	O
on	O
clinical	B-P
diagnosis	I-P
.	O

Dual-core	O
steered	O
non-rigid	O
registration	O
for	O
multi-modal	O
images	O
via	O
bi-directional	O
image	O
synthesis	O
.	O

In	O
prostate	O
cancer	O
radiotherapy	O
,	O
computed	B-P
tomography	I-P
(	O
CT	B-P
)	O
is	O
widely	O
used	O
for	O
dose	O
planning	O
purposes	O
.	O

However	O
,	O
because	O
CT	B-P
has	O
low	O
soft	O
tissue	O
contrast	O
,	O
it	O
makes	O
manual	O
contouring	O
difficult	O
for	O
major	O
pelvic	O
organs	O
.	O

In	O
contrast	O
,	O
magnetic	B-P
resonance	I-P
imaging	I-P
(	O
MRI	B-P
)	O
provides	O
high	O
soft	O
tissue	O
contrast	O
,	O
which	O
makes	O
it	O
ideal	O
for	O
accurate	O
manual	O
contouring	O
.	O

Therefore	O
,	O
the	O
contouring	O
accuracy	O
on	O
CT	B-P
can	O
be	O
significantly	O
improved	O
if	O
the	O
contours	O
in	O
MRI	B-P
can	O
be	O
mapped	O
to	O
CT	B-P
domain	O
by	O
registering	O
MRI	B-P
with	O
CT	B-P
of	O
the	O
same	O
subject	O
,	O
which	O
would	O
eventually	O
lead	O
to	O
high	O
treatment	O
efficacy	O
.	O

In	O
this	O
paper	O
,	O
we	O
propose	O
a	O
bi-directional	O
image	O
synthesis	O
based	O
approach	O
for	O
MRI	B-P
-to-	O
CT	B-P
pelvic	O
image	O
registration	O
.	O

First	O
,	O
we	O
use	O
patch-wise	O
random	O
forest	O
with	O
auto-context	O
model	O
to	O
learn	O
the	O
appearance	O
mapping	O
from	O
CT	B-P
to	O
MRI	B-P
domain	O
,	O
and	O
then	O
vice	O
versa	O
.	O

Consequently	O
,	O
we	O
can	O
synthesize	O
a	O
pseudo-MRI	B-P
whose	O
anatomical	O
structures	O
are	O
exactly	O
same	O
with	O
CT	B-P
but	O
with	O
MRI	B-P
-like	O
appearance	O
,	O
and	O
a	O
pseudo-CT	B-P
as	O
well	O
.	O

Then	O
,	O
our	O
MRI	B-P
-to-	O
CT	B-P
registration	O
can	O
be	O
steered	O
in	O
a	O
dual	O
manner	O
,	O
by	O
simultaneously	O
estimating	O
two	O
deformation	O
pathways	O
:	O
1	O
)	O
one	O
from	O
the	O
pseudo-CT	B-P
to	O
the	O
actual	O
CT	B-P
and	O
2	O
)	O
another	O
from	O
actual	O
MRI	B-P
to	O
the	O
pseudo-MRI	B-P
.	O

Next	O
,	O
a	O
dual-core	O
deformation	O
fusion	O
framework	O
is	O
developed	O
to	O
iteratively	O
and	O
effectively	O
combine	O
these	O
two	O
registration	O
pathways	O
by	O
using	O
complementary	O
information	O
from	O
both	O
modalities	O
.	O

Experiments	O
on	O
a	O
dataset	O
with	O
real	O
pelvic	O
CT	B-P
and	O
MRI	B-P
have	O
shown	O
improved	O
registration	O
performance	O
of	O
the	O
proposed	O
method	O
by	O
comparing	O
it	O
to	O
the	O
conventional	O
registration	O
methods	O
,	O
thus	O
indicating	O
its	O
high	O
potential	O
of	O
translation	O
to	O
the	O
routine	O
radiation	O
therapy	O
.	O

Presumptive	O
Spontaneous	O
Lysosomal	O
Storage-Like	O
Disease	O
in	O
a	O
Crl	O
:	O
CD1	O
(	O
ICR	O
)	O
Mouse	O
.	O

A	O
clinically	O
unremarkable	O
4.5-mo-old	O
female	O
Crl	O
:	O
CD1	O
(	O
ICR	O
)	O
VAF/Elite	O
mouse	O
was	O
euthanized	O
for	O
scheduled	O
sentinel	O
processing	O
.	O

Gross	B-P
necropsy	I-P
findings	O
included	O
significant	O
hepatosplenomegaly	O
and	O
visceral	O
lymphadenomegaly	O
,	O
resulting	O
in	O
a	O
preliminarygross	O
diagnosis	O
of	O
lymphoma	O
.	O

Histology	O
revealed	O
florid	O
accumulations	O
of	O
large	O
,	O
'foamy	O
'	O
macrophages	O
present	O
in	O
the	O
bone	O
marrow	O
,	O
small	O
intestines	O
,	O
and	O
viscera	O
including	O
liver	O
,	O
spleen	O
,	O
lymph	O
nodes	O
,	O
thymus	O
,	O
uterus	O
,	O
and	O
ovaries	O
.	O

The	O
cytoplasm	O
of	O
these	O
cells	O
was	O
abundant	O
,	O
stained	O
pale	O
blue	O
with	O
Wright-Giemsa	O
and	O
was	O
periodic	O
acid-Schiff	O
positive	O
.	O

Given	O
these	O
characteristic	O
gross	O
and	O
histologic	O
findings	O
,	O
a	O
spontaneous	O
lysosomal	O
storage-like	O
disease	O
was	O
diagnosed	O
in	O
this	O
mouse	O
.	O

Cholesterol	O
ester	O
storage	O
disease	O
is	O
likely	O
,	O
because	O
of	O
the	O
visceral	O
involvement	O
with	O
sparing	O
of	O
the	O
CNS	O
,	O
but	O
could	O
not	O
be	O
diagnosed	O
definitively	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
report	O
is	O
the	O
first	O
to	O
describe	O
a	O
case	O
of	O
spontaneous	O
lysosomal	O
storage	O
disease	O
in	O
an	O
outbred	O
mouse	O
of	O
the	O
CD1	O
(	O
ICR	O
)	O
background	O
.	O

A	O
Microfluidic	O
Platform	O
to	O
design	O
crosslinked	O
Hyaluronic	O
Acid	O
Nanoparticles	O
(	O
cHANPs	O
)	O
for	O
enhanced	B-P
MRI	I-P
.	O

Recent	O
advancements	O
in	O
imaging	B-P
diagnostics	I-P
have	O
focused	O
on	O
the	O
use	O
of	O
nanostructures	O
that	O
entrap	O
Magnetic	B-P
Resonance	I-P
Imaging	I-P
(	O
MRI	B-P
)	O
Contrast	O
Agents	O
(	O
CAs	O
)	O
,	O
without	O
the	O
need	O
to	O
chemically	O
modify	O
the	O
clinically	O
approved	O
compounds	O
.	O

Nevertheless	O
,	O
the	O
exploitation	O
of	O
microfluidic	O
platforms	O
for	O
their	O
controlled	O
and	O
continuous	O
production	O
is	O
still	O
missing	O
.	O

Here	O
,	O
a	O
microfluidic	O
platform	O
is	O
used	O
to	O
synthesize	O
crosslinked	O
Hyaluronic	O
Acid	O
NanoParticles	O
(	O
cHANPs	O
)	O
in	O
which	O
a	O
clinically	O
relevant	O
MRI	B-P
-	O
CAs	O
,	O
gadolinium	O
diethylenetriamine	O
penta-acetic	O
acid	O
(	O
Gd-DTPA	O
)	O
,	O
is	O
entrapped	O
.	O

This	O
microfluidic	O
process	O
facilitates	O
a	O
high	O
degree	O
of	O
control	O
over	O
particle	O
synthesis	O
,	O
enabling	O
the	O
production	O
of	O
monodisperse	O
particles	O
as	O
small	O
as	O
35	O
nm	O
.	O

Furthermore	O
,	O
the	O
interference	O
of	O
Gd-DTPA	O
during	O
polymer	O
precipitation	O
is	O
overcome	O
by	O
finely	O
tuning	O
process	O
parameters	O
and	O
leveraging	O
the	O
use	O
of	O
hydrophilic-lipophilic	O
balance	O
(	O
HLB	O
)	O
of	O
surfactants	O
and	O
pH	O
conditions	O
.	O

For	O
both	O
production	O
strategies	O
proposed	O
to	O
design	O
Gd	O
-loaded	O
cHANPs	O
,	O
a	O
boosting	O
of	O
the	O
relaxation	O
rate	O
T1	O
is	O
observed	O
since	O
a	O
T1	O
of	O
1562	O
is	O
achieved	O
with	O
a	O
10	O
μM	O
of	O
Gd	O
-loaded	O
cHANPs	O
while	O
a	O
similar	O
value	O
is	O
reached	O
with	O
100	O
μM	O
of	O
the	O
relevant	O
clinical	O
Gd-DTPA	O
in	O
solution	O
.	O

The	O
advanced	O
microfluidic	O
platform	O
to	O
synthesize	O
intravascularly	O
-	O
injectable	O
and	O
completely	O
biocompatible	O
hydrogel	O
nanoparticles	O
entrapping	O
clinically	O
approved	O
CAs	O
enables	O
the	O
implementation	O
of	O
straightforward	O
and	O
scalable	O
strategies	O
in	O
diagnostics	O
and	O
therapy	O
applications	O
.	O

Utility	O
of	O
an	O
Ultrasonic	O
Aspirator	O
in	O
Transcanal	O
Endoscopic	O
Resection	O
of	O
Temporal	O
Bone	O
Paraganglioma	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
role	O
of	O
removing	O
middle	O
ear	O
paragangliomas	O
using	O
an	O
ultrasonic	O
aspirator	O
(	O
UA	O
)	O
through	O
a	O
transcanal	O
,	O
exclusively	O
endoscopic	O
approach	O
.	O

Three	O
consecutive	O
patients	O
undergoing	O
transcanal	O
endoscopic	O
resection	O
of	O
middle	O
ear	O
paragangliomas	O
using	O
an	O
UA	O
were	O
retrospectively	O
studied	O
.	O

The	O
primary	O
outcome	O
measure	O
was	O
achieving	O
gross	O
total	O
tumor	O
resection	O
.	O

Secondary	O
outcomes	O
included	O
postoperative	O
hearing	O
and	O
early	O
convalescence	O
.	O

Two	O
glomus	O
tympanicum	O
tumors	O
and	O
one	O
small	O
glomus	O
jugulare	O
were	O
included	O
,	O
and	O
complete	O
tumor	O
resection	O
was	O
achieved	O
endoscopically	B-P
in	O
all	O
cases	O
.	O

All	O
patients	O
demonstrated	O
intact	O
tympanic	O
membranes	O
and	O
normal	O
facial	O
nerve	O
function	O
at	O
the	O
initial	O
postoperative	O
visit	O
.	O

There	O
were	O
no	O
cases	O
of	O
bone-conduction	O
pure	O
tone	O
threshold	O
increases	O
of	O
more	O
than	O
15	O
dB	O
.	O

The	O
UA	O
was	O
helpful	O
when	O
performing	O
exclusively	O
endoscopic	O
transcanal	O
resection	O
of	O
middle	O
ear	O
paraganglioma	O
given	O
its	O
simultaneous	O
suction-aspiration	O
capability	O
.	O

Multimodal	B-P
brain	I-P
imaging	I-P
with	O
magnetoencephalography	B-P
:	O
A	O
method	B-P
for	O
measuring	O
blood	O
pressure	O
and	O
cardiorespiratory	O
oscillations	O
.	O

Studies	O
with	O
magnetoencephalography	B-P
(	O
MEG	B-P
)	O
are	O
still	O
quite	O
rarely	O
combined	O
simultaneously	O
with	O
methods	B-P
that	O
can	O
provide	O
a	O
metabolic	O
dimension	O
to	O
MEG	B-P
investigation	O
s.	O
In	O
addition	O
,	O
continuous	O
blood	O
pressure	O
measurements	O
which	O
comply	O
with	O
MEG	B-P
compatibility	O
requirements	O
are	O
lacking	O
.	O

For	O
instance	O
,	O
by	O
combining	O
methods	B-P
reflecting	O
neurovascular	O
status	O
one	O
could	O
obtain	O
more	O
information	O
on	O
low	O
frequency	O
fluctuations	O
that	O
have	O
recently	O
gained	O
increasing	O
interest	O
as	O
a	O
mediator	O
of	O
functional	O
connectivity	O
within	O
brain	O
networks	O
.	O

This	O
paper	O
presents	O
a	O
multimodal	B-P
brain	I-P
imaging	I-P
setup	O
,	O
capable	O
to	O
non-invasively	O
and	O
continuously	O
measure	O
cerebral	O
hemodynamic	O
,	O
cardiorespiratory	B-P
and	O
blood	O
pressure	O
oscillations	O
simultaneously	O
with	O
MEG	B-P
.	O

In	O
the	O
setup	O
,	O
all	O
methods	B-P
apart	O
from	O
MEG	B-P
rely	O
on	O
the	O
use	O
of	O
fibre	O
optics	O
.	O

In	O
particular	O
,	O
we	O
present	O
a	O
method	B-P
for	O
measuring	O
of	O
blood	O
pressure	O
and	O
cardiorespiratory	O
oscillations	O
continuously	O
with	O
MEG	B-P
.	O

The	O
potential	O
of	O
this	O
type	O
of	O
multimodal	B-P
setup	O
for	O
brain	O
research	O
is	O
demonstrated	O
by	O
our	O
preliminary	O
studies	O
on	O
human	O
,	O
showing	O
effects	O
of	O
mild	O
hypercapnia	O
,	O
gathered	O
simultaneously	O
with	O
the	O
presented	O
modalities	O
.	O

Case	O
Report	O
of	O
Necrotizing	O
Fasciitis	O
Associated	O
with	O
Streptococcus	O
pneumoniae	O
.	O

Necrotizing	O
fasciitis	O
,	O
caused	O
by	O
Streptococcus	O
pneumoniae	O
,	O
is	O
an	O
extremely	O
rare	O
and	O
life-threatening	O
bacterial	O
soft	O
tissue	O
infection	O
.	O

We	O
report	O
a	O
case	O
of	O
early	O
necrotizing	O
fasciitis	O
associated	O
with	O
Streptococcus	O
pneumoniae	O
infection	O
in	O
a	O
26-	O
year	O
-old	O
man	O
who	O
was	O
immunocompromised	O
with	O
mixed	O
connective	O
tissue	O
disease	O
.	O

The	O
patient	O
presented	O
with	O
acute	O
,	O
painful	O
,	O
erythematous	O
,	O
and	O
edematous	O
skin	O
lesions	O
of	O
his	O
right	O
lower	O
back	O
,	O
which	O
rapidly	O
progressed	O
to	O
the	O
right	O
knee	O
.	O

The	O
patient	O
underwent	O
surgical	B-P
exploration	I-P
,	O
and	O
a	O
diagnosis	O
of	O
necrotizing	O
fasciitis	O
was	O
confirmed	O
by	O
pathological	O
evidence	O
of	O
necrosis	O
of	O
the	O
fascia	O
and	O
neutrophil	O
infiltration	O
in	O
tissue	B-P
biopsies	I-P
.	O

Cultures	O
of	O
fascial	O
tissue	B-P
biopsies	I-P
and	O
blood	O
samples	O
were	O
positive	O
for	O
Streptococcus	O
pneumoniae	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
necrotizing	O
fasciitis	O
resulting	O
from	O
Streptococcus	O
pneumoniae	O
diagnosed	O
at	O
early	O
phase	O
;	O
the	O
patient	O
recovered	O
well	O
without	O
surgical	O
debridement	O
.	O

Ergonomics	O
of	O
laparoscopic	O
graspers	O
and	O
the	O
importance	O
of	O
haptic	O
feedback	O
:	O
the	O
surgeons	O
'	O
perspective	O
.	O

Haptic	O
feedback	O
is	O
drastically	O
reduced	O
in	O
laparoscopic	O
surgery	O
compared	O
to	O
open	O
surgery	O
.	O

Introducing	O
enhanced	O
haptic	O
feedback	O
in	O
laparoscopic	O
instruments	O
might	O
well	O
improve	O
surgical	O
safety	O
and	O
efficiency	O
.	O

In	O
the	O
design	O
process	O
of	O
a	O
laparoscopic	O
grasper	O
with	O
enhanced	O
haptic	O
feedback	O
,	O
handle	O
design	O
should	O
be	O
addressed	O
to	O
strive	O
for	O
optimal	O
usability	O
and	O
comfort	O
.	O

Additionally	O
,	O
the	O
surgeons	O
'	O
perspective	O
on	O
the	O
potential	O
benefits	O
of	O
haptic	O
feedback	O
should	O
be	O
assessed	O
to	O
ascertain	O
the	O
clinical	O
interest	O
of	O
enhanced	O
haptic	O
feedback	O
.	O

A	O
questionnaire	O
was	O
designed	O
to	O
determine	O
surgeons	O
'	O
use	O
and	O
preferences	O
for	O
laparoscopic	O
instruments	O
and	O
expectations	O
about	O
enhanced	O
haptic	O
feedback	O
.	O

Surgeons	O
were	O
also	O
asked	O
whether	O
they	O
experience	O
physical	O
complaints	O
related	O
to	O
laparoscopic	O
instruments	O
.	O

The	O
questionnaire	O
was	O
distributed	O
to	O
a	O
group	O
of	O
laparoscopic	O
surgeons	O
based	O
in	O
Europe	O
.	O

From	O
the	O
279	O
contacted	O
subjects	O
,	O
98	O
completed	O
the	O
questionnaire	O
(	O
response	O
rate	O
35	O
%	O
)	O
.	O

Of	O
all	O
respondents	O
,	O
77	O
%	O
reported	O
physical	O
complaints	O
directly	O
attributable	O
to	O
the	O
use	O
of	O
laparoscopic	O
instruments	O
.	O

No	O
evident	O
similarity	O
in	O
the	O
main	O
preference	O
for	O
graspers	O
was	O
found	O
,	O
either	O
with	O
or	O
without	O
haptic	O
feedback	O
.	O

According	O
to	O
respondents	O
,	O
the	O
added	O
value	O
of	O
haptic	O
feedback	O
could	O
be	O
of	O
particular	O
use	O
in	O
feeling	O
differences	O
in	O
tissue	O
consistencies	O
,	O
feeling	O
the	O
applied	O
pressure	O
,	O
locating	O
a	O
tumor	O
or	O
enlarged	O
lymph	O
node	O
,	O
feeling	O
arterial	O
pulse	O
,	O
and	O
limiting	O
strain	O
in	O
the	O
surgeon	O
's	O
hand	O
.	O

This	O
study	O
stresses	O
that	O
the	O
high	O
prevalence	O
of	O
physical	O
complaints	O
directly	O
related	O
to	O
laparoscopic	O
instruments	O
among	O
laparoscopic	O
surgeons	O
is	O
still	O
relevant	O
.	O

Furthermore	O
,	O
the	O
potential	O
benefits	O
of	O
enhanced	O
haptic	O
feedback	O
in	O
laparoscopic	O
surgery	O
are	O
recognized	O
by	O
laparoscopic	O
specialists	O
.	O

Therefore	O
,	O
haptic	O
feedback	O
is	O
considered	O
an	O
unmet	O
need	O
in	O
laparoscopy	B-P
.	O

Biochemical	O
and	O
proteomic	O
analyses	O
of	O
the	O
physiological	O
response	O
induced	O
by	O
individual	O
housing	O
in	O
gilts	O
provide	O
new	O
potential	O
stress	O
markers	O
.	O

The	O
objective	O
assessment	O
of	O
animal	O
stress	O
and	O
welfare	O
requires	O
proper	O
laboratory	O
biomarkers	O
.	O

In	O
this	O
work	O
,	O
we	O
have	O
analyzed	O
the	O
changes	O
in	O
serum	O
composition	O
in	O
gilts	O
after	O
switching	O
their	O
housing	O
,	O
from	O
pen	O
to	O
individual	O
stalls	O
,	O
which	O
is	O
generally	O
accepted	O
to	O
cause	O
animal	O
discomfort	O
.	O

Blood	O
and	O
saliva	O
samples	O
were	O
collected	O
a	O
day	O
before	O
and	O
up	O
to	O
four	O
days	O
after	O
changing	O
the	O
housing	O
system	O
.	O

Biochemical	O
analyses	O
showed	O
adaptive	O
changes	O
in	O
lipid	O
and	O
protein	O
metabolism	O
after	O
the	O
housing	O
switch	O
,	O
whereas	O
cortisol	O
and	O
muscular	O
markers	O
showed	O
a	O
large	O
variability	O
between	O
animals	O
.	O

2D-DIGE	O
and	O
iTRAQ	O
proteomic	O
approaches	O
revealed	O
variations	O
in	O
serum	O
protein	O
composition	O
after	O
changing	O
housing	O
and	O
diet	O
of	O
gilts	O
.	O

Both	O
techniques	O
showed	O
alterations	O
in	O
two	O
main	O
homeostatic	O
mechanisms	O
:	O
the	O
innate	O
immune	O
and	O
redox	O
systems	O
.	O

The	O
acute	O
phase	O
proteins	O
haptoglobin	O
,	O
apolipoprotein	O
A-I	O
and	O
α1-antichymotrypsin	O
3	O
,	O
and	O
the	O
antioxidant	O
enzyme	O
peroxiredoxin	O
2	O
were	O
found	O
differentially	O
expressed	O
by	O
2D-DIGE	O
.	O

Other	O
proteins	O
related	O
to	O
the	O
innate	O
immune	O
system	O
,	O
including	O
lactotransferrin	O
,	O
protegrin	O
3	O
and	O
galectin	O
1	O
were	O
also	O
identified	O
by	O
iTRAQ	O
,	O
as	O
well	O
as	O
oxidative	O
stress	O
enzymes	O
such	O
as	O
peroxiredoxin	O
2	O
and	O
glutathione	O
peroxidase	O
3	O
.	O

Proteomics	O
also	O
revealed	O
the	O
decrease	O
of	O
apolipoproteins	O
,	O
and	O
the	O
presence	O
of	O
intracellular	O
proteins	O
in	O
serum	O
,	O
which	O
may	O
indicate	O
physical	O
injury	O
to	O
tissues	O
.	O

Housing	O
of	O
gilts	O
in	O
individual	O
stalls	O
and	O
diet	O
change	O
increase	O
lipid	O
and	O
protein	O
catabolism	O
,	O
oxidative	O
stress	O
,	O
activate	O
the	O
innate	O
immune	O
system	O
and	O
cause	O
a	O
certain	O
degree	O
of	O
tissue	O
damage	O
.	O

We	O
propose	O
that	O
valuable	O
assays	O
for	O
stress	B-P
assessment	I-P
in	O
gilts	O
may	O
be	O
based	O
on	O
a	O
score	O
composed	O
by	O
a	O
combination	O
of	O
salivary	O
cortisol	O
,	O
lipid	O
metabolites	O
,	O
innate	O
immunity	O
and	O
oxidative	O
stress	O
markers	O
and	O
intracellular	O
proteins	O
.	O

What	O
Is	O
the	O
Real	O
Impact	O
of	O
Urinary	O
Incontinence	O
on	O
Female	O
Sexual	O
Dysfunction	O
?	O

A	O
Case	O
Control	O
Study	O
.	O

Urinary	O
incontinence	O
(	O
UI	O
)	O
has	O
been	O
associated	O
with	O
negative	O
effects	O
on	O
women	O
's	O
sexuality	O
.	O

Women	O
's	O
sexuality	O
and	O
sexual	O
function	O
are	O
a	O
complex	O
issue	O
,	O
and	O
the	O
role	O
of	O
UI	O
is	O
not	O
completely	O
clear	O
.	O

To	O
assess	O
the	O
impact	O
of	O
UI	O
on	O
female	O
sexual	O
function	O
by	O
comparing	O
this	O
population	O
with	O
a	O
control	O
group	O
of	O
continent	O
women	O
.	O

We	O
performed	O
a	O
case-control	O
study	O
from	O
August	O
2012	O
to	O
September	O
2013	O
.	O

We	O
evaluated	O
continent	O
and	O
incontinent	O
women	O
(	O
age	O
range	O
=	O
30-70	O
years	O
)	O
for	O
their	O
sexuality	O
.	O

All	O
patients	O
were	O
evaluated	O
by	O
anamnesis	O
,	O
physical	O
examination	O
,	O
and	O
self-report	O
quality-of-life	O
questionnaires	O
.	O

In	O
addition	O
,	O
incontinent	O
women	O
underwent	O
a	O
1-hour	O
pad	B-P
test	I-P
.	O

Patients	O
without	O
sexual	O
activity	O
were	O
evaluated	O
for	O
the	O
role	O
of	O
UI	O
in	O
their	O
sexual	O
abstinence	O
.	O

Sexual	O
abstinence	O
was	O
defined	O
as	O
the	O
absence	O
of	O
sexual	O
activity	O
for	O
more	O
than	O
6	O
months	O
.	O

All	O
sexually	O
active	O
women	O
completed	O
the	O
self-report	O
Sexuality	O
Quotient	O
-	O
Female	O
Version	O
(	O
SQ-F	O
)	O
questionnaire	O
.	O

A	O
total	O
of	O
356	O
women	O
were	O
included	O
in	O
the	O
study	O
(	O
incontinent	O
,	O
n	O
=	O
243	O
;	O
continent	O
,	O
n	O
=	O
113	O
)	O
.	O

Sexual	O
abstinence	O
was	O
found	O
in	O
162	O
women	O
(	O
45	O
%	O
)	O
.	O

Incontinent	O
women	O
presented	O
a	O
higher	O
prevalence	O
(	O
P	O
<	O
.001	O
)	O
of	O
sexual	O
abstinence	O
than	O
their	O
counterparts	O
(	O
129	O
[	O
53	O
%	O
]	O
and	O
33	O
[	O
29.2	O
%	O
]	O
,	O
respectively	O
)	O
.	O

Age	O
,	O
marital	O
status	O
,	O
and	O
UI	O
were	O
found	O
to	O
be	O
isolated	O
predictive	O
factors	O
for	O
more	O
sexual	O
abstinence	O
in	O
incontinent	O
women	O
.	O

Sexually	O
active	O
women	O
(	O
incontinent	O
,	O
n	O
=	O
114	O
;	O
continent	O
,	O
n	O
=	O
80	O
)	O
presented	O
similar	O
demographic	O
data	O
.	O

Despite	O
a	O
similar	O
frequency	O
of	O
sexual	O
activity	O
,	O
incontinent	O
women	O
had	O
less	O
sexual	O
desire	O
,	O
foreplay	O
,	O
harmony	O
with	O
a	O
partner	O
,	O
sexual	O
comfort	O
,	O
and	O
sexual	O
satisfaction	O
than	O
their	O
counterparts	O
.	O

Women	O
with	O
greater	O
urinary	O
leakage	O
during	O
the	O
1-hour	O
pad	B-P
test	I-P
(	O
weight	O
>	O
11	O
g	O
)	O
had	O
the	O
worst	O
sexual	O
function	O
(	O
SQ-F	O
)	O
score	O
.	O

Women	O
with	O
UI	O
were	O
more	O
likely	O
to	O
be	O
sexual	O
abstinent	O
than	O
continent	O
women	O
.	O

Furthermore	O
,	O
women	O
with	O
UI	O
showed	O
less	O
sexual	O
desire	O
,	O
sexual	O
comfort	O
,	O
and	O
sexual	O
satisfaction	O
than	O
their	O
counterparts	O
despite	O
having	O
a	O
similar	O
frequency	O
of	O
sexual	O
activity	O
.	O

A	O
Biomechanical	O
Modeling	O
Guided	O
CBCT	B-P
Estimation	O
Technique	O
.	O

Two-dimensional	O
-to-	O
three-dimensional	O
(	O
2D	O
-	O
3D	O
)	O
deformation	O
has	O
emerged	O
as	O
a	O
new	O
technique	O
to	O
estimate	O
cone-beam	B-P
computed	I-P
tomography	I-P
(	O
CBCT	B-P
)	O
images	O
.	O

The	O
technique	B-P
is	O
based	O
on	O
deforming	O
a	O
prior	O
high-quality	O
3D	O
CT	B-P
/	O
CBCT	B-P
image	O
to	O
form	O
a	O
new	O
CBCT	B-P
image	O
,	O
guided	O
by	O
limited-view	O
2D	O
projections	O
.	O

The	O
accuracy	O
of	O
this	O
intensity-based	O
technique	B-P
,	O
however	O
,	O
is	O
often	O
limited	O
in	O
low-contrast	O
image	O
regions	O
with	O
subtle	O
intensity	O
differences	O
.	O

The	O
solved	O
deformation	O
vector	O
fields	O
(	O
DVFs	O
)	O
can	O
also	O
be	O
biomechanical	O
ly	O
unrealistic	O
.	O

To	O
address	O
these	O
problems	O
,	O
we	O
have	O
developed	O
a	O
biomechanical	O
modeling	O
guided	O
CBCT	B-P
estimation	O
technique	O
(	O
Bio-CBCT-est	O
)	O
by	O
combining	O
2D	O
-	O
3D	O
deformation	O
with	O
finite	O
element	O
analysis	O
(	O
FEA	O
)	O
-based	O
biomechanical	O
modeling	O
of	O
anatomical	O
structures	O
.	O

Specifically	O
,	O
Bio-CBCT-est	O
first	O
extracts	O
the	O
2D	O
-	O
3D	O
deformation	O
-generated	O
displacement	O
vectors	O
at	O
the	O
high-contrast	O
anatomical	O
structure	O
boundaries	O
.	O

The	O
extracted	O
surface	O
deformation	O
fields	O
are	O
subsequently	O
used	O
as	O
the	O
boundary	O
conditions	O
to	O
drive	O
structure	O
-based	O
FEA	O
to	O
correct	O
and	O
fine-tune	O
the	O
overall	O
deformation	O
fields	O
,	O
especially	O
those	O
at	O
low-contrast	O
regions	O
within	O
the	O
structure	O
.	O

The	O
resulting	O
FEA	O
-corrected	O
deformation	O
fields	O
are	O
then	O
fed	O
back	O
into	O
2D	O
-	O
3D	O
deformation	O
to	O
form	O
an	O
iterative	O
loop	O
,	O
combining	O
the	O
benefits	O
of	O
intensity-based	O
deformation	O
and	O
biomechanical	O
modeling	O
for	O
CBCT	B-P
estimation	O
.	O

Using	O
eleven	O
lung	O
cancer	O
patient	O
cases	O
,	O
the	O
accuracy	O
of	O
the	O
Bio-CBCT-est	O
technique	B-P
has	O
been	O
compared	O
to	O
that	O
of	O
the	O
2D	O
-	O
3D	O
deformation	O
technique	O
and	O
the	O
traditional	O
CBCT	B-P
reconstruction	O
techniques	O
.	O

The	O
accuracy	O
was	O
evaluated	O
in	O
the	O
image	O
domain	O
,	O
and	O
also	O
in	O
the	O
DVF	O
domain	O
through	O
clinician	O
-tracked	O
lung	O
landmarks	O
.	O

Evolution	O
of	O
Cardiac	O
Biomodels	O
from	O
Computational	O
to	O
Therapeutics	O
.	O

Biomodeling	O
the	O
human	O
anatomy	O
in	O
exact	O
structure	O
and	O
size	O
is	O
an	O
exciting	O
field	O
of	O
medical	O
science	O
.	O

Utilizing	O
medical	O
data	O
from	O
various	O
medical	B-P
imaging	I-P
topography	I-P
,	O
the	O
data	O
of	O
an	O
anatomical	O
structure	O
can	O
be	O
extracted	O
and	O
converted	O
into	O
a	O
three-dimensional	O
virtual	O
biomodel	O
;	O
thereafter	O
a	O
physical	O
biomodel	O
can	O
be	O
generated	O
utilizing	O
rapid	O
prototyping	O
machines	O
.	O

Here	O
,	O
we	O
have	O
reviewed	O
the	O
utilization	O
of	O
this	O
technology	O
and	O
have	O
provided	O
some	O
guidelines	O
to	O
develop	O
biomodels	O
of	O
cardiac	O
structures	O
.	O

Cardiac	O
biomodels	O
provide	O
insights	O
for	O
cardiothoracic	O
surgeons	O
,	O
cardiologists	O
,	O
and	O
patients	O
alike	O
.	O

Additionally	O
,	O
the	O
technology	O
may	O
have	O
future	O
usability	O
for	O
tissue	O
engineering	O
,	O
robotic	O
surgery	O
,	O
or	O
routine	O
hospital	O
usage	O
as	O
a	O
diagnostic	B-P
and	I-P
therapeutic	I-P
tool	I-P
for	O
cardiovascular	O
diseases	O
(	O
CVD	O
)	O
.	O

Given	O
the	O
broad	O
areas	O
of	O
application	O
of	O
cardiac	O
biomodels	O
,	O
attention	O
should	O
be	O
given	O
to	O
further	O
research	O
and	O
development	O
of	O
their	O
potential	O
.	O

Percutaneous	O
forefoot	O
surgery	O
for	O
treatment	O
of	O
hallux	O
valgus	O
deformity	O
:	O
an	O
intermediate	O
prospective	O
study	O
.	O

This	O
study	O
aims	O
to	O
illustrate	O
the	O
results	O
of	O
percutaneous	O
forefoot	O
surgery	O
(	O
PFS	O
)	O
for	O
correction	O
of	O
hallux	O
valgus	O
.	O

A	O
prospective	O
study	O
of	O
108	O
patients	O
,	O
with	O
hallux	O
valgus	O
deformity	O
,	O
who	O
underwent	O
PFS	O
was	O
conducted	O
.	O

The	O
minimum	O
clinical	O
and	O
radiological	O
follow-up	O
was	O
two	O
years	O
(	O
mean	O
57.3	O
months	O
,	O
range	O
22-112	O
)	O
.	O

Preoperative	B-P
mean	I-P
visual	I-P
analog	I-P
scale	I-P
was	O
6.3	O
±	O
1.5	O
points	O
,	O
and	O
AOFAS	O
scores	O
were	O
50.6	O
±	O
11	O
points	O
.	O

At	O
the	O
last	O
follow-up	O
,	O
both	O
scores	O
improved	O
to	O
1.9	O
±	O
2.4	O
points	O
and	O
85.9	O
±	O
1.83	O
points	O
,	O
respectively	O
.	O

Mean	O
hallux	O
valgus	O
angle	O
changed	O
from	O
34.3°	O
±	O
9.3°	O
preoperatively	O
to	O
22.5°	O
±	O
11.1°	O
at	O
follow-up	O
.	O

At	O
follow-up	O
,	O
76.5	O
%	O
of	O
the	O
subjects	O
were	O
satisfied	O
or	O
very	O
satisfied	O
.	O

Recurrence	O
of	O
medial	O
1st	O
MT	O
head	O
pain	O
happened	O
in	O
22	O
cases	O
(	O
16.7	O
%	O
)	O
.	O

PFS	O
,	O
in	O
our	O
study	O
,	O
does	O
not	O
improve	O
the	O
radiological	O
and	O
patient	O
satisfaction	O
rate	O
results	O
compared	O
with	O
conventional	O
procedures	O
.	O

The	O
main	O
advantage	O
is	O
a	O
low	O
postoperative	O
pain	O
level	O
,	O
but	O
with	O
an	O
insufficient	O
HVA	O
correction	O
.	O

II	O
,	O
prospective	O
study	O
.	O

The	O
``	O
tight	O
orbit	O
''	O
:	O
Incidence	O
and	O
management	O
of	O
the	O
orbital	O
compartment	O
syndrome	O
.	O

The	O
orbital	O
compartment	O
syndrome	O
(	O
OCS	O
)	O
constitutes	O
a	O
severe	O
emergency	O
,	O
requiring	O
immediate	O
clinical	B-P
diagnosis	I-P
and	O
surgical	O
decompression	O
.	O

The	O
key	O
symptom	O
is	O
progressive	O
visual	O
impairment	O
caused	O
by	O
an	O
increase	O
in	O
intraorbital	O
pressure	O
,	O
impairing	O
the	O
perfusion	O
of	O
relevant	O
neurovascular	O
and	O
neurosensory	O
structures	O
.	O

Intraorbital	O
bleeding	O
due	O
to	O
trauma	O
and	O
surgical	O
intervention	O
is	O
known	O
to	O
be	O
the	O
main	O
etiological	O
factor	O
.	O

A	O
retrospective	O
analysis	O
of	O
all	O
patients	O
affected	O
by	O
an	O
OCS	O
between	O
January	O
1	O
,	O
2012	O
,	O
and	O
May	O
31	O
,	O
2015	O
,	O
was	O
performed	O
.	O

Patients	O
'	O
records	O
were	O
reviewed	O
with	O
regard	O
to	O
etiology	O
,	O
initial	O
ophthalmologic	O
status	O
,	O
fracture	O
pattern	O
,	O
concomitant	O
medication	O
,	O
surgical	O
management	O
,	O
and	O
postoperative	O
outcome	O
.	O

The	O
incidence	O
of	O
OCS	O
was	O
calculated	O
based	O
on	O
the	O
total	O
number	O
of	O
craniomaxillofacial	O
(	O
CMF	O
)	O
emergencies	O
.	O

Within	O
3.5	O
years	O
,	O
a	O
total	O
of	O
18,093	O
CMF	O
emergencies	O
were	O
registered	O
.	O

In	O
16	O
patients	O
,	O
an	O
OCS	O
was	O
documented	O
,	O
corresponding	O
to	O
an	O
incidence	O
of	O
0.088	O
%	O
.	O

The	O
mean	O
patient	O
age	O
was	O
67.31	O
±	O
23.86	O
years	O
,	O
ranging	O
from	O
22	O
to	O
102	O
years	O
.	O

The	O
etiology	O
varied	O
,	O
but	O
trauma	O
with	O
subsequent	O
intraorbital	O
bleeding	O
was	O
the	O
main	O
cause	O
.	O

The	O
use	O
of	O
anticoagulative	O
medication	O
was	O
documented	O
in	O
50	O
%	O
of	O
the	O
cases	O
.	O

In	O
14	O
patients	O
,	O
immediate	O
surgical	O
orbital	O
decompression	O
was	O
performed	O
:	O
in	O
10	O
patients	O
,	O
vision	O
could	O
be	O
preserved	O
;	O
in	O
three	O
patients	O
,	O
blindness	O
resulted	O
;	O
and	O
one	O
patient	O
was	O
lost	O
to	O
follow-up	O
.	O

Two	O
patients	O
were	O
managed	O
without	O
surgery	O
.	O

With	O
regard	O
to	O
the	O
total	O
number	O
of	O
CMF	O
emergencies	O
,	O
OCS	O
is	O
a	O
rare	O
condition	O
.	O

Early	O
clinical	B-P
diagnosis	I-P
and	O
surgical	O
decompression	O
are	O
required	O
to	O
prevent	O
permanent	O
vision	O
impairment	O
.	O

Anticoagulative	O
medication	O
must	O
be	O
considered	O
as	O
a	O
predisposing	O
factor	O
for	O
an	O
orbital	O
compartment	O
syndrome	O
in	O
patients	O
affected	O
by	O
periorbital	O
trauma	O
.	O

The	O
Optical	B-P
Coherence	I-P
Tomographic	I-P
Profile	O
of	O
Leber	O
Hereditary	O
Optic	O
Neuropathy	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
describe	O
the	O
changes	O
in	O
the	O
retinal	O
ganglion	O
cell	O
complex	O
(	O
GCC	O
)	O
relative	O
to	O
the	O
retinal	O
nerve	O
fibre	O
layer	O
(	O
RNFL	O
)	O
over	O
time	O
in	O
Leber	O
hereditary	O
optic	O
neuropathy	O
(	O
LHON	O
)	O
patients	O
.	O

Average	O
RNFL	O
and	O
GCC	O
thickness	O
was	O
measured	O
in	O
seven	O
patients	O
in	O
the	O
early	O
acute	O
(	O
123	O
,	O
68.4	O
μm	O
)	O
,	O
late	O
acute	O
(	O
113.5	O
,	O
57.4	O
μm	O
)	O
,	O
and	O
chronic	O
(	O
72.7	O
,	O
50.8	O
μm	O
)	O
phases	O
.	O

Patients	O
showed	O
thinning	O
of	O
the	O
GCC	O
with	O
RNFL	O
swelling	O
in	O
the	O
early	O
acute	O
phase	O
.	O

GCC	O
thinning	O
became	O
severe	O
within	O
weeks	O
and	O
persisted	O
.	O

RNFL	O
swelling	O
normalised	O
during	O
the	O
late	O
acute	O
phase	O
with	O
eventual	O
thinning	O
in	O
the	O
chronic	O
phase	O
.	O

GCC	O
changes	O
appear	O
at	O
the	O
commencement	O
of	O
visual	O
loss	O
and	O
in	O
some	O
cases	O
prior	O
to	O
vision	O
loss	O
.	O

These	O
findings	O
define	O
an	O
optical	B-P
coherence	I-P
tomography	I-P
(	O
OCT	B-P
)	O
profile	O
in	O
LHON	O
.	O

Panitumumab	O
-Associated	O
Encephalopathy	O
after	O
Accidental	O
Intra-arterial	O
Application	O
through	O
Dislocated	O
Central	O
Venous	O
Access	O
Device	O
.	O

Acute	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
toxicity	O
and	O
immune	O
-related	O
side	O
effects	O
are	O
increasingly	O
recognized	O
with	O
the	O
use	O
of	O
monoclonal	O
antibodies	O
for	O
cancer	O
therapy	O
.	O

Here	O
,	O
we	O
report	O
a	O
patient	O
who	O
developed	O
of	O
acute-onset	O
encephalopathy	O
and	O
coma	O
,	O
which	O
began	O
shortly	O
after	O
administration	O
of	O
panitumumab	O
for	O
the	O
treatment	O
of	O
metastatic	O
colorectal	O
cancer	O
.	O

Echocardiography	B-P
revealed	O
that	O
the	O
drug	O
had	O
been	O
infused	O
into	O
the	O
left	O
cardiac	O
ventricle	O
via	O
a	O
dislocated	O
central	O
venous	O
line	O
.	O

Diffusion-weighted	B-P
magnetic	I-P
resonance	I-P
imaging	I-P
disclosed	O
multiple	O
cortical	O
hyperintensities	O
,	O
which	O
were	O
preferentially	O
located	O
in	O
the	O
frontal	O
lobes	O
.	O

While	O
the	O
neurological	O
condition	O
improved	O
within	O
a	O
few	O
days	O
,	O
the	O
patient	O
died	O
4	O
weeks	O
later	O
.	O

It	O
seems	O
likely	O
that	O
the	O
administration	O
of	O
the	O
antibody	O
via	O
the	O
intra-arterial	O
route	O
contributed	O
to	O
the	O
development	O
of	O
this	O
condition	O
.	O

Toxic	O
encephalopathy	O
may	O
be	O
a	O
hitherto	O
unrecognized	O
complication	O
of	O
panitumumab	O
treatment	O
and	O
should	O
be	O
taken	O
into	O
consideration	O
in	O
patients	O
developing	O
CNS	O
symptoms	O
undergoing	O
this	O
therapy	O
.	O

IFN-γ	O
-producing	O
Th1-like	O
regulatory	O
T	O
cells	O
may	O
limit	O
acute	O
cellular	O
renal	O
allograft	O
rejection	O
:	O
Paradoxical	O
post-transplantation	O
effects	O
of	O
IFN-γ	O
.	O

IFN-γ	O
is	O
a	O
protypical	O
proinflammatory	O
cytokine	O
that	O
plays	O
a	O
central	O
role	O
in	O
inflammation	O
and	O
acute	O
graft	O
rejection	O
.	O

Accumulating	O
evidence	O
indicates	O
that	O
IFN-γ	O
can	O
exert	O
previously	O
unexpected	O
immunoregulatory	O
activities	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
role	O
of	O
IFN-γ	O
secreted	O
by	O
Th1-like	O
regulatory	O
T	O
cells	O
in	O
human	O
kidney	O
transplantation	O
.	O

To	O
determine	O
the	O
function	O
of	O
IFN-γ	O
in	O
acute	O
T	O
cell-mediated	O
renal	O
allograft	O
rejection	O
(	O
ACR	O
)	O
,	O
we	O
examined	O
serum	O
cytokine	O
expression	O
profiles	O
in	O
ACR	O
patients	O
by	O
human	O
cytokine	O
multiplex	O
immunoassay	O
and	O
analyzed	O
the	O
cellular	O
origins	O
of	O
IFN-γ	O
in	O
peripheral	O
blood	O
and	O
renal	O
allograft	O
biopsies	B-P
from	O
ACR	O
cases	O
and	O
controls	O
by	O
flow	O
cytometry	O
and	O
immunohistochemistry	B-P
,	O
respectively	O
.	O

The	O
results	O
showed	O
significant	O
reduction	O
in	O
serum	O
concentrations	O
of	O
Th1	O
-inducing	O
cytokines	O
IL-12p70	O
and	O
IFN-γ	O
as	O
well	O
as	O
Th2	O
-related	O
cytokine	O
IL-4	O
in	O
ACR	O
patients	O
compared	O
with	O
stable	O
controls	O
.	O

However	O
,	O
levels	O
of	O
several	O
Th1	O
-	O
,	O
Th2	O
-	O
and	O
Th17	O
-related	O
cytokines	O
,	O
such	O
as	O
IL-2	O
,	O
TNF-α	O
,	O
TNF-β	O
,	O
IL-12	O
(	O
p40	O
)	O
,	O
IL-10	O
,	O
IL-15	O
,	O
IL-17	O
,	O
IL-21	O
,	O
and	O
IL-23	O
,	O
as	O
well	O
as	O
the	O
frequencies	O
of	O
Th1	O
and	O
Th17	O
cell	O
,	O
did	O
not	O
differ	O
between	O
ACR	O
cases	O
and	O
stable	O
controls	O
.	O

Moreover	O
,	O
we	O
found	O
the	O
levels	O
of	O
IFN-γ	O
were	O
correlated	O
with	O
those	O
of	O
the	O
anti-inflammatory	O
factor	O
,	O
IL-1	O
receptor	O
antagonist	O
(	O
IL-1Ra	O
)	O
in	O
ACR	O
.	O

Notably	O
,	O
the	O
Th1-like	O
Treg	O
cell	O
-to-	O
Foxp3	O
(	O
-	O
)	O
Th1	O
cell	O
ratio	O
was	O
significantly	O
lower	O
in	O
ACR	O
patients	O
compared	O
with	O
that	O
in	O
stable	O
controls	O
.	O

In	O
graft	O
biopsies	B-P
from	O
ACR	O
patients	O
,	O
Treg	O
cells	O
and	O
Th1-like	O
Treg	O
cells	O
were	O
less	O
abundant	O
than	O
those	O
without	O
ACR	O
.	O

Our	O
study	O
indicates	O
that	O
IFN-γ	O
secreted	O
from	O
Th1-like	O
Treg	O
cells	O
negatively	O
modulates	O
ACR	O
.	O

High	B-P
throughput	I-P
selection	O
of	O
antibiotic-resistant	O
transgenic	O
Arabidopsis	O
plants	O
.	O

Kanamycin	O
resistance	O
is	O
the	O
most	O
frequently	O
used	O
antibiotic-resistance	O
marker	O
for	O
Arabidopsis	O
transformations	O
,	O
however	O
,	O
this	O
method	O
frequently	O
causes	O
escape	O
of	O
untransformed	O
plants	O
,	O
particularly	O
at	O
the	O
high	O
seedling	O
density	O
during	O
the	O
selection	O
.	O

Here	O
we	O
developed	O
a	O
robust	O
high	O
-	O
density	O
selection	O
method	O
using	O
top	O
agar	O
for	O
Arabidopsis	O
thaliana	O
.	O

Top	O
agar	O
effectively	O
suppressed	O
growth	O
of	O
untransformed	O
wild-type	O
plants	O
on	O
selection	O
media	O
at	O
high	O
density	O
.	O

Survival	O
of	O
the	O
transformed	O
plants	O
during	O
the	O
selection	O
were	O
confirmed	O
by	O
production	O
of	O
green	O
true	O
leaves	O
and	O
expression	O
of	O
a	O
firefly	O
luciferase	O
reporter	O
gene	O
.	O

Top	O
agar	O
method	O
allowed	O
selection	O
using	O
a	O
large	O
amount	O
of	O
seeds	O
in	O
Arabidopsis	O
transformation	O
.	O

Clinical	O
heterogeneity	O
of	O
LRRK2	O
p.I2012T	O
mutation	O
.	O

Leucine-rich	O
repeat	O
kinase	O
2	O
(	O
LRRK2	O
)	O
mutations	O
are	O
the	O
most	O
common	O
genetic	O
cause	O
of	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
.	O

However	O
,	O
only	O
few	O
cases	O
carrying	O
LRRK2	O
mutations	O
have	O
been	O
reported	O
in	O
Taiwanese	O
PD	O
patients	O
.	O

We	O
used	O
targeted	O
next	O
generation	O
sequencing	O
(	O
NGS	O
)	O
,	O
covering	O
24	O
candidate	O
genes	O
involved	O
in	O
neurodegenerative	O
disorders	O
,	O
to	O
analyze	O
40	O
probands	O
with	O
familial	O
PD	O
,	O
and	O
10	O
patients	O
with	O
mixed	O
neurodegenerative	O
disorders	O
.	O

Sanger	O
sequencing	O
of	O
the	O
identified	O
mutation	O
in	O
the	O
first	O
set	O
of	O
the	O
study	O
was	O
performed	O
in	O
additional	O
270	O
PD	O
patients	O
,	O
including	O
139	O
familial	O
PD	O
and	O
131	O
early-onset	O
PD	O
(	O
onset	O
age	O
less	O
than	O
50	O
years	O
old	O
)	O
,	O
and	O
300	O
age/gender	O
matched	O
control	O
subjects	O
.	O

We	O
found	O
a	O
missense	O
variant	O
,	O
p.I2012T	O
,	O
in	O
the	O
LRRK2	O
gene	O
in	O
one	O
sporadic	O
patient	O
having	O
early-onset	O
frontotemporal	O
dementia	O
with	O
parkinsonism	O
and	O
dystonia	O
.	O

Sanger	O
sequencing	O
this	O
substitution	O
in	O
additional	O
270	O
PD	O
patients	O
in	O
the	O
second	O
set	O
of	O
the	O
study	O
revealed	O
two	O
additional	O
variant	O
carriers	O
:	O
one	O
having	O
autosomal-dominant	O
familial	O
PD	O
,	O
and	O
one	O
with	O
sporadic	O
PD	O
.	O

The	O
p.I2012T	O
substitution	O
was	O
absent	O
in	O
300	O
normal	O
control	O
subjects	O
.	O

Analyzing	O
family	O
members	O
of	O
the	O
proband	O
with	O
p.I2012T	O
revealed	O
co-segregation	O
of	O
the	O
variant	O
and	O
parkinsonism	O
.	O

Clinical	O
presentations	O
,	O
levodopa	O
responses	O
,	O
and	O
(	O
Tc99m	O
)	O
TRODAT	O
-	O
SPECT	O
imaging	O
findings	O
of	O
this	O
index	O
family	O
were	O
similar	O
to	O
idiopathic	O
PD	O
.	O

Our	O
results	O
revealed	O
clinical	O
heterogeneity	O
of	O
the	O
LRRK2	O
p.I2012T	O
substitution	O
,	O
and	O
demonstrated	O
the	O
use	O
of	O
targeted	O
NGS	O
for	O
genetic	B-P
diagnosis	I-P
in	O
multiplex	O
families	O
with	O
PD	O
or	O
mixed	O
neurodegenerative	O
disorders	O
.	O

Does	O
orthodontic	O
debonding	O
lead	O
to	O
tooth	O
sensitivity	O
?	O

Comparison	O
of	O
teeth	O
with	O
and	O
without	O
visible	O
enamel	O
microcracks	O
.	O

Our	O
aim	O
was	O
to	O
assess	O
the	O
possible	O
changes	O
in	O
sensitivity	O
of	O
teeth	O
with	O
and	O
without	O
visible	O
enamel	O
microcracks	O
(	O
EMCs	O
)	O
up	O
to	O
1	O
week	O
after	O
the	O
removal	O
of	O
metal	O
brackets	O
.	O

After	O
debonding	O
,	O
15	O
patients	O
possessing	O
teeth	O
with	O
visible	O
EMCs	O
and	O
15	O
subjects	O
whose	O
teeth	O
were	O
free	O
of	O
EMCs	O
were	O
enrolled	O
in	O
the	O
study	O
.	O

For	O
each	O
experimental	O
group	O
,	O
a	O
control	O
group	O
was	O
formed	O
.	O

The	O
assessments	O
of	O
tooth	O
sensitivity	O
elicited	O
by	O
compressed	O
air	O
and	O
cold	O
testing	O
were	O
performed	O
5	O
times	O
:	O
just	O
before	O
debonding	O
,	O
immediately	O
after	O
debonding	O
,	O
and	O
at	O
1	O
,	O
3	O
,	O
and	O
7	O
days	O
after	O
debonding	O
.	O

Tooth	O
sensitivity	O
was	O
recorded	O
on	O
a	O
100-mm	O
visual	B-P
analog	I-P
scale	I-P
.	O

For	O
the	O
patients	O
without	O
visible	O
EMCs	O
,	O
discomfort	O
peaked	O
immediately	O
after	O
debonding	O
and	O
started	O
to	O
decrease	O
on	O
day	O
1	O
;	O
at	O
1	O
week	O
after	O
debonding	O
,	O
the	O
visual	B-P
analog	I-P
scale	I-P
scores	O
were	O
lower	O
than	O
just	O
before	O
debonding	O
and	O
immediately	O
after	O
debonding	O
.	O

For	O
the	O
subjects	O
possessing	O
teeth	O
with	O
visible	O
EMCs	O
,	O
the	O
pattern	O
of	O
sensitivity	O
dynamic	O
was	O
inherently	O
the	O
same	O
.	O

However	O
,	O
the	O
patients	O
with	O
visible	O
EMCs	O
showed	O
higher	O
visual	B-P
analog	I-P
scale	I-P
values	O
at	O
each	O
time	O
interval	O
.	O

Debonding	O
leads	O
to	O
a	O
short-term	O
increase	O
in	O
tooth	O
sensitivity	O
.	O

EMCs	O
,	O
a	O
form	O
of	O
enamel	O
damage	O
,	O
do	O
not	O
predispose	O
to	O
greater	O
sensitivity	O
perception	O
in	O
relation	O
to	O
bracket	O
removal	O
.	O

Effects	O
of	O
high-intensity	O
training	O
on	O
cardiovascular	O
risk	O
factors	O
in	O
premenopausal	O
and	O
postmenopausal	O
women	O
.	O

Menopause	O
is	O
associated	O
with	O
increased	O
risk	O
of	O
cardiovascular	O
disease	O
and	O
the	O
causal	O
factors	O
have	O
been	O
proposed	O
to	O
be	O
the	O
loss	O
of	O
estrogen	O
and	O
the	O
subsequent	O
alterations	O
of	O
the	O
hormonal	O
milieu	O
.	O

However	O
,	O
which	O
factors	O
contribute	O
to	O
the	O
deterioration	O
of	O
cardiometabolic	O
health	O
in	O
postmenopausal	O
women	O
is	O
debated	O
as	O
the	O
menopausal	O
transition	O
is	O
also	O
associated	O
with	O
increased	O
age	O
and	O
fat	O
mass	O
.	O

Furthermore	O
,	O
indications	O
of	O
reduced	O
cardiometabolic	O
adaptations	O
to	O
exercise	O
in	O
postmenopausal	O
women	O
add	O
to	O
the	O
adverse	O
health	O
profile	O
.	O

We	O
sought	O
to	O
evaluate	O
risk	O
factors	O
for	O
type	O
2	O
diabetes	O
and	O
cardiovascular	O
disease	O
in	O
late	O
premenopausal	O
and	O
early	O
postmenopausal	O
women	O
,	O
matched	O
by	O
age	O
and	O
body	O
composition	O
,	O
and	O
investigate	O
the	O
effect	O
of	O
high-intensity	O
training	O
.	O

A	O
3-month	O
high-intensity	O
aerobic	O
training	O
intervention	O
,	O
involving	O
healthy	O
,	O
nonobese	O
,	O
late	O
premenopausal	O
(	O
n	O
=	O
40	O
)	O
and	O
early	O
postmenopausal	O
(	O
n	O
=	O
39	O
)	O
women	O
was	O
conducted	O
and	O
anthropometrics	O
,	O
body	O
composition	O
,	O
blood	O
pressure	O
,	O
lipid	O
profile	O
,	O
glucose	O
tolerance	O
,	O
and	O
maximal	O
oxygen	O
consumption	O
were	O
determined	O
at	O
baseline	O
and	O
after	O
the	O
intervention	O
.	O

At	O
baseline	O
,	O
the	O
groups	O
matched	O
in	O
anthropometrics	O
and	O
body	O
composition	O
,	O
and	O
only	O
differed	O
by	O
4.2	O
years	O
in	O
age	O
(	O
mean	O
[	O
95	O
%	O
confidence	O
limits	O
]	O
49.2	O
[	O
48.5-49.9	O
]	O
vs	O
53.4	O
[	O
52.4-54.4	O
]	O
years	O
)	O
.	O

Time	O
since	O
last	O
menstrual	O
period	O
for	O
the	O
postmenopausal	O
women	O
was	O
(	O
mean	O
[	O
95	O
%	O
confidecnce	O
limits	O
]	O
3.1	O
[	O
2.6-3.7	O
]	O
years	O
)	O
.	O

Hormonal	O
levels	O
(	O
estrogen	O
,	O
follicle	O
stimulation	O
hormone	O
,	O
luteinizing	O
hormone	O
)	O
confirmed	O
menopausal	O
status	O
.	O

At	O
baseline	O
the	O
postmenopausal	O
women	O
had	O
higher	O
total	O
cholesterol	O
(	O
P	O
<	O
.001	O
)	O
,	O
low-density	O
lipoprotein-cholesterol	O
(	O
P	O
<	O
.05	O
)	O
,	O
and	O
high-density	O
lipoprotein-cholesterol	O
(	O
P	O
<	O
.001	O
)	O
than	O
the	O
premenopausal	O
women	O
.	O

The	O
training	O
intervention	O
reduced	O
body	O
weight	O
(	O
P	O
<	O
.01	O
)	O
,	O
waist	O
circumference	O
(	O
P	O
<	O
.01	O
)	O
,	O
and	O
improved	O
body	O
composition	O
by	O
increasing	O
lean	O
body	O
mass	O
(	O
P	O
<	O
.001	O
)	O
and	O
decreasing	O
fat	O
mass	O
(	O
P	O
<	O
.001	O
)	O
similarly	O
in	O
both	O
groups	O
.	O

Moreover	O
,	O
training	O
resulted	O
in	O
lower	O
diastolic	O
blood	O
pressure	O
(	O
P	O
<	O
.05	O
)	O
,	O
resting	O
heart	O
rate	O
(	O
P	O
<	O
.001	O
)	O
,	O
total	O
cholesterol	O
(	O
P	O
<	O
.01	O
)	O
,	O
low-density	O
lipoprotein-cholesterol	O
(	O
P	O
<	O
.01	O
)	O
,	O
total	O
cholesterol	O
/	O
high-density	O
lipoprotein-cholesterol	O
index	O
(	O
P	O
<	O
.01	O
)	O
,	O
and	O
improved	O
plasma	O
insulin	O
concentration	O
during	O
the	O
oral	B-P
glucose	I-P
tolerance	I-P
test	I-P
(	O
P	O
<	O
.05	O
)	O
in	O
both	O
groups	O
.	O

Cardiovascular	O
risk	O
factors	O
are	O
similar	O
in	O
late	O
premenopausal	O
and	O
early	O
postmenopausal	O
women	O
,	O
matched	O
by	O
age	O
and	O
body	O
composition	O
,	O
with	O
the	O
exception	O
that	O
postmenopausal	O
women	O
have	O
higher	O
high-	O
and	O
low-density	O
lipoprotein-cholesterol	O
levels	O
.	O

A	O
3-month	O
intervention	O
of	O
high-intensity	O
aerobic	O
training	O
reduces	O
risk	O
factors	O
for	O
type	O
2	O
.diabetes	O
and	O
cardiovascular	O
disease	O
to	O
a	O
similar	O
extent	O
in	O
late	O
premenopausal	O
and	O
early	O
postmenopausal	O
women	O
.	O

Indications	O
for	O
embolization	O
in	O
a	O
French	O
level	O
1	O
trauma	O
center	O
.	O

Abdominal	O
trauma	O
accounts	O
for	O
nearly	O
20	O
%	O
of	O
all	O
traumatic	O
injuries	O
.	O

It	O
often	O
involves	O
young	O
patients	O
sustaining	O
multiple	O
injuries	O
,	O
with	O
a	O
high	O
associated	O
mortality	O
rate	O
.	O

Management	O
should	O
begin	O
at	O
the	O
scene	O
of	O
injury	O
and	O
relies	O
on	O
a	O
structured	O
chain	O
of	O
care	O
in	O
order	O
to	O
transport	O
the	O
trauma	O
patient	O
to	O
the	O
appropriate	O
hospital	O
center	O
.	O

Management	O
is	O
multi-disciplinary	O
,	O
involving	O
intensive	O
care	O
specialists	O
,	O
surgeons	O
and	O
radiologists	O
.	O

Imaging	O
to	O
precisely	O
define	O
injury	O
is	O
best	O
performed	O
with	O
whole	B-P
body	I-P
dual	I-P
phase	I-P
computed	I-P
tomography	I-P
,	O
which	O
can	O
also	O
identify	O
the	O
source	O
of	O
bleeding	O
.	O

Non-operative	O
management	O
has	O
developed	O
considerably	O
over	O
the	O
years	O
:	O
this	O
includes	O
selective	O
embolization	O
in	O
case	O
of	O
active	O
bleeding	O
or	O
vascular	O
anomalies	O
in	O
stable	O
or	O
stabilized	O
patients	O
after	O
resuscitation	O
.	O

Embolization	O
has	O
become	O
one	O
of	O
the	O
corner	O
stones	O
of	O
abdominal	O
trauma	O
management	O
and	O
interventional	O
radiologists	O
must	O
play	O
an	O
active	O
role	O
on	O
the	O
trauma	O
team	O
.	O

This	O
overview	O
details	O
the	O
different	O
embolization	O
procedures	O
according	O
to	O
the	O
involved	O
organ	O
and	O
embolic	O
agent	O
used	O
.	O

Activation	O
of	O
ephrinB-EphB	O
receptor	O
signalling	O
in	O
rat	O
spinal	O
cord	O
contributes	O
to	O
maintenance	O
of	O
diabetic	O
neuropathic	O
pain	O
.	O

Diabetic	O
neuropathic	O
pain	O
(	O
DNP	O
)	O
is	O
severe	O
and	O
intractable	O
in	O
clinic	O
.	O

The	O
specific	O
cellular	O
and	O
molecular	O
mechanisms	O
underlying	O
DNP	O
remain	O
elusive	O
and	O
its	O
treatment	O
are	O
limited	O
.	O

We	O
investigated	O
roles	O
of	O
EphB1	O
receptor	O
in	O
the	O
development	O
of	O
DNP	O
.	O

Diabetic	O
neuropathic	O
pain	O
was	O
produced	O
in	O
male	O
,	O
adult	O
,	O
Sprague-Dawley	O
rats	O
by	O
a	O
single	O
i.p	O
.	O

streptozotocin	O
(	O
STZ	O
)	O
or	O
alloxan	O
.	O

Western	O
blot	O
analysis	O
and	O
immunohistochemistry	B-P
were	O
used	O
to	O
analyse	O
expression	O
of	O
EphB1	O
receptor	O
as	O
well	O
as	O
the	O
activation	O
of	O
the	O
glial	O
cells	O
and	O
the	O
pro-inflammatory	O
cytokines	O
in	O
the	O
spinal	O
cord	O
.	O

DNP	O
manifested	O
as	O
mechanical	O
allodynia	O
,	O
which	O
was	O
determined	O
by	O
measuring	O
incidence	O
of	O
foot	O
withdrawal	O
in	O
response	O
to	O
mechanical	O
indentation	O
of	O
the	O
hind	O
paw	O
by	O
an	O
electro	O
von	O
Frey	O
filament	O
.	O

Diabetic	O
neuropathic	O
pain	O
and	O
high	O
blood	O
glucose	O
were	O
exhibited	O
simultaneously	O
in	O
around	O
70	O
%	O
of	O
animals	O
that	O
received	O
i.p	O
.	O

STZ	O
or	O
alloxan	O
.	O

Phosphorylation	O
of	O
EphB1	O
,	O
activation	O
of	O
the	O
astrocytes	O
and	O
microglial	O
cells	O
,	O
and	O
level	O
of	O
tumour	O
necrosis	O
factor	O
(	O
TNF	O
)	O
-α	O
and	O
interleukin	O
(	O
IL	O
)	O
-1β	O
in	O
the	O
spinal	O
cord	O
were	O
significantly	O
increased	O
in	O
rats	O
with	O
DNP	O
.	O

Spinal	O
blocking	O
EphB1	O
receptor	O
activation	O
in	O
the	O
late	O
phase	O
after	O
STZ	O
injection	O
significantly	O
suppressed	O
the	O
established	O
mechanical	O
allodynia	O
as	O
well	O
as	O
activation	O
of	O
the	O
astrocytes	O
and	O
microglial	O
cells	O
and	O
activity	O
of	O
TNF-α	O
and	O
IL-1β	O
.	O

However	O
,	O
spinal	O
treatment	O
of	O
EphB1	O
-	O
Fc	O
in	O
the	O
early	O
phase	O
after	O
STZ	O
injection	O
did	O
not	O
prevent	O
the	O
induction	O
of	O
DNP	O
.	O

EphB1	O
receptor	O
activation	O
in	O
the	O
spinal	O
cord	O
is	O
critical	O
to	O
the	O
maintenance	O
,	O
but	O
not	O
induction	O
of	O
diabetic	O
pain	O
.	O

EphB1	O
receptor	O
may	O
be	O
a	O
potential	O
target	O
for	O
relieving	O
the	O
established	O
diabetic	O
pain	O
.	O

Activation	O
of	O
EphB1	O
receptor	O
in	O
the	O
spinal	O
cord	O
is	O
critical	O
to	O
maintaining	O
the	O
established	O
diabetic	O
neuropathic	O
pain	O
,	O
but	O
not	O
to	O
diabetic	O
pain	O
induction	O
.	O

Spinal	O
blocking	O
EphB1	O
receptor	O
activation	O
suppresses	O
ongoing	O
diabetic	O
neuropathic	O
pain	O
.	O

American	O
cutaneous	O
leishmaniasis	O
:	O
In	O
situ	O
immune	O
response	O
of	O
patients	O
with	O
recent	O
and	O
late	O
lesions	O
.	O

TNF-α	O
,	O
IFN-γ	O
,	O
IL-10	O
,	O
IL-17	O
,	O
CD68	O
and	O
CD57	O
were	O
evaluated	O
in	O
biopsies	B-P
of	O
patients	O
with	O
American	O
cutaneous	O
leishmaniasis	O
living	O
in	O
Sorocaba	O
,	O
Brazil	O
.	O

The	O
analyses	O
were	O
performed	O
considering	O
the	O
time	O
of	O
lesions	O
from	O
23	O
patients	O
with	O
recent	O
lesions	O
(	O
Group	O
I	O
)	O
and	O
19	O
patients	O
with	O
late	O
lesions	O
(	O
Group	O
II	O
)	O
.	O

All	O
patients	O
were	O
infected	O
with	O
Leishmania	O
(	O
Viannia	O
)	O
braziliensis	O
.	O

Immunostaining	O
cells	O
for	O
CD68	O
,	O
CD57	O
,	O
TNF-	O
α	O
,	O
IFN-γ	O
,	O
IL-10	O
and	O
IL-17	O
were	O
performed	O
by	O
immunohistochemistry	B-P
.	O

Except	O
for	O
CD68	O
and	O
IL-17	O
,	O
the	O
distribution	O
of	O
in	O
situ	O
for	O
CD57	O
,	O
IL-10	O
,	O
TNF-α	O
and	O
IFN-γ	O
showed	O
that	O
patients	O
with	O
recent	O
lesions	O
expressed	O
higher	O
levels	O
than	O
those	O
with	O
late	O
lesions	O
.	O

The	O
comparison	O
of	O
cytokine	O
expression	O
/	O
group	O
showed	O
that	O
IL-10	O
was	O
significantly	O
higher	O
than	O
IL-17	O
and	O
IFN-γ	O
(	O
similar	O
data	O
were	O
shown	O
in	O
IL-17	O
compared	O
with	O
TNF-α	O
)	O
,	O
suggesting	O
an	O
immunological	O
balance	O
between	O
inflammatory	O
-	O
anti-inflammatory	O
agents	O
.	O

This	O
balance	O
was	O
similar	O
for	O
two	O
groups	O
of	O
patients	O
.	O

In	O
conclusion	O
,	O
these	O
data	O
suggested	O
that	O
(	O
i	O
)	O
patients	O
from	O
Group	O
I	O
had	O
recent	O
lesions	O
(	O
in	O
the	O
beginning	O
of	O
chronic	O
phase	O
)	O
compared	O
to	O
those	O
from	O
Group	O
II	O
and	O
(	O
ii	O
)	O
the	O
modulation	O
of	O
inflammatory	O
response	O
in	O
patients	O
with	O
recent	O
American	O
cutaneous	O
leishmaniasis	O
was	O
correlated	O
with	O
IL-10	O
expression	O
in	O
skin	O
lesions	O
preventing	O
the	O
development	O
of	O
mucosal	O
forms	O
.	O

The	O
parasite	O
treatment	O
also	O
prevented	O
the	O
evolution	O
of	O
severe	O
forms	O
.	O

Locating	O
the	O
Seventh	O
Cervical	O
Spinous	O
Process	O
:	O
Development	O
and	O
Validation	O
of	O
a	O
Multivariate	O
Model	O
Using	O
Palpation	B-P
and	O
Personal	O
Information	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
develop	O
and	O
validate	O
a	O
multivariate	O
prediction	O
model	O
,	O
guided	O
by	O
palpation	B-P
and	O
personal	O
information	O
,	O
for	O
locating	O
the	O
seventh	O
cervical	O
spinous	O
process	O
(	O
C7SP	O
)	O
.	O

A	O
single-blinded	O
,	O
cross-sectional	O
study	O
at	O
a	O
primary	O
to	O
tertiary	O
health	O
care	O
center	O
was	O
conducted	O
for	O
model	O
development	O
and	O
temporal	O
validation	O
.	O

One-hundred	O
sixty	O
participants	O
were	O
prospectively	O
included	O
for	O
model	O
development	O
(	O
n	O
=	O
80	O
)	O
and	O
time-split	O
validation	O
stages	O
(	O
n	O
=	O
80	O
)	O
.	O

The	O
C7SP	O
was	O
located	O
using	O
the	O
thorax-rib	B-P
static	I-P
method	I-P
(	O
TRSM	B-P
)	O
.	O

Participants	O
underwent	O
chest	B-P
radiography	I-P
for	O
assessment	O
of	O
the	O
inner	O
body	O
structure	O
located	O
with	O
TRSM	B-P
and	O
using	O
radio-opaque	O
markers	O
placed	O
over	O
the	O
skin	O
.	O

Age	O
,	O
sex	O
,	O
height	O
,	O
body	O
mass	O
,	O
body	O
mass	O
index	O
,	O
and	O
vertex-marker	O
distanc	O
e	O
(	O
DV-M	O
)	O
were	O
used	O
to	O
predict	O
the	O
distance	O
from	O
the	O
C7SP	O
to	O
the	O
vertex	O
(	O
DV-C7	O
)	O
.	O

Multivariate	O
linear	O
regression	O
modeling	O
,	O
limits	O
of	O
agreement	O
plot	O
,	O
histogram	O
of	O
residues	O
,	O
receiver	O
operating	O
characteristic	O
curves	O
,	O
and	O
confusion	O
tables	O
were	O
analyzed	O
.	O

The	O
multivariate	O
linear	O
prediction	O
model	O
for	O
DV-C7	O
(	O
in	O
centimeters	O
)	O
was	O
DV-C7	O
=	O
0.986DV-M	O
+	O
0.018	O
(	O
mass	O
)	O
+	O
0.014	O
(	O
age	O
)	O
-	O
1.008	O
.	O

Receiver	O
operating	O
characteristic	O
curves	O
had	O
better	O
discrimination	O
of	O
DV-C7	O
(	O
area	O
under	O
the	O
curve	O
=	O
0.661	O
;	O
95	O
%	O
confidence	O
interval	O
=	O
0.541-0.782	O
;	O
P	O
=	O
.015	O
)	O
than	O
DV-M	O
(	O
area	O
under	O
the	O
curve	O
=	O
0.480	O
;	O
95	O
%	O
confidence	O
interval	O
=	O
0.345-0.614	O
;	O
P	O
=	O
.761	O
)	O
,	O
with	O
respective	O
cutoff	O
points	O
at	O
23.40	O
cm	O
(	O
sensitivity	O
=	O
41	O
%	O
,	O
specificity	O
=	O
63	O
%	O
)	O
and	O
24.75	O
cm	O
(	O
sensitivity	O
=	O
69	O
%	O
,	O
specificity	O
=	O
52	O
%	O
)	O
.	O

The	O
C7SP	O
was	O
correctly	O
located	O
more	O
often	O
when	O
using	O
predicted	O
DV-C7	O
in	O
the	O
validation	O
sample	O
than	O
when	O
using	O
the	O
TRSM	B-P
in	O
the	O
development	O
sample	O
:	O
n	O
=	O
53	O
(	O
66	O
%	O
)	O
vs	O
n	O
=	O
32	O
(	O
40	O
%	O
)	O
,	O
P	O
<	O
.001	O
.	O

Better	O
accuracy	O
was	O
obtained	O
when	O
locating	O
the	O
C7SP	O
by	O
use	O
of	O
a	O
multivariate	O
model	O
that	O
incorporates	O
palpation	B-P
and	O
personal	O
information	O
.	O

Axially	O
Chiral	O
Dimeric	O
Naphthalene	O
and	O
Naphthoquinone	O
Metabolites	O
,	O
from	O
Root	O
Cultures	O
of	O
the	O
West	O
African	O
Liana	O
Triphyophyllum	O
peltatum	O
.	O

Root	O
cultures	O
of	O
the	O
West	O
African	O
liana	O
Triphyophyllum	O
peltatum	O
were	O
initiated	O
from	O
stem	O
explants	O
of	O
in	O
vitro	O
cultivated	O
shoots	O
.	O

From	O
these	O
organ	O
cultures	O
,	O
three	O
new	O
binaphthalenes	O
,	O
one	O
binaphthoquinone	O
,	O
and	O
two	O
(	O
bi	O
)	O
naphthalene	O
glucosides	O
were	O
isolated	O
,	O
with	O
substitution	O
patterns	O
related	O
to	O
those	O
of	O
the	O
naphthylisoquinoline	O
alkaloids	O
,	O
which	O
are	O
the	O
``	O
normal	O
''	O
main	O
metabolites	O
of	O
T.	O
peltatum	O
.	O

The	O
structures	O
of	O
the	O
diglucoside	O
dioncoquinoside	O
A	O
(	O
1	O
)	O
and	O
of	O
the	O
axially	O
chiral	O
biaryls	O
triphyoquinols	O
A1	O
(	O
3	O
)	O
,	O
A2	O
(	O
4	O
)	O
,	O
and	O
B	O
(	O
5	O
)	O
,	O
triphyoquinoside	O
A	O
(	O
6	O
)	O
,	O
and	O
triphyoquinone	O
A	O
(	O
7	O
)	O
were	O
elucidated	O
by	O
spectroscopic	O
analysis	O
(	O
HRESIMS	O
,	O
1D	B-P
and	O
2D	B-P
NMR	I-P
)	O
and	O
by	O
application	O
of	O
electronic	O
circular	O
dichroism	O
(	O
ECD	O
)	O
spectroscopy	O
in	O
combination	O
with	O
the	O
exciton	O
chirality	O
method	O
and	O
quantum-chemical	O
ECD	O
calculations	O
.	O

The	O
root	O
cultures	O
likewise	O
produced	O
the	O
known	O
alkaloids	O
dioncophylline	O
A	O
(	O
8	O
)	O
,	O
5'-O-demethyldioncophylline	O
A	O
(	O
9	O
)	O
,	O
dioncopeltine	O
A	O
(	O
10	O
)	O
,	O
habropetaline	O
A	O
(	O
11	O
)	O
,	O
and	O
5'-O-methyldioncophylline	O
D	O
(	O
12a/b	O
)	O
,	O
the	O
naphthalene	O
glucoside	O
plumbaside	O
A	O
(	O
2	O
)	O
,	O
and	O
the	O
naphthoquinones	O
plumbagin	O
(	O
13	O
)	O
,	O
droserone	O
(	O
14	O
)	O
,	O
and	O
8-hydroxydroserone	O
(	O
15	O
)	O
.	O

Effectiveness	O
of	O
Intracavitary	O
Electrocardiogram	O
Guidance	O
in	O
Peripherally	O
Inserted	O
Central	O
Catheter	O
Tip	O
Placement	O
in	O
Neonates	O
.	O

Correct	O
tip	O
location	O
is	O
crucial	O
for	O
a	O
peripherally	O
inserted	O
central	O
catheter	O
(	O
PICC	O
)	O
to	O
maximize	O
the	O
effects	O
of	O
central	O
venous	O
infusion	O
.	O

However	O
,	O
it	O
is	O
difficult	O
to	O
place	O
the	O
tip	O
in	O
a	O
correct	O
location	O
in	O
neonates	O
because	O
of	O
the	O
unreliable	O
estimated	O
length	O
by	O
surface	O
landmark	O
.	O

Therefore	O
,	O
we	O
evaluated	O
the	O
feasibility	O
and	O
safety	O
of	O
an	O
improved	O
intracavitary	O
electrocardiogram	O
(	O
IC	O
-	O
ECG	O
)	O
technique	O
in	O
guiding	O
PICC	O
placement	O
in	O
neonates	O
based	O
on	O
the	O
ratios	O
of	O
P/R	O
wave	O
amplitudes	O
on	O
IC	O
-	O
ECG	O
.	O

The	O
results	O
showed	O
that	O
all	O
of	O
the	O
32	O
neonates	O
whose	O
PICCs	O
had	O
been	O
successfully	O
placed	O
and	O
correct	O
tip	O
position	O
verified	O
by	O
chest	B-P
radiography	I-P
acquired	O
qualified	O
P	O
wave	O
on	O
IC	O
-	O
ECG	O
.	O

The	O
average	O
ratio	O
of	O
P/R	O
wave	O
amplitude	O
was	O
0.6	O
±	O
0.1	O
,	O
with	O
a	O
range	O
of	O
0.4	O
to	O
0.8	O
.	O

The	O
49	O
neonates	O
who	O
received	O
IC	O
-	O
ECG	O
-guided	O
PICC	O
catheterization	O
showed	O
higher	O
success	O
rates	O
of	O
correct	O
PICC	O
tip	O
position	O
on	O
the	O
first	O
attempt	O
than	O
traditional	O
,	O
predetermined	O
length	O
estimation	O
on	O
surface	O
landmark	O
(	O
93.9	O
%	O
vs	O
62.5	O
%	O
,	O
χ	O
=	O
18.01	O
,	O
P	O
<	O
.001	O
)	O
.	O

No	O
significant	O
complications	O
occurred	O
in	O
the	O
studied	O
neonates	O
.	O

Based	O
on	O
these	O
findings	O
,	O
IC	O
-	O
ECG	O
-guided	O
tip	O
placement	O
appears	O
to	O
be	O
a	O
promising	O
approach	O
in	O
improving	O
the	O
success	O
rate	O
of	O
tip	O
location	O
when	O
placing	O
a	O
PICC	O
in	O
neonates	O
.	O

Glomus	O
tumor	O
in	O
teen	O
and	O
repetition	O
pneumonia	O
:	O
Case	O
report	O
.	O

Glomus	O
tumors	O
are	O
uncommon	O
tumors	O
that	O
are	O
originated	O
from	O
smooth	O
muscle	O
cells	O
of	O
the	O
neuromioarterials	O
glomus	O
bodies	O
located	O
in	O
the	O
arteriovenous	O
anastomoses	O
subcutaneous	O
tissue	O
or	O
deep	O
dermis	O
of	O
the	O
extremities	O
,	O
mainly	O
in	O
the	O
palms	O
of	O
the	O
hands	O
,	O
wrists	O
and	O
subungual	O
areas	O
of	O
the	O
fingers	O
.	O

Carcinoid	O
tumor	O
,	O
as	O
the	O
glomus	O
tumor	O
,	O
can	O
show	O
an	O
organoid	O
pattern	O
,	O
increased	O
vascularity	O
,	O
and	O
uniform	O
,	O
round	O
cells	O
with	O
eosinophilic	O
cytoplasm	O
,	O
but	O
usually	O
are	O
positive	O
for	O
cytokeratin	O
and	O
always	O
stained	O
with	O
chromogranin	O
and	O
synaptophysin	O
showing	O
negative	O
for	O
smooth	O
muscle	O
markers	O
which	O
is	O
presented	O
in	O
our	O
case	O
.	O

Glomus	O
tumors	O
have	O
a	O
good	O
prognosis	O
and	O
surgical	O
resection	O
is	O
the	O
treatment	O
of	O
choice	O
.	O

In	O
our	O
case	O
,	O
the	O
patient	O
underwent	O
pulmonary	O
bilobectomy	O
because	O
of	O
the	O
location	O
of	O
the	O
tumor	O
in	O
the	O
transition	O
between	O
the	O
middle	O
lobe	O
and	O
the	O
basal	O
bronchial	O
trunk	O
right	O
lower	O
lobe	O
divisions	O
.	O

It	O
is	O
presented	O
thus	O
a	O
glomus	O
tumor	O
with	O
exceptional	O
localization	O
(	O
pulmonary	O
and	O
bronchial	O
)	O
of	O
benign	O
histological	O
features	O
,	O
according	O
to	O
most	O
of	O
the	O
cases	O
reported	O
in	O
the	O
literature	O
emphasizing	O
their	O
particular	O
rare	O
location	O
,	O
histological	O
,	O
and	O
immunohistochemical	O
profile	O
,	O
which	O
helps	O
the	O
differential	B-P
diagnosis	I-P
with	O
other	O
most	O
common	O
tumors	O
of	O
bronchial	O
location	O
.	O

Associations	O
between	O
human	O
breast	O
milk	O
hormones	O
and	O
adipocytokines	O
and	O
infant	O
growth	O
and	O
body	O
composition	O
in	O
the	O
first	O
6	O
months	O
of	O
life	O
.	O

Much	O
is	O
to	O
be	O
learnt	O
about	O
human	O
breast	O
milk	O
(	O
HBM	O
)	O
.	O

The	O
purpose	O
of	O
this	O
study	O
is	O
to	O
extend	O
our	O
knowledge	O
of	O
HBM	O
by	O
investigating	O
the	O
role	O
of	O
maternal	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
,	O
sex	O
and	O
stage	O
of	O
lactation	O
(	O
month	O
1	O
vs.	O
6	O
)	O
on	O
HBM	O
insulin	O
,	O
glucose	O
,	O
leptin	O
,	O
IL-6	O
and	O
TNF-α	O
and	O
their	O
associations	O
with	O
infant	O
body	O
composition	O
.	O

Thirty-seven	O
exclusively	O
breastfeeding	O
infants	O
(	O
n	O
=	O
37	O
;	O
16♀	O
,	O
21♂	O
)	O
,	O
and	O
their	O
mothers	O
(	O
19-47	O
kg	O
m	O
(	O
-2	O
)	O
)	O
were	O
studied	O
at	O
1	O
and	O
6	O
months	O
of	O
lactation	O
.	O

Infants	O
had	O
body	O
composition	O
measured	O
(	O
using	O
dual-energy	B-P
X-ray	I-P
absorptiometry	I-P
)	O
and	O
HBM	O
collected	O
.	O

A	O
significant	O
interaction	O
between	O
maternal	O
BMI	O
and	O
infant	O
sex	O
on	O
insulin	O
levels	O
(	O
p	O
=	O
0.0322	O
)	O
was	O
observed	O
such	O
that	O
insulin	O
was	O
229	O
%	O
higher	O
in	O
obese	O
mothers	O
nursing	O
female	O
infants	O
than	O
in	O
normal	O
weight	O
mothers	O
nursing	O
female	O
infants	O
and	O
179	O
%	O
higher	O
than	O
obese	O
mothers	O
nursing	O
male	O
infants	O
.	O

For	O
leptin	O
,	O
a	O
significant	O
association	O
with	O
BMI	O
category	O
was	O
observed	O
(	O
p	O
<	O
0.0001	O
)	O
such	O
that	O
overweight	O
and	O
obese	O
mothers	O
had	O
96.5	O
%	O
and	O
315.1	O
%	O
higher	O
leptin	O
levels	O
than	O
normal	O
weight	O
mothers	O
,	O
respectively	O
.	O

Leptin	O
was	O
also	O
found	O
to	O
have	O
a	O
significant	O
(	O
p	O
=	O
0.0004	O
)	O
33.7	O
%	O
decrease	O
from	O
months	O
1	O
to	O
6	O
,	O
controlling	O
for	O
BMI	O
category	O
and	O
sex	O
.	O

A	O
significant	O
inverse	O
relationship	O
between	O
month	O
1	O
leptin	O
levels	O
and	O
infant	O
length	O
(	O
p	O
=	O
0.0257	O
)	O
,	O
percent	O
fat	O
(	O
p	O
=	O
0.0223	O
)	O
,	O
total	O
fat	O
mass	O
(	O
p	O
=	O
0.0226	O
)	O
and	O
trunk	O
fat	O
mass	O
(	O
p	O
=	O
0.0111	O
)	O
at	O
month	O
6	O
was	O
also	O
found	O
.	O

No	O
associations	O
or	O
interactions	O
were	O
observed	O
for	O
glucose	O
,	O
TNF-α	O
or	O
IL-6	O
.	O

These	O
data	O
demonstrate	O
that	O
maternal	O
BMI	O
,	O
infant	O
sex	O
and	O
stage	O
of	O
lactation	O
affect	O
the	O
compositional	O
make-up	O
of	O
insulin	O
and	O
leptin	O
.	O

Surrogate	O
inaccuracy	O
in	O
predicting	O
older	O
adults	O
'	O
desire	O
for	O
life-sustaining	O
interventions	O
in	O
the	O
event	O
of	O
decisional	O
incapacity	O
:	O
is	O
it	O
due	O
in	O
part	O
to	O
erroneous	O
quality-of-life	B-P
assessments	I-P
?	O
.	O

Family	O
members	O
are	O
often	O
called	O
upon	O
to	O
make	O
decisions	O
for	O
an	O
incapacitated	O
relative	O
.	O

Yet	O
they	O
have	O
difficulty	O
predicting	O
a	O
loved	O
one	O
's	O
desire	O
to	O
receive	O
treatments	O
in	O
hypothetical	O
situations	O
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
this	O
difficulty	O
could	O
in	O
part	O
be	O
explained	O
by	O
discrepant	O
quality-of-life	B-P
assessments	I-P
.	O

The	O
data	O
come	O
from	O
235	O
community-dwelling	O
adults	O
aged	O
70	O
years	O
and	O
over	O
who	O
rated	O
their	O
quality	O
of	O
life	O
and	O
desire	O
for	O
specified	O
interventions	O
in	O
four	O
health	O
states	O
(	O
current	O
state	O
,	O
mild	O
to	O
moderate	O
stroke	O
,	O
incurable	O
brain	O
cancer	O
,	O
and	O
severe	O
dementia	O
)	O
.	O

All	O
ratings	O
were	O
made	O
on	O
Likert-type	O
scales	O
.	O

Using	O
identical	O
rating	O
scales	O
,	O
a	O
surrogate	O
chosen	O
by	O
the	O
older	O
adult	O
was	O
asked	O
to	O
predict	O
the	O
latter	O
's	O
responses	O
.	O

Linear	O
mixed	O
models	O
were	O
fitted	O
to	O
determine	O
whether	O
differences	O
in	O
quality-of-life	O
ratings	O
between	O
the	O
older	O
adult	O
and	O
surrogate	O
were	O
associated	O
with	O
surrogates	O
'	O
inaccuracy	O
in	O
predicting	O
desire	O
for	O
treatment	O
.	O

The	O
difference	O
in	O
quality-of-life	O
ratings	O
was	O
a	O
significant	O
predictor	O
of	O
prediction	O
inaccuracy	O
for	O
the	O
three	O
hypothetical	O
health	O
states	O
(	O
p	O
<	O
0.01	O
)	O
and	O
nearly	O
significant	O
for	O
the	O
current	O
health	O
state	O
(	O
p	O
=	O
0.077	O
)	O
.	O

All	O
regression	O
coefficients	O
were	O
negative	O
,	O
implying	O
that	O
the	O
more	O
the	O
surrogate	O
overestimated	O
quality	O
of	O
life	O
compared	O
to	O
the	O
older	O
adult	O
,	O
the	O
more	O
he	O
or	O
she	O
overestimated	O
the	O
older	O
adult	O
's	O
desire	O
to	O
be	O
treated	O
.	O

Discrepant	O
quality-of-life	O
ratings	O
are	O
associated	O
with	O
surrogates	O
'	O
difficulty	O
in	O
predicting	O
desire	O
for	O
life-sustaining	O
interventions	O
in	O
hypothetical	O
situations	O
.	O

This	O
finding	O
underscores	O
the	O
importance	O
of	O
discussing	O
anticipated	O
quality	O
of	O
life	O
in	O
states	O
of	O
cognitive	O
decline	O
,	O
to	O
better	O
prepare	O
family	O
members	O
for	O
making	O
difficult	O
decisions	O
for	O
their	O
loved	O
ones	O
.	O

ISRCTN89993391	O
.	O

Ischemic	O
myopathy	O
revealing	O
systemic	O
calciphylaxis	O
.	O

Patients	O
with	O
renal	O
failure	O
who	O
are	O
being	O
treated	O
with	O
dialysis	O
frequently	O
develop	O
neuromuscular	O
manifestations	O
.	O

Renal	O
failure	O
-associated	O
calciphylaxis	O
,	O
also	O
termed	O
calcific	O
uremic	O
arteriolopathy	O
(	O
CUA	O
)	O
,	O
is	O
a	O
life-threatening	O
condition	O
usually	O
observed	O
in	O
patients	O
with	O
end-stage	O
renal	O
disease	O
on	O
chronic	O
dialysis	O
or	O
after	O
renal	O
transplantation	O
.	O

We	O
describe	O
a	O
hemodialyzed	O
patient	O
who	O
presented	O
with	O
rapidly	O
progressive	O
unexplained	O
systemic	O
vasculopathy	O
,	O
muscle	O
atrophy	O
,	O
and	O
proximal	O
weakness	O
,	O
that	O
unexpectedly	O
proved	O
to	O
be	O
caused	O
by	O
calciphylaxis	O
.	O

Quadriceps	O
muscle	O
biopsy	B-P
disclosed	O
diffuse	O
vascular	O
calcific	O
deposits	O
on	O
medium-	O
and	O
small-sized	O
vessels	O
,	O
characteristic	O
of	O
CUA	O
.	O

Other	O
changes	O
included	O
ischemic	O
myopathy	O
,	O
focal	O
intracellular	O
calcium	O
accumulation	O
within	O
myofibers	O
,	O
and	O
calcium	O
deposits	O
in	O
endomysial	O
capillaries	O
associated	O
with	O
marked	O
complement	O
activation	O
and	O
C5b9	O
formation	O
.	O

There	O
are	O
only	O
a	O
few	O
descriptions	O
of	O
muscle	O
involvement	O
in	O
the	O
context	O
of	O
CUA	O
,	O
a	O
condition	O
with	O
a	O
prognosis	O
that	O
depends	O
on	O
early	O
diagnosis	O
and	O
treatment	O
.	O

This	O
report	O
underscores	O
the	O
usefulness	O
of	O
muscle	B-P
biopsy	I-P
in	O
the	O
diagnosis	O
of	O
systemic	O
calciphylaxis	O
.	O

Muscle	O
Nerve	O
,	O
2017	O
.	O

Diffusion	B-P
kurtosis	I-P
imaging	I-P
of	O
the	O
liver	O
at	O
3	O
Tesla	O
:	O
in	O
vivo	O
comparison	O
to	O
standard	O
diffusion-weighted	B-P
imaging	I-P
.	O

Background	O
Functional	O
techniques	B-P
like	O
diffusion-weighted	B-P
imaging	I-P
(	O
DWI	B-P
)	O
are	O
gaining	O
more	O
and	O
more	O
importance	O
in	O
liver	O
magnetic	B-P
resonance	I-P
imaging	I-P
(	O
MRI	B-P
)	O
.	O

Diffusion	B-P
kurtosis	I-P
imaging	I-P
(	O
DKI	B-P
)	O
is	O
an	O
advanced	O
technique	B-P
that	O
might	O
help	O
to	O
overcome	O
current	O
limitations	O
of	O
DWI	B-P
.	O

Purpose	O
To	O
evaluate	O
DKI	B-P
for	O
the	O
differentiation	O
of	O
hepatic	O
lesions	O
in	O
comparison	O
to	O
conventional	O
DWI	B-P
at	O
3	O
Tesla	O
.	O

Material	O
and	O
Methods	O
Fifty-six	O
consecutive	O
patients	O
were	O
examined	O
using	O
a	O
routine	O
abdominal	B-P
MR	I-P
protocol	I-P
at	O
3	O
Tesla	O
which	O
included	O
DWI	B-P
with	O
b-values	O
of	O
50	O
,	O
400	O
,	O
800	O
,	O
and	O
1000	O
s/mm	O
(	O
2	O
)	O
.	O

Apparent	O
diffusion	O
coefficient	O
maps	O
were	O
calculated	O
applying	O
a	O
standard	O
mono-exponential	O
fit	O
,	O
while	O
a	O
non-Gaussian	O
kurtosis	O
fit	O
was	O
used	O
to	O
obtain	O
DKI	B-P
maps	O
.	O

ADC	O
as	O
well	O
as	O
Kurtosis-corrected	O
diffusion	O
(	O
D	O
)	O
values	O
were	O
quantified	O
by	O
region	O
of	O
interest	O
analysis	O
and	O
compared	O
between	O
lesions	O
.	O

Results	O
Sixty-eight	O
hepatic	O
lesions	O
(	O
hepatocellular	O
carcinoma	O
[	O
HCC	O
]	O
[	O
n	O
=	O
25	O
]	O
;	O
hepatic	O
adenoma	O
[	O
n	O
=	O
4	O
]	O
,	O
cysts	O
[	O
n	O
=	O
18	O
]	O
;	O
hepatic	O
hemangioma	O
[	O
HH	O
]	O
[	O
n	O
=	O
18	O
]	O
;	O
and	O
focal	O
nodular	O
hyperplasia	O
[	O
n	O
=	O
3	O
]	O
)	O
were	O
identified	O
.	O

Differentiation	O
of	O
malignant	O
and	O
benign	O
lesions	O
was	O
possible	O
based	O
on	O
both	O
DWI	B-P
ADC	O
as	O
well	O
as	O
DKI	B-P
D-values	O
(	O
P	O
values	O
were	O
in	O
the	O
range	O
of	O
0.04	O
to	O
<	O
0.0001	O
)	O
.	O

Conclusion	O
In	O
vivo	O
abdominal	O
DKI	B-P
calculated	O
using	O
standard	O
b-values	O
is	O
feasible	O
and	O
enables	O
quantitative	O
differentiation	O
between	O
malignant	O
and	O
benign	O
liver	O
lesions	O
.	O

Assessment	O
of	O
conventional	O
ADC	O
values	O
leads	O
to	O
similar	O
results	O
when	O
using	O
b-values	O
below	O
1000	O
s/mm	O
(	O
2	O
)	O
for	O
DKI	B-P
calculation	O
.	O

Molecular	B-P
Imaging	I-P
of	O
Tumor	O
Angiogenesis	O
and	O
Therapeutic	O
Effects	O
with	O
Dual	O
Bioluminescence	O
.	O

Angiogenesis	O
is	O
critical	O
for	O
the	O
growth	O
of	O
tumor	O
by	O
supplying	O
nutrients	O
and	O
oxygen	O
that	O
exacerbates	O
the	O
metastasis	O
and	O
progression	O
of	O
cancer	O
.	O

Noninvasive	O
imaging	B-P
of	O
angiogenesis	O
during	O
the	O
tumor	O
therapeutic	O
processes	O
may	O
provide	O
novel	O
opportunities	O
for	O
image-guided	O
tumor	O
management	O
.	O

Here	O
,	O
we	O
want	O
to	O
develop	O
a	O
mouse	O
animal	O
model	O
for	O
assessing	O
cancer	O
progression	O
and	O
angiogenesis	O
in	O
the	O
same	O
individuals	O
by	O
molecular	B-P
imaging	I-P
.	O

Breast	O
cancer	O
model	O
was	O
developed	O
with	O
mouse	O
breast	O
cancer	O
cell	O
line	O
4T1	O
carrying	O
a	O
reporter	O
system	O
encoding	O
a	O
triple	O
fusion	O
(	O
TF	O
)	O
reporter	O
gene	O
consisting	O
of	O
renilla	O
luciferase	O
(	O
Rluc	O
)	O
,	O
red	O
fluorescent	O
protein	O
(	O
RFP	O
)	O
and	O
herpes	O
simplex	O
virus	O
truncated	O
thymidine	O
kinase	O
(	O
HSV-ttk	O
)	O
in	O
transgenic	O
mice	O
,	O
which	O
expressed	O
firefly	O
luciferase	O
(	O
Fluc	O
)	O
under	O
the	O
promoter	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
2	O
(	O
Vegfr2-luc	O
)	O
.	O

The	O
mice	O
were	O
subsequently	O
treated	O
with	O
ganciclovir	O
(	O
GCV	O
)	O
and	O
the	O
tumor	O
angiogenesis	O
was	O
tracked	O
by	O
Fluc	O
imaging	B-P
and	O
the	O
growth	O
status	O
of	O
tumor	O
was	O
monitored	O
by	O
imaging	B-P
of	O
Rluc	O
simultaneously	O
.	O

Overall	O
,	O
this	O
traceable	O
breast	O
cancer	O
model	O
can	O
simultaneously	O
image	O
the	O
tumor	O
growth	O
and	O
angiogenesis	O
in	O
single	O
individual	O
,	O
which	O
may	O
facilitate	O
a	O
better	O
understanding	O
the	O
mechanisms	O
of	O
angiogenesis	O
in	O
the	O
progression	O
and	O
regression	O
of	O
tumor	O
.	O

Heart	O
beat	O
characterization	O
from	O
ballistocardiogram	B-P
signals	I-P
using	O
extended	O
functions	O
of	O
multiple	O
instances	O
.	O

A	O
multiple	O
instance	O
learning	O
(	O
MIL	O
)	O
method	O
,	O
extended	O
Function	O
of	O
Multiple	O
Instances	O
(	O
eFUMI	O
)	O
,	O
is	O
applied	O
to	O
ballistocardiogram	B-P
(	O
BCG	B-P
)	O
signals	O
produced	O
by	O
a	O
hydraulic	O
bed	O
sensor	O
.	O

The	O
goal	O
of	O
this	O
approach	O
is	O
to	O
learn	O
a	O
personalized	O
heartbeat	O
``	O
concept	O
``	O
for	O
an	O
individual	O
.	O

This	O
heartbeat	O
concept	O
is	O
a	O
prototype	O
(	O
or	O
``	O
signature	O
``	O
)	O
that	O
characterizes	O
the	O
heartbeat	O
pattern	O
for	O
an	O
individual	O
in	O
ballistocardiogram	B-P
data	O
.	O

The	O
eFUMI	O
method	O
models	O
the	O
problem	O
of	O
learning	O
a	O
heartbeat	O
concept	O
from	O
a	O
BCG	B-P
signal	I-P
as	O
a	O
MIL	O
problem	O
.	O

This	O
approach	O
elegantly	O
addresses	O
the	O
uncertainty	O
inherent	O
in	O
a	O
BCG	B-P
signal	I-P
(	O
e.	O
g.	O
,	O
misalignment	O
between	O
training	O
data	O
and	O
ground	O
truth	O
,	O
mis-collection	O
of	O
heartbeat	O
by	O
some	O
transducers	O
,	O
etc.	O
)	O
.	O

Given	O
a	O
BCG	B-P
training	O
signal	O
coupled	O
with	O
a	O
ground	O
truth	O
signal	O
(	O
e.g.	O
,	O
a	O
pulse	O
finger	O
sensor	O
)	O
,	O
training	O
``	O
bags	O
''	O
labeled	O
with	O
only	O
binary	O
labels	O
denoting	O
if	O
a	O
training	O
bag	O
contains	O
a	O
heartbeat	O
signal	O
or	O
not	O
can	O
be	O
generated	O
.	O

Then	O
,	O
using	O
these	O
bags	O
,	O
eFUMI	O
learns	O
a	O
personalized	O
concept	O
of	O
heartbeat	O
for	O
a	O
subject	O
as	O
well	O
as	O
several	O
non-	O
heartbeat	O
background	O
concepts	O
.	O

After	O
learning	O
the	O
heartbeat	O
concept	O
,	O
heartbeat	O
detection	O
and	O
heart	O
rate	O
estimation	O
can	O
be	O
applied	O
to	O
test	O
data	O
.	O

Experimental	O
results	O
show	O
that	O
the	O
estimated	O
heartbeat	O
concept	O
found	O
by	O
eFUMI	O
is	O
more	O
representative	O
and	O
a	O
more	O
discriminative	O
prototype	O
of	O
the	O
heartbeat	O
signals	O
than	O
those	O
found	O
by	O
comparison	O
MIL	O
methods	O
in	O
the	O
literature	O
.	O

Altered	O
Effects	O
of	O
Perspective-Taking	O
on	O
Functional	O
Connectivity	O
during	O
Self-	O
and	O
Other-Referential	O
Processing	O
in	O
Adults	O
with	O
Autism	O
Spectrum	O
Disorder	O
.	O

In	O
interactive	O
social	O
situations	O
,	O
it	O
is	O
often	O
crucial	O
to	O
be	O
able	O
to	O
take	O
another	O
person	O
's	O
perspective	O
when	O
evaluating	O
one	O
's	O
own	O
or	O
another	O
person	O
's	O
specific	O
trait	O
;	O
individuals	O
with	O
ASD	O
critically	O
lack	O
this	O
social	O
skill	O
.	O

To	O
examine	O
how	O
perspective	O
-	O
dependent	O
self-	O
and	O
other-	O
evaluation	O
processes	O
modulate	O
functional	O
connectivity	O
in	O
ASD	O
,	O
we	O
conducted	O
an	O
fMRI	B-P
study	O
in	O
which	O
26	O
high-functioning	O
adults	O
with	O
ASD	O
and	O
24	O
typically	O
developed	O
(	O
TD	O
)	O
controls	O
were	O
asked	O
to	O
decide	O
whether	O
an	O
adjective	O
describing	O
a	O
personality	O
trait	O
correctly	O
described	O
the	O
participant	O
himself/herself	O
(	O
``	O
self	O
``	O
)	O
or	O
the	O
participant	O
's	O
mother	O
(	O
``	O
other	O
''	O
)	O
by	O
taking	O
either	O
the	O
first	O
(	O
1P	O
)	O
or	O
third	O
person	O
(	O
3P	O
)	O
perspective	O
.	O

We	O
observed	O
that	O
functional	O
connectivity	O
between	O
the	O
left	O
sensorimotor	O
cortex	O
and	O
the	O
left	O
middle	O
cingulate	O
cortex	O
was	O
enhanced	O
in	O
TD	O
taking	O
the	O
3P	O
perspective	O
,	O
this	O
enhancement	O
was	O
significantly	O
reduced	O
in	O
ASD	O
,	O
and	O
the	O
degree	O
of	O
reduction	O
was	O
significantly	O
correlated	O
with	O
the	O
severity	O
of	O
autistic	O
traits	O
.	O

Furthermore	O
,	O
the	O
self-reference	O
effect	O
on	O
functional	O
connectivity	O
between	O
the	O
left	O
inferior	O
frontal	O
cortex	O
and	O
frontopolar	O
cortices	O
was	O
significantly	O
enhanced	O
in	O
TD	O
taking	O
the	O
3P	O
perspective	O
,	O
whereas	O
such	O
effect	O
was	O
reversed	O
in	O
ASD	O
.	O

These	O
findings	O
indicate	O
altered	O
effects	O
of	O
perspective	O
on	O
the	O
functional	O
connectivity	O
,	O
which	O
may	O
underlie	O
the	O
deficits	O
in	O
social	O
interaction	O
and	O
communication	O
observed	O
in	O
individuals	O
with	O
ASD	O
.	O

Recommendations	O
for	O
CSF	O
AD	O
biomarkers	O
in	O
the	O
diagnostic	B-P
evaluation	O
of	O
dementia	O
.	O

This	O
article	O
presents	O
recommendations	O
,	O
based	O
on	O
the	O
Grading	O
of	O
Recommendations	O
,	O
Assessment	O
,	O
Development	O
,	O
and	O
Evaluation	O
method	O
,	O
for	O
the	O
clinical	O
application	O
of	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
amyloid-β1-42	O
,	O
tau	O
,	O
and	O
phosphorylated	O
tau	O
in	O
the	O
diagnostic	B-P
evaluation	O
of	O
patients	O
with	O
dementia	O
.	O

The	O
recommendations	O
were	O
developed	O
by	O
a	O
multidisciplinary	O
working	O
group	O
based	O
on	O
the	O
available	O
evidence	O
and	O
consensus	O
from	O
focused	O
discussions	O
for	O
(	O
i	O
)	O
identification	O
of	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
as	O
the	O
cause	O
of	O
dementia	O
,	O
(	O
ii	O
)	O
prediction	O
of	O
rate	O
of	O
decline	O
,	O
(	O
iii	O
)	O
cost-effectiveness	O
,	O
and	O
(	O
iv	O
)	O
interpretation	O
of	O
results	O
.	O

The	O
working	O
group	O
found	O
sufficient	O
evidence	O
to	O
support	O
a	O
recommendation	O
to	O
use	O
CSF	O
AD	O
biomarkers	O
as	O
a	O
supplement	O
to	O
clinical	O
evaluation	O
,	O
particularly	O
in	O
uncertain	O
and	O
atypical	O
cases	O
,	O
to	O
identify	O
or	O
exclude	O
AD	O
as	O
the	O
cause	O
of	O
dementia	O
.	O

Because	O
of	O
insufficient	O
evidence	O
,	O
it	O
was	O
uncertain	O
whether	O
CSF	O
AD	O
biomarkers	O
outperform	O
imaging	O
biomarkers	O
.	O

Operational	O
recommendations	O
for	O
the	O
interpretation	O
of	O
ambiguous	O
CSF	O
biomarker	O
results	O
were	O
also	O
provided	O
.	O

Hip	O
segmentation	O
from	O
MRI	B-P
volumes	O
in	O
infants	O
for	O
DDH	O
diagnosis	O
and	O
treatment	O
planning	O
.	O

Diagnosis	O
and	O
surgical	O
management	O
of	O
Developmental	O
Dysplasia	O
of	O
the	O
Hip	O
(	O
DDH	O
)	O
relies	O
on	O
physical	O
examination	O
and	O
2D	O
ultrasound	B-P
scanning	I-P
.	O

Magnetic	B-P
Resonance	I-P
Imaging	I-P
(	O
MRI	B-P
)	O
can	O
be	O
used	O
to	O
complement	O
existing	O
techniques	O
and	O
could	O
be	O
advantageous	O
in	O
treatment	O
planning	O
due	O
to	O
its	O
larger	O
field	O
of	O
view	O
.	O

In	O
this	O
paper	O
we	O
propose	O
a	O
semi-automatic	O
method	O
to	O
segment	O
surface	O
models	O
of	O
the	O
acetabulum	O
from	O
MRI	B-P
images	O
.	O

The	O
method	O
incorporates	O
clinical	O
knowledge	O
in	O
the	O
form	O
of	O
intensity	O
priors	O
which	O
are	O
integrated	O
into	O
a	O
Random	O
Walker	O
(	O
RW	O
)	O
formulation	O
.	O

We	O
use	O
a	O
modified	O
RW	O
framework	O
which	O
compensates	O
for	O
incomplete	O
or	O
blurred	O
boundaries	O
in	O
the	O
image	O
by	O
using	O
information	O
from	O
neighboring	O
slices	O
in	O
the	O
sequence	O
incorporated	O
as	O
node	O
weights	O
.	O

We	O
conducted	O
a	O
pilot	O
study	O
to	O
evaluate	O
the	O
segmentation	O
on	O
a	O
set	O
of	O
10	O
infant	O
hip	O
MRI	B-P
sequences	O
using	O
a	O
1.5	O
Tesla	O
MR	O
scanner	O
.	O

Contours	O
obtained	O
from	O
the	O
semi-automated	O
segmentation	O
were	O
compared	O
against	O
manually	O
segmented	O
hip	O
contours	O
using	O
Dice	O
Ratio	O
(	O
DR	O
)	O
,	O
Hausdorff	O
Distance	O
(	O
HD	O
)	O
and	O
Root	O
Mean	O
Square	O
(	O
RMS	O
)	O
distance	O
.	O

The	O
proposed	O
method	O
gave	O
values	O
of	O
(	O
DR	O
=	O
0.84	O
±	O
0.5	O
,	O
HD	O
=3.0	O
±	O
0.7	O
,	O
RMS	O
=1.9	O
±	O
0.3	O
)	O
and	O
(	O
DR	O
=0.86	O
±	O
0.2	O
,	O
HD	O
=3.0	O
±	O
0.1	O
,	O
RMS	O
=	O
2.0	O
±	O
0.6	O
)	O
for	O
right	O
and	O
left	O
acetabular	O
contours	O
respectively	O
which	O
was	O
higher	O
than	O
the	O
corresponding	O
values	O
obtained	O
from	O
conventional	O
RW	O
segmentation	O
.	O

The	O
execution	O
time	O
of	O
the	O
segmentation	O
algorithm	O
was	O
less	O
than	O
~4	O
seconds	O
on	O
a	O
3.5	O
GHz	O
CPU	O
.	O

Maternal	O
vascular	O
responses	O
to	O
hypoxia	O
in	O
a	O
rat	O
model	O
of	O
intrauterine	O
growth	O
restriction	O
.	O

Intrauterine	O
growth	O
restriction	O
(	O
IUGR	O
)	O
is	O
a	O
common	O
pregnancy	O
complication	O
and	O
is	O
a	O
leading	O
cause	O
of	O
fetal	O
morbidity	O
and	O
mortality	O
.	O

Placental	O
hypoxia	O
contributes	O
to	O
adverse	O
fetal	O
consequences	O
,	O
such	O
as	O
IUGR	O
.	O

Exposing	O
pregnant	O
rats	O
to	O
hypoxia	O
can	O
lead	O
to	O
IUGR	O
;	O
however	O
,	O
assessment	O
of	O
maternal	O
vascular	O
function	O
in	O
a	O
rat	O
model	O
of	O
hypoxia	O
,	O
and	O
the	O
mechanisms	O
that	O
may	O
contribute	O
to	O
adverse	O
pregnancy	O
outcomes	O
,	O
has	O
not	O
been	O
extensively	O
studied	O
.	O

We	O
hypothesized	O
that	O
exposing	O
pregnant	O
rats	O
to	O
hypoxia	O
will	O
affect	O
maternal	O
systemic	O
vascular	O
function	O
and	O
increase	O
the	O
uterine	O
artery	O
resistance	O
index	O
(	O
RI	O
)	O
,	O
which	O
will	O
be	O
associated	O
with	O
IUGR	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
pregnant	O
rats	O
were	O
kept	O
in	O
normoxia	O
(	O
21	O
%	O
O2	O
)	O
or	O
hypoxia	O
(	O
11	O
%	O
O2	O
)	O
from	O
gestational	O
day	O
(	O
GD	O
)	O
6	O
to	O
20	O
Maternal	O
blood	O
pressure	O
,	O
uteroplacental	O
resistance	O
index	O
(	O
RI	O
)	O
(	O
ultrasound	B-P
biomicroscopy	I-P
)	O
,	O
and	O
vascular	O
function	O
(	O
wire	B-P
myography	I-P
)	O
were	O
assessed	O
in	O
uterine	O
and	O
mesenteric	O
arteries	O
.	O

Fetal	O
weight	O
was	O
significantly	O
reduced	O
(	O
P	O
<	O
0.001	O
)	O
,	O
while	O
maternal	O
blood	O
pressure	O
was	O
increased	O
(	O
P	O
<	O
0.05	O
)	O
in	O
rats	O
exposed	O
to	O
hypoxia	O
.	O

Maternal	O
vascular	O
function	O
was	O
also	O
affected	O
after	O
exposure	O
to	O
hypoxia	O
,	O
including	O
impaired	O
endothelium	O
-dependent	O
vasodilation	O
responses	O
to	O
methacholine	O
in	O
isolated	O
uterine	O
arteries	O
(	O
pEC50	O
normoxia	O
:	O
6.55	O
±	O
0.23	O
vs.	O
hypoxia	O
:	O
5.02	O
±	O
0.35	O
,	O
P	O
<	O
0.01	O
)	O
and	O
a	O
reduced	O
uterine	O
artery	O
RI	O
in	O
vivo	O
(	O
normoxia	O
:	O
0.63	O
±	O
0.04	O
vs.	O
hypoxia	O
:	O
0.53	O
±	O
0.01	O
,	O
P	O
<	O
0.05	O
)	O
;	O
associated	O
with	O
an	O
increase	O
in	O
umbilical	O
vein	O
RI	O
(	O
normoxia	O
:	O
0.35	O
±	O
0.02	O
vs.	O
hypoxia	O
:	O
0.45	O
±	O
0.04	O
,	O
P	O
<	O
0.05	O
)	O
.	O

These	O
data	O
demonstrate	O
maternal	O
and	O
fetal	O
alterations	O
in	O
vascular	O
function	O
due	O
to	O
prenatal	O
exposure	O
to	O
hypoxia	O
.	O

Further	O
,	O
although	O
there	O
was	O
a	O
compensatory	O
reduction	O
in	O
uterine	O
artery	O
RI	O
in	O
the	O
hypoxia	O
groups	O
,	O
this	O
was	O
not	O
sufficient	O
to	O
prevent	O
IUGR	O
.	O

Development	O
of	O
a	O
platelet	O
adhesion	O
transport	O
equation	O
for	O
a	O
computational	O
thrombosis	O
model	O
.	O

Thrombosis	O
is	O
a	O
significant	O
issue	O
for	O
cardiovascular	O
device	O
development	O
and	O
use	O
.	O

While	O
thrombosis	O
models	O
are	O
available	O
,	O
very	O
few	O
are	O
device	O
-	O
related	O
and	O
none	O
have	O
been	O
thoroughly	O
validated	O
experimentally	O
.	O

Here	O
,	O
we	O
introduce	O
a	O
surface	O
adherent	O
platelet	O
transport	O
equation	O
into	O
a	O
continuum	O
model	O
to	O
account	O
for	O
the	O
biomaterial	O
interface/blood	O
interaction	O
.	O

Using	O
a	O
rotating	O
disc	O
system	O
and	O
polyurethane-urea	O
material	O
,	O
we	O
characterize	O
steady	O
and	O
pulsatile	O
flow	O
fields	O
using	O
laser	B-P
Doppler	I-P
velocimetry	I-P
.	O

In	O
vitro	O
measurements	O
of	O
platelet	O
adhesion	O
are	O
used	O
in	O
combination	O
with	O
the	O
LDV	B-P
data	O
to	O
provide	O
further	O
experimental	O
validation	O
.	O

The	O
rotating	O
disc	O
system	O
is	O
computationally	O
studied	O
using	O
the	O
device	O
-	O
induced	O
thrombosis	O
model	O
with	O
the	O
surface	O
platelet	O
adherent	O
transport	O
equation	O
.	O

The	O
results	O
indicate	O
that	O
the	O
flow	O
field	O
is	O
in	O
excellent	O
agreement	O
to	O
the	O
experimental	O
LDV	B-P
data	O
and	O
that	O
the	O
platelet	O
adhesion	O
simulations	O
are	O
in	O
good	O
agreement	O
with	O
the	O
in	O
vitro	O
platelet	O
data	O
.	O

These	O
results	O
provide	O
good	O
evidence	O
that	O
this	O
transport	O
equation	O
can	O
be	O
used	O
to	O
express	O
the	O
relationship	O
between	O
blood	O
and	O
a	O
biomaterial	O
if	O
the	O
correct	O
platelet	O
adhesion	O
characteristics	O
are	O
known	O
for	O
the	O
biomaterial	O
.	O

Further	O
validation	O
is	O
necessary	O
with	O
other	O
materials	O
.	O

A	O
Single	O
Nanoprobe	O
for	O
Ratiometric	B-P
Imaging	I-P
and	O
Biosensing	O
of	O
Hypochlorite	O
and	O
Glutathione	O
in	O
Live	O
Cells	O
Using	O
Surface-Enhanced	O
Raman	O
Scattering	O
.	O

Hypochlorite	O
(	O
ClO	O
(	O
-	O
)	O
)	O
and	O
glutathione	O
(	O
GSH	O
)	O
have	O
been	O
reported	O
to	O
closely	O
correlate	O
with	O
oxidative	O
stress	O
and	O
related	O
diseases	O
;	O
however	O
,	O
a	O
clear	O
mechanism	O
is	O
still	O
unknown	O
,	O
mainly	O
owing	O
to	O
a	O
lack	O
of	O
accurate	O
analytical	O
methods	O
for	O
live	O
cells	O
.	O

Herein	O
we	O
create	O
a	O
novel	O
surface-enhanced	O
Raman	O
scattering	O
(	O
SERS	O
)	O
nanoprobe	O
,	O
4-mercaptophenol	O
(	O
4-MP	O
)	O
-functionalized	O
gold	O
flowers	O
(	O
AuF	O
/	O
MP	O
)	O
,	O
for	O
imaging	B-P
and	O
biosensing	O
of	O
ClO	O
(	O
-	O
)	O
and	O
GSH	O
in	O
RAW	O
264.7	O
macrophage	O
cells	O
upon	O
oxidative	O
stress	O
.	O

The	O
SERS	O
spectra	O
of	O
AuF	O
/	O
MP	O
change	O
with	O
the	O
reaction	O
between	O
ClO	O
(	O
-	O
)	O
and	O
4-MP	O
on	O
AuFs	O
within	O
1	O
min	O
and	O
then	O
recover	O
after	O
reaction	O
with	O
GSH	O
,	O
resulting	O
in	O
the	O
ratiometric	O
detection	O
of	O
ClO	O
(	O
-	O
)	O
and	O
GSH	O
with	O
high	O
accuracy	O
.	O

The	O
single	O
SERS	O
probe	O
also	O
shows	O
high	O
selectivity	O
for	O
ClO	O
(	O
-	O
)	O
and	O
GSH	O
detection	O
against	O
other	O
reactive	O
oxygen	O
species	O
and	O
amino	O
acids	O
which	O
may	O
exist	O
in	O
biological	O
systems	O
,	O
as	O
well	O
as	O
remarkable	O
sensitivity	O
ascribed	O
to	O
a	O
larger	O
amount	O
of	O
hot	O
spots	O
on	O
AuFs	O
.	O

The	O
significant	O
analytical	O
performance	O
of	O
the	O
developed	O
nanoprobe	O
,	O
together	O
with	O
good	O
biocompatibility	O
and	O
high	O
cell-permeability	O
,	O
enables	O
the	O
present	O
SERS	B-P
probe	I-P
imaging	I-P
and	O
real-time	O
detection	O
of	O
ClO	O
(	O
-	O
)	O
and	O
GSH	O
in	O
live	O
cells	O
upon	O
oxidative	O
stress	O
.	O

One-hour	O
post-load	O
hyperglycemia	O
combined	O
with	O
HbA1c	O
identifies	O
pre-diabetic	O
individuals	O
with	O
a	O
higher	O
cardio-metabolic	O
risk	O
burden	O
.	O

Evidence	O
suggests	O
that	O
combining	O
1-hour	O
plasma	O
glucose	O
≥155	O
mg/dl	O
during	O
an	O
oral	B-P
glucose	I-P
tolerance	I-P
test	I-P
(	O
OGTT	B-P
)	O
with	O
glycosylated	O
hemoglobin	O
(	O
HbA1c	O
)	O
significantly	O
increases	O
their	O
predictive	O
power	O
for	O
incident	O
diabetes	O
,	O
while	O
their	O
individual	O
and	O
joint	O
associations	O
with	O
cardio-metabolic	O
risk	O
factors	O
remain	O
undefined	O
.	O

Herein	O
,	O
we	O
evaluated	O
whether	O
1-hour	O
post-load	O
plasma	O
glucose	O
≥155	O
mg/dl	O
combined	O
with	O
HbA1c	O
may	O
identify	O
pre-diabetic	O
individuals	O
with	O
a	O
higher	O
cardio-metabolic	O
risk	O
.	O

Anthropometric	B-P
and	O
metabolic	O
characteristics	O
,	O
insulin	O
sensitivity	O
and	O
insulin	O
secretion	O
assessed	O
by	O
OGTT	B-P
-derived	O
indexes	O
,	O
carotid	O
intima-media	O
thickness	O
(	O
IMT	O
)	O
,	O
pulse	O
pressure	O
,	O
and	O
rate	O
pressure	O
product	O
were	O
evaluated	O
in	O
1495	O
individuals	O
.	O

As	O
compared	O
with	O
subjects	O
with	O
1-hour	O
post-load	O
glucose	O
<	O
155	O
mg/dl	O
,	O
individuals	O
with	O
1-hour	O
post-load	O
glucose	O
≥155	O
mg/dl	O
exhibited	O
a	O
significantly	O
worse	O
cardio	O
metabolic	O
profile	O
,	O
both	O
in	O
the	O
group	O
with	O
HbA1c	O
<	O
5.7	O
%	O
,	O
and	O
in	O
the	O
group	O
with	O
prediabetes	O
(	O
HbA1c	O
5.7-6.4	O
%	O
)	O
.	O

Specifically	O
,	O
in	O
both	O
groups	O
,	O
subjects	O
with	O
1-hour	O
post-load	O
glucose	O
≥155	O
mg/dl	O
had	O
higher	O
fasting	O
and	O
2-h	O
post-load	O
glucose	O
(	O
p	O
<	O
0.0001	O
for	O
all	O
in	O
both	O
group	O
s	O
)	O
,	O
higher	O
HOMA-IR	O
(	O
p	O
<	O
0.0001	O
in	O
both	O
groups	O
)	O
,	O
and	O
carotid	O
IMT	O
(	O
p	O
=	O
0.05	O
in	O
the	O
group	O
with	O
HbA1c	O
<	O
5.7	O
%	O
and	O
p	O
=	O
0.03	O
in	O
the	O
group	O
HbA1c	O
5.7-6.4	O
%	O
)	O
,	O
as	O
well	O
as	O
lower	O
Matsuda	O
index	O
,	O
insulinogenic	O
index	O
and	O
disposition	O
index	O
(	O
p	O
<	O
0.0001	O
in	O
both	O
groups	O
)	O
,	O
and	O
lower	O
insulin	O
-	O
stimulated	O
glucose	O
disposal	O
(	O
p	O
<	O
0.0001	O
in	O
the	O
group	O
with	O
HbA1c	O
<	O
5.7	O
%	O
and	O
p	O
=	O
0.03	O
in	O
the	O
group	O
HbA1c	O
5.7-6.4	O
%	O
)	O
.	O

Hyperglycemia	O
at	O
1-hour	O
during	O
an	O
OGTT	B-P
may	O
be	O
a	O
useful	O
tool	O
to	O
identify	O
a	O
subset	O
of	O
individuals	O
within	O
HbA1c	O
-defined	O
glycemic	O
categories	O
at	O
higher	O
risk	O
of	O
developing	O
type	O
2	O
diabetes	O
and	O
cardiovascular	O
disease	O
.	O

The	O
effects	O
of	O
a	O
data	O
driven	O
maximum	O
surgical	O
blood	O
ordering	O
schedule	O
on	O
preoperative	O
blood	O
ordering	O
practices	O
.	O

The	O
maximum	O
surgical	O
blood	O
ordering	O
schedule	O
(	O
MSBOS	O
)	O
provides	O
guidelines	O
for	O
pre-operative	O
pre-transfusion	O
testing	B-P
for	O
elective	O
surgical	O
procedures	O
.	O

This	O
study	O
compared	O
blood	O
ordering	O
and	O
utilization	O
during	O
the	O
period	O
when	O
the	O
MSBOS	O
was	O
created	O
by	O
achieving	O
consensus	O
between	O
the	O
blood	O
bank	O
and	O
the	O
various	O
surgical	O
specialties	O
,	O
and	O
after	O
the	O
introduction	O
of	O
an	O
MSBOS	O
created	O
by	O
using	O
department-specific	O
red	O
blood	O
cell	O
(	O
RBC	O
)	O
transfusion	O
data	O
(	O
data	O
driven	O
MSBOS	O
,	O
dMSBOS	O
)	O
.	O

The	O
dMSBOS	O
was	O
created	O
by	O
analyzing	O
12	O
months	O
of	O
RBC	O
transfusion	O
data	O
for	O
each	O
procedure	O
across	O
a	O
regional	O
health	O
system	O
.	O

Pre-transfusion	O
testing	B-P
and	O
the	O
RBC	O
crossmatch	O
:	O
transfusion	O
(	O
C	O
:	O
T	O
)	O
ratios	O
at	O
8	O
of	O
the	O
hospitals	O
were	O
compared	O
between	O
the	O
12	O
month	O
period	O
before	O
the	O
dMSBOS	O
was	O
introduced	O
,	O
and	O
the	O
15	O
months	O
after	O
its	O
introduction	O
.	O

There	O
were	O
significant	O
reductions	O
in	O
the	O
median	O
monthly	O
number	O
of	O
type	O
and	O
screens	O
not	O
associated	O
with	O
RBC	O
crossmatches	O
(	O
10	O
714-10	O
061	O
;	O
p	O
<	O
0.0001	O
)	O
and	O
the	O
median	O
number	O
of	O
type	O
and	O
screens	O
associated	O
with	O
RBC	O
crossmatches	O
(	O
10	O
127-9	O
349	O
;	O
p	O
=	O
0.0014	O
)	O
on	O
surgical	O
patients	O
after	O
dMSBOS	O
implementation	O
.	O

There	O
were	O
significant	O
decreases	O
in	O
the	O
median	O
number	O
of	O
monthly	O
RBC	O
units	O
crossmatched	O
(	O
2	O
981-2	O
444	O
;	O
p	O
<	O
0.0001	O
)	O
and	O
transfused	O
(	O
890-791	O
;	O
p	O
<	O
0.0001	O
)	O
to	O
surgical	O
patients	O
after	O
implementing	O
the	O
dMSBOS	O
.	O

The	O
overall	O
system-wide	O
C	O
:	O
T	O
ratio	O
trended	O
down	O
after	O
dMSBOS	O
implementation	O
(	O
from	O
3.34	O
to	O
3.17	O
,	O
p	O
=	O
0.067	O
)	O
.	O

Crossmatching	O
fewer	O
RBC	O
units	O
facilitates	O
more	O
efficient	O
management	O
of	O
the	O
blood	O
bank	O
's	O
inventory	O
.	O

The	O
dMSBOS	O
was	O
effective	O
in	O
reducing	O
the	O
extent	O
of	O
unnecessary	O
pre-transfusion	O
testing	B-P
before	O
surgery	O
and	O
reduced	O
the	O
number	O
of	O
RBCs	O
that	O
were	O
crossmatched	O
for	O
specific	O
patients	O
.	O

Relationship	O
between	O
polycythemia	O
and	O
in-hospital	O
mortality	O
in	O
chronic	O
obstructive	O
pulmonary	O
disease	O
patients	O
with	O
low-risk	O
pulmonary	O
embolism	O
.	O

Pulmonary	O
embolism	O
(	O
PE	O
)	O
is	O
frequent	O
in	O
subjects	O
with	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
and	O
associated	O
with	O
high	O
mortality	O
.	O

This	O
multi-center	O
retrospective	O
study	O
was	O
performed	O
to	O
investigate	O
if	O
secondary	O
polycythemia	O
is	O
associated	O
with	O
in-hospital	O
mortality	O
in	O
COPD	O
patients	O
with	O
low-risk	O
PE	O
.	O

We	O
identified	O
COPD	O
patients	O
with	O
proven	O
PE	O
between	O
October	O
,	O
2005	O
and	O
October	O
,	O
2015	O
.	O

Patients	O
in	O
risk	O
classes	O
III-V	O
on	O
the	O
basis	O
of	O
the	O
PESI	O
score	O
were	O
excluded	O
.	O

We	O
extracted	O
demographic	O
,	O
clinical	O
and	O
laboratory	O
information	O
at	O
the	O
time	O
of	O
admission	O
from	O
medical	O
records	O
.	O

All	O
subjects	O
were	O
followed	O
until	O
hospital	O
discharge	O
to	O
identify	O
all-cause	O
mortality	O
.	O

We	O
enrolled	O
629	O
consecutive	O
patients	O
with	O
COPD	O
and	O
PE	O
at	O
low	O
risk	O
:	O
132	O
of	O
them	O
(	O
21.0	O
%	O
)	O
with	O
and	O
497	O
(	O
79.0	O
%	O
)	O
without	O
secondary	O
polycythemia	O
.	O

Compared	O
with	O
those	O
without	O
polycythemia	O
,	O
the	O
polycythemia	O
group	O
had	O
significantly	O
lower	O
forced	B-P
expiratory	I-P
volume	I-P
in	I-P
one	I-P
second	I-P
(	I-P
FEV1	I-P
)	I-P
level	I-P
(	O
0.9±0.3	O
vs.	O
1.4±0.5	O
,	O
P=0.000	O
)	O
,	O
lower	O
PaO2	O
and	O
SpO2	O
as	O
well	O
as	O
higher	O
PaCO2	O
(	O
P=0.03	O
,	O
P=0.03	O
and	O
P=0.000	O
,	O
respectively	O
)	O
.	O

COPD	O
patients	O
with	O
polycythemia	O
had	O
a	O
higher	O
proportion	O
of	O
arrhythmia	O
in	O
electrocardiogram	O
(	O
ECG	O
)	O
(	O
49.5	O
%	O
vs.	O
35.7	O
%	O
,	O
P=0.02	O
)	O
,	O
a	O
longer	O
hospital	O
duration	O
time	O
(	O
15.3±10.1	O
vs.	O
9.7±9.1	O
,	O
P=0.001	O
)	O
,	O
a	O
higher	O
mechanical	O
ventilation	O
rate	O
(	O
noninvasive	O
and	O
invasive	O
,	O
51.7	O
%	O
vs.	O
30.3	O
%	O
,	O
P=0.04	O
and	O
31.0	O
%	O
vs.	O
7.9	O
%	O
,	O
P=0.04	O
,	O
respectively	O
)	O
,	O
and	O
a	O
higher	O
in-hospital	O
mortality	O
(	O
12.1	O
%	O
vs.	O
6.6	O
%	O
,	O
P=0.04	O
)	O
.	O

Multivariate	O
logistic	O
regression	O
analysis	O
revealed	O
that	O
polycythemia	O
was	O
associated	O
with	O
mortality	O
in	O
COPD	O
patients	O
with	O
low-risk	O
PE	O
(	O
adjusted	O
OR	O
1.11	O
;	O
95	O
%	O
CI	O
,	O
1.04-1.66	O
)	O
.	O

Polycythemia	O
is	O
an	O
independent	O
risk	O
factor	O
for	O
all-cause	O
in-hospital	O
mortality	O
in	O
COPD	O
patients	O
with	O
PE	O
at	O
low	O
risk	O
.	O

Discovery	O
and	O
Optimization	O
of	O
a	O
Novel	O
Triazole	O
Series	O
of	O
GPR142	O
Agonists	O
for	O
the	O
Treatment	O
of	O
Type	O
2	O
Diabetes	O
.	O

GPR142	O
has	O
been	O
identified	O
as	O
a	O
potential	O
glucose-stimulated	O
insulin	O
secretion	O
(	O
GSIS	O
)	O
target	O
for	O
the	O
treatment	O
of	O
type	O
2	O
diabetes	O
mellitus	O
(	O
T2DM	O
)	O
.	O

A	O
class	O
of	O
triazole	O
GPR142	O
agonists	O
was	O
discovered	O
through	O
a	O
high	B-P
throughput	I-P
screen	I-P
.	O

The	O
lead	O
compound	O
4	O
suffered	O
from	O
poor	O
metabolic	O
stability	O
and	O
poor	O
solubility	O
.	O

Lead	O
optimization	O
strategies	O
to	O
improve	O
potency	O
,	O
efficacy	O
,	O
metabolic	O
stability	O
,	O
and	O
solubility	O
are	O
described	O
.	O

This	O
optimization	O
led	O
to	O
compound	O
20e	O
,	O
which	O
showed	O
significant	O
reduction	O
of	O
glucose	O
excursion	O
in	O
wild-type	O
but	O
not	O
in	O
GPR142	O
deficient	O
mice	O
in	O
an	O
oral	B-P
glucose	I-P
tolerance	I-P
test	I-P
(	O
oGTT	B-P
)	O
study	O
.	O

These	O
studies	O
provide	O
strong	O
evidence	O
that	O
reduction	O
of	O
glucose	O
excursion	O
through	O
treatment	O
with	O
20e	O
is	O
GPR142	O
-mediated	O
,	O
and	O
GPR142	O
agonists	O
could	O
be	O
used	O
as	O
a	O
potential	O
treatment	O
for	O
type	O
2	O
diabetes	O
.	O

Visual	O
outcome	O
,	O
endocrine	O
function	O
and	O
tumor	O
control	O
after	O
fractionated	O
stereotactic	O
radiation	O
therapy	O
of	O
craniopharyngiomas	O
in	O
adults	O
:	O
findings	O
in	O
a	O
prospective	O
cohort	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
examine	O
visual	O
outcome	O
,	O
endocrine	O
function	O
and	O
tumor	O
control	O
in	O
a	O
prospective	O
cohort	O
of	O
craniopharyngioma	O
patients	O
,	O
treated	O
with	O
fractionated	O
stereotactic	O
radiation	O
therapy	O
(	O
FSRT	O
)	O
.	O

Sixteen	O
adult	O
patients	O
with	O
craniopharyngiomas	O
were	O
eligible	O
for	O
analysis	O
.	O

They	O
were	O
treated	O
with	O
linear	O
accelerator-based	O
FSRT	O
during	O
1999-2015	O
.	O

In	O
all	O
cases	O
,	O
diagnosis	O
was	O
confirmed	O
by	O
histological	O
analysis	O
.	O

The	O
prescription	O
dose	O
to	O
the	O
tumor	O
was	O
54	O
Gy	O
(	O
median	O
,	O
range	O
48-54	O
)	O
in	O
1.8	O
or	O
2.0	O
Gy	O
per	O
fraction	O
,	O
and	O
the	O
maximum	O
radiation	O
dose	O
to	O
the	O
optic	O
nerves	O
and	O
chiasm	O
was	O
54.2	O
Gy	O
(	O
median	O
,	O
range	O
48.6-60.0	O
)	O
for	O
the	O
cohort	O
.	O

Serial	O
ophthalmological	O
and	O
endocrine	O
evaluations	O
and	O
magnetic	B-P
resonance	I-P
imaging	I-P
(	O
MRI	B-P
)	O
scans	B-P
were	O
performed	O
at	O
regular	O
intervals	O
.	O

Median	O
follow-up	O
was	O
3.3	O
years	O
(	O
range	O
1.1-14.1	O
)	O
,	O
3.7	O
years	O
(	O
range	O
0.8-15.2	O
)	O
,	O
and	O
3.6	O
years	O
(	O
range	O
0.7-13.1	O
)	O
for	O
visual	O
outcome	O
,	O
endocrine	O
function	O
,	O
and	O
tumor	O
control	O
,	O
respectively	O
.	O

Visual	O
acuity	O
impairment	O
was	O
present	O
in	O
10	O
patients	O
(	O
62.5	O
%	O
)	O
and	O
visual	O
field	O
defects	O
were	O
present	O
in	O
12	O
patients	O
(	O
75	O
%	O
)	O
before	O
FSRT	O
.	O

One	O
patient	O
developed	O
radiation-induced	O
optic	O
neuropathy	O
at	O
seven	O
years	O
after	O
FSRT	O
.	O

Thirteen	O
of	O
16	O
patients	O
(	O
81.3	O
%	O
)	O
had	O
pituitary	O
deficiency	O
before	O
FSRT	O
,	O
and	O
did	O
not	O
develop	O
further	O
pituitary	O
deficiency	O
after	O
FSRT	O
.	O

Mean	O
tumor	O
volume	O
pre-	O
FSRT	O
was	O
2.72	O
cm	O
(	O
3	O
)	O
(	O
range	O
0.20-9.90	O
)	O
and	O
post-	O
FSRT	O
1.2	O
cm	O
(	O
3	O
)	O
(	O
range	O
0.00-13.10	O
)	O
.	O

Tumor	O
control	O
rate	O
was	O
81.3	O
%	O
at	O
two	O
,	O
five	O
,	O
and	O
10	O
years	O
after	O
FSRT	O
.	O

FSRT	O
was	O
relatively	O
safe	O
in	O
this	O
prospective	O
cohort	O
of	O
craniopharyngiomas	O
,	O
with	O
only	O
one	O
case	O
of	O
radiation-induced	O
optic	O
neuropathy	O
and	O
no	O
case	O
of	O
new	O
endocrinopathy	O
.	O

Tumor	O
control	O
rate	O
was	O
acceptable	O
.	O

Autoimmune	O
Myelofibrosis	O
in	O
Systemic	O
Lupus	O
Erythematosus	O
Report	O
of	O
Two	O
Cases	O
and	O
Review	O
of	O
the	O
Literature	O
.	O

Autoimmune	O
myelofibrosis	O
(	O
AIMF	O
)	O
is	O
a	O
rare	O
entity	O
of	O
steroid	O
-	O
responsive	O
bone	O
marrow	O
fibrosis	O
that	O
accompanies	O
a	O
variety	O
of	O
autoimmune	O
diseases	O
,	O
particularly	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
.	O

Rarely	O
it	O
may	O
occur	O
in	O
patients	O
with	O
autoimmune	O
markers	O
but	O
no	O
definable	O
autoimmune	O
disease	O
(	O
Primary-AIMF	O
)	O
.	O

We	O
report	O
the	O
cases	O
of	O
two	O
young	O
women	O
with	O
SLE	O
-	O
associated	O
AIMF	O
(	O
SLE	O
-	O
AIMF	O
)	O
.	O

The	O
first	O
patient	O
was	O
a	O
young	O
woman	O
who	O
had	O
pancytopenia	O
,	O
massive	O
splenomegaly	O
and	O
reticulin	O
fibrosis	O
in	O
the	O
marrow	B-P
biopsy	I-P
.	O

The	O
pancytopenia	O
and	O
splenomegaly	O
resolved	O
completely	O
within	O
weeks	O
of	O
treatment	O
with	O
corticosteroids	O
.	O

Repeat	O
marrow	B-P
biopsy	I-P
showed	O
marked	O
regression	O
of	O
marrow	O
fibrosis	O
.	O

The	O
second	O
patient	O
was	O
a	O
young	O
woman	O
with	O
fever	O
,	O
anasarca	O
,	O
bicytopenia	O
and	O
reticulin	O
fibrosis	O
in	O
the	O
marrow	B-P
biopsy	I-P
.	O

Steroid	O
therapy	O
resulted	O
in	O
rapid	O
clinical	O
improvement	O
and	O
resolution	O
of	O
pancytopenia	O
.	O

A	O
review	O
of	O
the	O
literature	O
revealed	O
a	O
total	O
of	O
30	O
patients	O
with	O
SLE	O
-	O
AIMF	O
reported	O
to-	O
date	O
.	O

Patients	O
with	O
SLE	O
-	O
AIMF	O
are	O
young	O
women	O
with	O
SLE	O
and	O
blood	O
cytopenia	O
who	O
are	O
found	O
to	O
have	O
increased	O
bone	O
marrow	O
reticulin	O
on	O
marrow	B-P
biopsy	I-P
.	O

Steroid	O
therapy	O
results	O
in	O
rapid	O
hematological	O
recovery	O
and	O
regression	O
of	O
marrow	O
fibrosis	O
.	O

Whether	O
AIMF	O
is	O
one	O
of	O
several	O
hematological	O
complications	O
of	O
SLE	O
,	O
or	O
represents	O
a	O
unique	O
and	O
distinct	O
subset	O
of	O
patients	O
with	O
SLE	O
in	O
not	O
clear	O
.	O

Prospective	O
studies	O
with	O
longer	O
follow-up	O
are	O
needed	O
to	O
better	O
define	O
the	O
prevalence	O
and	O
clinical	O
spectrum	O
of	O
SLE	O
-	O
AIMF	O
.	O

Relevance	O
of	O
ID3	O
-	O
TCF3	O
-	O
CCND3	O
pathway	O
mutations	O
in	O
pediatric	O
aggressive	O
B-cell	O
lymphoma	O
treated	O
according	O
to	O
the	O
NHL-BFM	O
protocols	O
.	O

Mature	O
B-cell	O
Non-Hodgkin	O
lymphoma	O
is	O
the	O
most	O
common	O
subtype	O
of	O
Non-Hodgkin	O
lymphoma	O
in	O
childhood	O
and	O
adolescence	O
.	O

B-cell	O
Non-Hodgkin	O
lymphoma	O
are	O
further	O
classified	O
into	O
histological	O
subtypes	O
,	O
with	O
Burkitt	O
lymphoma	O
and	O
Diffuse	O
large	O
B-cell	O
lymphoma	O
being	O
the	O
most	O
common	O
subgroups	O
in	O
pediatric	O
patients	O
.	O

Translocations	O
involving	O
the	O
MYC	O
oncogene	O
are	O
known	O
as	O
relevant	O
but	O
not	O
sufficient	O
hit	O
for	O
Burkitt	O
lymphoma	O
pathogenesis	O
.	O

Recently	O
published	O
large-scale	O
next-generation	O
sequencing	O
studies	O
unveiled	O
sets	O
of	O
additional	O
recurrently	O
mutated	O
genes	O
in	O
samples	O
of	O
pediatric	O
and	O
adult	O
B-cell	O
Non-Hodgkin	O
lymphoma	O
patients	O
.	O

ID3	O
,	O
TCF3	O
and	O
CCND3	O
are	O
potential	O
drivers	O
of	O
Burkitt-lymphomagenesis	O
.	O

In	O
the	O
present	O
study	O
frequency	O
and	O
clinical	O
relevance	O
of	O
mutations	O
in	O
ID3	O
,	O
TCF3	O
and	O
CCND3	O
were	O
analyzed	O
within	O
a	O
well-defined	O
cohort	O
of	O
84	O
uniformly	O
diagnosed	O
and	O
treated	O
pediatric	O
B-cell	O
Non-Hodgkin	O
lymphoma	O
patients	O
of	O
the	O
Berlin-Frankfurt-Munster	O
group	O
(	O
NHL-BFM	O
)	O
.	O

Mutation	O
frequency	O
was	O
78	O
%	O
(	O
ID3	O
)	O
,	O
13	O
%	O
(	O
TCF3	O
)	O
and	O
36	O
%	O
(	O
CCND3	O
)	O
in	O
Burkitt	O
lymphoma	O
(	O
including	O
Burkitt	O
leukemia	O
)	O
.	O

ID3	O
and	O
CCND3	O
mutations	O
were	O
associated	O
with	O
more	O
advanced	O
stages	B-P
of	I-P
the	I-P
disease	I-P
in	O
MYC	O
rearrangement	O
positive	O
Burkitt	O
lymphoma	O
.	O

In	O
conclusion	O
ID3	O
-	O
TCF3	O
-	O
CCND3	O
pathway	O
genes	O
are	O
mutated	O
in	O
more	O
than	O
88	O
%	O
of	O
MYC	O
-	O
rearranged	O
pediatric	O
B-cell	O
Non-Hodgkin	O
lymphoma	O
and	O
the	O
pathway	O
may	O
represent	O
a	O
highly	O
relevant	O
second	O
hit	O
of	O
Burkitt	O
lymphoma	O
pathogenesis	O
especially	O
in	O
children	O
and	O
adolescents	O
.	O

High-fructose	O
diet	O
is	O
as	O
detrimental	O
as	O
high-fat	O
diet	O
in	O
the	O
induction	O
of	O
insulin	O
resistance	O
and	O
diabetes	O
mediated	O
by	O
hepatic	O
/	O
pancreatic	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
stress	O
.	O

In	O
the	O
context	O
of	O
high	O
human	O
consumption	O
of	O
fructose	O
diets	O
,	O
there	O
is	O
an	O
imperative	O
need	O
to	O
understand	O
how	O
dietary	O
fructose	O
intake	O
influence	O
cellular	O
and	O
molecular	O
mechanisms	O
and	O
thereby	O
affect	O
β-cell	O
dysfunction	O
and	O
insulin	O
resistance	O
.	O

While	O
evidence	O
exists	O
for	O
a	O
relationship	O
between	O
high	O
-	O
fat	O
-	O
induced	O
insulin	O
resistance	O
and	O
metabolic	O
disorders	O
,	O
there	O
is	O
lack	O
of	O
studies	O
in	O
relation	O
to	O
high-fructose	O
diet	O
.	O

Therefore	O
,	O
we	O
attempted	O
to	O
study	O
the	O
effect	O
of	O
different	O
diets	O
viz.	O
,	O
high-fat	O
diet	O
(	O
HFD	O
)	O
,	O
high-fructose	O
diet	O
(	O
HFS	O
)	O
,	O
and	O
a	O
combination	O
(	O
HFS	O
+	O
HFD	O
)	O
diet	O
on	O
glucose	O
homeostasis	O
and	O
insulin	O
sensitivity	O
in	O
male	O
Wistar	O
rats	O
compared	O
to	O
control	O
animals	O
fed	O
with	O
normal	O
pellet	O
diet	O
.	O

Investigations	O
include	O
oral	B-P
glucose	I-P
tolerance	I-P
test	I-P
,	O
insulin	O
tolerance	O
test	O
,	O
histopathology	O
by	O
H	O
&	O
E	O
and	O
Masson	O
's	O
trichrome	O
staining	O
,	O
mRNA	O
expression	O
by	O
real-time	O
PCR	O
,	O
protein	O
expression	O
by	O
Western	O
blot	O
,	O
and	O
caspase-3	O
activity	O
by	O
colorimetry	O
.	O

Rats	O
subjected	O
to	O
high-fat	O
/	O
fructose	O
diets	O
became	O
glucose	O
intolerant	O
,	O
insulin-resistant	O
,	O
and	O
dyslipidemic	O
.	O

Compared	O
to	O
control	O
animals	O
,	O
rats	O
subjected	O
to	O
different	O
combination	O
of	O
fat	O
/	O
fructose	O
diets	O
showed	O
increased	O
mRNA	O
and	O
protein	O
expression	O
of	O
a	O
battery	O
of	O
ER	O
stress	O
markers	O
both	O
in	O
pancreas	O
and	O
liver	O
.	O

Transcription	O
factors	O
of	O
β-cell	O
function	O
(	O
INSIG1	O
,	O
SREBP1c	O
and	O
PDX1	O
)	O
as	O
well	O
as	O
hepatic	O
gluconeogenesis	O
(	O
FOXO1	O
and	O
PEPCK	O
)	O
were	O
adversely	O
affected	O
in	O
diet	O
-	O
induced	O
insulin-resistant	O
rats	O
.	O

The	O
convergence	O
of	O
chronic	O
ER	O
stress	O
towards	O
apoptosis	O
in	O
pancreas	O
/	O
liver	O
was	O
also	O
indicated	O
by	O
increased	O
levels	O
of	O
CHOP	O
mRNA	O
&	O
increased	O
activity	O
of	O
both	O
JNK	O
and	O
Caspase-3	O
in	O
rats	O
subjected	O
to	O
high-fat	O
/	O
fructose	O
diets	O
.	O

Our	O
study	O
exposes	O
the	O
experimental	O
support	O
in	O
that	O
high-fructose	O
diet	O
is	O
equally	O
detrimental	O
in	O
causing	O
metabolic	O
disorders	O
.	O

Successful	O
Fetal	B-P
Tele-Echo	I-P
at	O
a	O
Small	O
Regional	O
Hospital	O
.	O

Prenatal	B-P
diagnosis	I-P
of	O
complex	O
congenital	O
heart	O
disease	O
(	O
CHD	O
)	O
has	O
been	O
shown	O
to	O
improve	O
newborn	O
outcomes	O
.	O

The	O
rate	O
of	O
prenatal	B-P
diagnosis	I-P
and	O
access	O
to	O
fetal	B-P
echocardiography	I-P
vary	O
widely	O
across	O
the	O
United	O
States	O
.	O

A	O
clinical	B-P
fetal	I-P
tele-echo	I-P
service	O
was	O
established	O
at	O
King	O
's	O
Daughters	O
Medical	O
Center	O
(	O
KDMC	O
)	O
in	O
Ashland	O
,	O
KY	O
,	O
a	O
region	O
in	O
eastern	O
Kentucky	O
that	O
is	O
3	O
h	O
from	O
the	O
nearest	O
congenital	O
heart	O
surgeon	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
fetal	B-P
tele-echo	I-P
utilizing	O
local	O
sonographers	O
at	O
a	O
small	O
regional	O
hospital	O
can	O
accurately	O
and	O
efficiently	O
identify	O
fetuses	O
with	O
complex	O
CHD	O
.	O

Medical	O
records	O
were	O
reviewed	O
for	O
all	O
mother-infant	O
pairs	O
who	O
had	O
fetal	B-P
tele-echoes	I-P
performed	O
at	O
KDMC	O
and	O
interpreted	O
by	O
University	O
of	O
Louisville	O
pediatric	O
cardiology	O
between	O
March	O
2011	O
and	O
December	O
2013	O
.	O

Findings	O
on	O
fetal	B-P
tele-echo	I-P
were	O
compared	O
to	O
newborn	O
echo	B-P
and	O
clinical	O
course	O
,	O
and	O
divided	O
into	O
four	O
groups	O
:	O
(	O
1	O
)	O
Correct	O
-	O
no	O
difference	O
between	O
fetal	B-P
tele-echo	I-P
and	O
newborn	O
echo	B-P
,	O
(	O
2	O
)	O
Likely	O
Correct-normal	O
fetal	B-P
tele-echo	I-P
and	O
benign	O
newborn	O
course	O
,	O
(	O
3	O
)	O
Major	O
Difference	O
-one	O
that	O
affected	O
newborn	O
clinical	O
course	O
,	O
and	O
(	O
4	O
)	O
Minor	O
Difference	O
-did	O
not	O
affect	O
clinical	O
course	O
.	O

Seventy-five	O
mother-infant	O
pairs	O
were	O
analyzed	O
.	O

Fetal	B-P
tele-echoes	I-P
were	O
Correct	O
in	O
21	O
%	O
,	O
Likely	O
Correct	O
in	O
56	O
%	O
,	O
showed	O
Major	O
Differences	O
in	O
0	O
%	O
,	O
and	O
showed	O
Minor	O
Differences	O
in	O
23	O
%	O
.	O

For	O
identifying	O
complex	O
CHD	O
,	O
fetal	B-P
tele-echo	I-P
had	O
a	O
sensitivity	O
and	O
specificity	O
of	O
100	O
%	O
.	O

The	O
average	O
number	O
of	O
fetal	B-P
echocardiograms	I-P
per	O
mother-infant	O
pair	O
was	O
1.1	O
.	O

Fetal	B-P
tele-echocardiography	I-P
performed	O
by	O
local	O
sonographers	O
at	O
a	O
small	O
regional	O
hospital	O
can	O
accurately	O
and	O
efficiently	O
identify	O
fetuses	O
with	O
complex	O
CHD	O
.	O

Clinical	O
Significance	O
of	O
2	O
Deep	O
Posterior	O
Perianal	O
Spaces	O
to	O
Complex	O
Cryptoglandular	O
Fistulas	O
.	O

Confusion	O
exists	O
regarding	O
the	O
clinical	O
significance	O
of	O
the	O
deep	O
posterior	O
intersphincteric	O
space	O
and	O
deep	O
postanal	O
space	O
to	O
complex	O
perianal	O
fistulas	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
clinical	O
significance	O
of	O
the	O
2	O
deep	O
posterior	O
perianal	O
spaces	O
and	O
to	O
describe	O
in	O
detail	O
the	O
courses	O
of	O
posterior	O
complex	O
cryptoglandular	O
fistula	O
extensions	O
.	O

This	O
was	O
a	O
retrospective	O
study	O
.	O

MRI	B-P
-	O
based	O
characteristics	O
of	O
selected	O
perianal	O
fistulas	O
were	O
independently	O
evaluated	O
by	O
examiners	O
who	O
focused	O
on	O
lesions	O
in	O
these	O
2	O
spaces	O
and	O
were	O
blinded	O
to	O
each	O
other	O
's	O
findings	O
.	O

This	O
study	O
was	O
conducted	O
in	O
the	O
colorectal	O
surgery	O
and	O
radiology	O
departments	O
of	O
a	O
large	O
university	O
teaching	O
hospital	O
in	O
China	O
.	O

Included	O
in	O
the	O
study	O
were	O
patients	O
who	O
underwent	O
pelvic	B-P
MRI	I-P
for	O
posterior	O
perianal	O
fistula	O
between	O
October	O
2012	O
and	O
December	O
2014	O
.	O

The	O
occurrence	O
rates	O
of	O
these	O
2	O
deep	O
perianal	O
space	O
lesions	O
in	O
posterior	O
cryptoglandular	O
fistulas	O
were	O
determined	O
.	O

A	O
total	O
of	O
513	O
primary	O
posterior	O
cryptoglandular	O
fistulas	O
were	O
identified	O
in	O
508	O
patients	O
,	O
including	O
167	O
deep	O
posterior	O
intersphincteric	O
space	O
lesions	O
(	O
32.6	O
%	O
)	O
and	O
23	O
deep	O
postanal	O
space	O
lesions	O
(	O
4.5	O
%	O
)	O
.	O

Of	O
those	O
,	O
173	O
fistulas	O
(	O
33.7	O
%	O
)	O
were	O
evaluated	O
as	O
complex	O
.	O

The	O
former	O
and	O
latter	O
spaces	O
were	O
involved	O
in	O
79.2	O
%	O
(	O
137/173	O
)	O
and	O
13.3	O
%	O
(	O
23/173	O
)	O
of	O
posterior	O
complex	O
fistulas	O
.	O

Compared	O
with	O
deep	O
postanal	O
space	O
lesions	O
,	O
deep	O
posterior	O
intersphincteric	O
space	O
lesions	O
were	O
more	O
common	O
in	O
cases	O
with	O
high	O
transsphincteric	O
or	O
suprasphincteric	O
fistulas	O
(	O
80.1	O
%	O
vs	O
15.8	O
%	O
)	O
,	O
synchronous	O
multiple	O
transsphincteric	O
fistulas	O
(	O
82.4	O
%	O
vs	O
20.6	O
%	O
)	O
,	O
horseshoe-like	O
fistulas	O
(	O
85.5	O
%	O
vs	O
14.5	O
%	O
)	O
,	O
and	O
supralevator	O
fistulas	O
(	O
93.5	O
%	O
vs	O
16.1	O
%	O
)	O
.	O

Similar	O
incidences	O
were	O
also	O
seen	O
in	O
cases	O
with	O
ischioanal	O
-	O
involved	O
horseshoe-like	O
fistulas	O
(	O
75.0	O
%	O
vs	O
25.0	O
%	O
)	O
.	O

This	O
study	O
was	O
limited	O
by	O
its	O
retrospective	O
nature	O
.	O

The	O
deep	O
posterior	O
intersphincteric	O
space	O
is	O
more	O
likely	O
than	O
the	O
deep	O
postanal	O
space	O
to	O
be	O
involved	O
in	O
complex	O
cryptoglandular	O
fistulas	O
and	O
is	O
likely	O
to	O
play	O
a	O
more	O
important	O
role	O
in	O
the	O
management	O
of	O
complex	O
cryptoglandular	O
fistulas	O
.	O

Physical	O
and	O
virtual	O
modelling	O
of	O
the	O
head	O
and	O
neck	O
for	O
surgical	O
simulation	O
and	O
training	O
.	O

Investigation	O
and	O
surgical	O
manipulation	O
of	O
the	O
larynx	O
,	O
pharynx	O
,	O
and	O
oesophagus	O
suffer	O
from	O
inherent	O
challenges	O
with	O
access	O
to	O
the	O
sites	O
of	O
interest	O
.	O

To	O
reduce	O
trauma	O
and	O
external	O
scarring	O
,	O
visualization	O
and	O
minimally	O
invasive	O
interventions	O
by	O
the	O
transnasal	O
or	O
transoral	O
routes	O
have	O
become	O
more	O
prevalent	O
.	O

This	O
article	O
discusses	O
engineering	O
methods	O
used	O
to	O
understand	O
and	O
overcome	O
the	O
mechanical	O
constraints	O
inside	O
the	O
airway	O
and	O
upper	O
gastrointestinal	O
tract	O
,	O
and	O
examines	O
the	O
role	O
that	O
robotics	O
and	O
engineering	O
are	O
beginning	O
to	O
play	O
in	O
modelling	O
of	O
surgical	O
interventions	O
in	O
this	O
region	O
.	O

Although	O
robotic	O
solutions	O
to	O
minimally	O
invasive	O
surgery	O
of	O
the	O
airway	O
and	O
upper	O
gastrointestinal	O
tract	O
already	O
exist	O
,	O
there	O
is	O
still	O
scope	O
for	O
increasing	O
the	O
breadth	O
of	O
their	O
use	O
.	O

Physical	O
and	O
virtual	O
models	O
of	O
these	O
organs	O
are	O
used	O
to	O
investigate	O
the	O
capability	O
and	O
limitations	O
of	O
manual	O
and	O
robotic	O
surgical	O
interventions	O
in	O
this	O
region	O
.	O

Understanding	O
the	O
tissue	O
mechanics	O
and	O
tool	O
capabilities	O
is	O
central	O
to	O
improving	O
outcomes	O
in	O
the	O
clinical	O
setting	O
.	O

Both	O
physical	O
and	O
virtual	O
modelling	O
modalities	O
are	O
used	O
in	O
training	O
surgeons	O
for	O
both	O
manual	O
-	O
assisted	O
and	O
robot-assisted	O
surgeries	O
.	O

Minimally	O
invasive	O
surgical	O
interventions	O
via	O
the	O
transnasal	O
and	O
the	O
transoral	O
route	O
are	O
strong	O
candidates	O
for	O
overcoming	O
access	O
issues	O
to	O
the	O
airway	O
.	O

They	O
are	O
likely	O
to	O
become	O
more	O
robotically	O
driven	O
as	O
the	O
demand	O
for	O
higher	O
dexterity	O
and	O
accuracy	O
increases	O
for	O
fine	O
manipulation	O
.	O

Physical	O
and	O
virtual	B-P
organ	O
models	O
are	O
required	O
to	O
enable	O
surgical	O
training	O
for	O
these	O
procedures	O
.	O

Insulin	O
-mediated	O
hypoglycaemia	O
secondary	O
to	O
recurrent	O
clear	O
cell	O
renal	O
carcinoma	O
.	O

Renal	O
cell	O
carcinoma	O
has	O
previously	O
been	O
associated	O
with	O
hypoglycaemia	O
in	O
the	O
setting	O
of	O
non-islet	O
cell	O
tumours	O
,	O
caused	O
by	O
a	O
paraneoplastic	O
phenomenon	O
relating	O
to	O
the	O
production	O
of	O
insulin-like	O
growth	O
factor	O
type	O
II	O
.	O

We	O
present	O
a	O
case	O
of	O
recurrent	O
clear	O
cell	O
renal	O
cell	O
carcinoma	O
,	O
leading	O
to	O
an	O
insulin	O
-mediated	O
paraneoplastic	O
phenomenon	O
causing	O
severe	O
recurrent	O
hypoglycaemia	O
.	O

Hypoglycaemina	O
was	O
managed	O
successfully	O
using	O
diazoxide	O
therapy	O
,	O
in	O
conjunction	O
with	O
pazopanib	O
and	O
radiotherapy	O
to	O
reduce	O
tumour	B-P
burden	I-P
.	O

Patient	O
Factors	O
Associated	O
With	O
Higher	O
Expectations	O
From	O
Foot	O
and	O
Ankle	O
Surgery	O
.	O

Few	O
authors	O
have	O
investigated	O
patients	O
'	O
expectations	O
from	O
foot	O
and	O
ankle	O
surgery	O
.	O

In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
examine	O
relationships	O
between	O
patients	O
'	O
preoperative	O
expectations	O
and	O
their	O
demographic	O
and	O
clinical	O
characteristics	O
.	O

We	O
hypothesized	O
that	O
patients	O
with	O
more	O
disability	O
and	O
those	O
with	O
anxiety	O
or	O
depressive	O
symptoms	O
would	O
have	O
greater	O
expectations	O
.	O

All	O
adult	O
patients	O
scheduled	O
for	O
elective	O
foot	O
or	O
ankle	O
surgery	O
by	O
1	O
of	O
6	O
orthopaedic	O
foot	O
and	O
ankle	O
surgeons	O
were	O
screened	O
for	O
inclusion	O
over	O
8	O
months	O
.	O

Preoperatively	O
,	O
all	O
patients	O
completed	O
the	O
Hospital	O
for	O
Special	O
Surgery	O
Foot	O
&	O
Ankle	O
Surgery	O
Expectations	O
Survey	O
in	O
addition	O
to	O
the	O
Foot	O
&	O
Ankle	O
Outcome	O
Score	O
(	O
FAOS	O
)	O
,	O
Short	O
Form	O
(	O
SF	O
)	O
-12	O
,	O
Patient	O
Health	O
Questionnaire	O
(	O
PHQ	O
)	O
-8	O
,	O
Generalized	O
Anxiety	O
Disorder	O
7-item	O
scale	O
(	O
GAD-7	O
)	O
,	O
and	O
pain	B-P
visual	I-P
analog	I-P
scale	I-P
(	O
VAS	B-P
)	O
.	O

The	O
expectations	O
survey	O
contained	O
23	O
expectations	O
categories	O
,	O
each	O
with	O
5	O
answer	O
choices	O
ranging	O
from	O
``	O
I	O
do	O
not	O
have	O
this	O
expectation	O
``	O
to	O
``	O
complete	O
improvement	O
``	O
expected	O
.	O

It	O
was	O
scored	O
from	O
0	O
to	O
100	O
,	O
with	O
higher	O
scores	O
indicating	O
more	O
expectations	O
.	O

Differences	O
in	O
expectations	O
relating	O
to	O
numerous	O
patient	O
demographic	O
and	O
clinical	O
variables	O
were	O
assessed	O
.	O

In	O
total	O
,	O
352	O
patients	O
with	O
an	O
average	O
age	O
of	O
55	O
±	O
15	O
(	O
range	O
,	O
18-86	O
)	O
years	O
were	O
enrolled	O
.	O

Expectations	O
scores	O
were	O
not	O
related	O
to	O
age	O
(	O
P	O
=	O
.36	O
)	O
.	O

On	O
average	O
,	O
women	O
expected	O
to	O
achieve	O
complete	O
improvement	O
more	O
often	O
than	O
men	O
(	O
P	O
=	O
.011	O
)	O
.	O

Variables	O
that	O
were	O
significantly	O
associated	O
with	O
higher	O
expectations	O
scores	O
(	O
P	O
<	O
.05	O
)	O
included	O
nonwhite	O
race	O
,	O
use	O
of	O
a	O
cane	O
or	O
other	O
assistive	O
device	O
,	O
and	O
greater	O
medical	O
comorbidity	O
.	O

Worse	O
function	O
and	O
quality	O
of	O
life	O
(	O
as	O
assessed	O
by	O
all	O
FAOS	O
subscales	O
and	O
the	O
SF-12	O
physical	O
and	O
mental	O
components	O
)	O
,	O
more	O
depressive	O
and	O
anxiety	O
symptoms	O
,	O
and	O
higher	O
pain	O
VAS	O
scores	O
were	O
associated	O
with	O
higher	O
expectations	O
scores	O
and	O
more	O
expectations	O
(	O
P	O
<	O
.01	O
for	O
all	O
)	O
.	O

The	O
results	O
of	O
this	O
study	O
may	O
help	O
inform	O
surgeons	O
'	O
preoperative	O
discussions	O
with	O
their	O
patients	O
regarding	O
realistic	O
expectations	O
from	O
surgery	O
.	O

Generally	O
,	O
patients	O
with	O
worse	O
function	O
and	O
more	O
disability	O
had	O
higher	O
expectations	O
from	O
surgery	O
.	O

Addressing	O
these	O
patients	O
'	O
expectations	O
preoperatively	O
may	O
help	O
improve	O
their	O
ultimate	O
satisfaction	O
with	O
surgery	O
.	O

Level	O
II	O
,	O
cross	O
sectional	O
study	O
.	O

Assessing	O
the	O
learning	O
potential	O
of	O
an	O
interactive	O
digital	O
game	O
versus	O
an	O
interactive-style	O
didactic	O
lecture	O
:	O
the	O
continued	O
importance	O
of	O
didactic	O
teaching	O
in	O
medical	O
student	O
education	O
.	O

Games	O
with	O
educational	O
intent	O
offer	O
a	O
possible	O
advantage	O
of	O
being	O
more	O
interactive	O
and	O
increasing	O
learner	O
satisfaction	O
.	O

We	O
conducted	O
a	O
two-armed	O
experiment	O
to	O
evaluate	O
student	O
satisfaction	O
and	O
content	O
mastery	O
for	O
an	O
introductory	O
pediatric	O
radiology	O
topic	O
,	O
taught	O
by	O
either	O
an	O
interactive	O
digital	O
game	O
or	O
with	O
a	O
traditional	O
didactic	O
lecture	O
.	O

Medical	O
students	O
participating	O
in	O
a	O
fourth-year	O
radiology	O
elective	O
were	O
invited	O
to	O
participate	O
.	O

Student	O
cohorts	O
were	O
alternatively	O
given	O
a	O
faculty	O
-	O
supervised	O
1h	O
session	O
playing	O
a	O
simple	O
interactive	O
digital	O
Tic-tac-toe	O
quiz	O
module	O
on	O
pediatric	B-P
gastrointestinal	I-P
radiology	I-P
or	O
a	O
1h	O
didactic	O
introductory	O
lecture	O
on	O
the	O
same	O
topic	O
.	O

Survey	O
questions	O
assessed	O
the	O
learners	O
'	O
perceived	O
ability	O
to	O
recall	O
the	O
material	O
as	O
well	O
as	O
their	O
satisfaction	O
with	O
the	O
educational	O
experience	O
.	O

Results	O
of	O
an	O
end-of-rotation	O
exam	O
were	O
reviewed	O
to	O
evaluate	O
a	O
quantitative	O
measure	O
of	O
learning	O
between	O
groups	O
.	O

Survey	O
responses	O
were	O
analyzed	O
with	O
a	O
chi-squared	O
test	O
.	O

Exam	O
results	O
for	O
both	O
groups	O
were	O
analyzed	O
with	O
a	O
paired	O
Student	O
's	O
t-test	O
.	O

Students	O
in	O
the	O
lecture	O
group	O
had	O
higher	O
test	O
scores	O
compared	O
to	O
students	O
in	O
the	O
game	O
group	O
(	O
4.0/5	O
versus	O
3.6/5	O
,	O
P	O
=	O
0.045	O
)	O
.	O

Students	O
in	O
the	O
lecture	O
group	O
reported	O
greater	O
understanding	O
and	O
recall	O
of	O
the	O
material	O
than	O
students	O
in	O
the	O
game	O
group	O
(	O
P	O
<	O
0.001	O
and	O
P	O
=	O
0.004	O
,	O
respectively	O
)	O
.	O

Students	O
in	O
the	O
lecture	O
group	O
perceived	O
the	O
lecture	O
to	O
be	O
more	O
enjoyable	O
and	O
a	O
better	O
use	O
of	O
their	O
time	O
compared	O
to	O
those	O
in	O
the	O
game	O
group	O
(	O
P	O
=	O
0.04	O
and	O
P	O
<	O
0.001	O
,	O
respectively	O
)	O
.	O

There	O
was	O
no	O
statistically	O
significant	O
difference	O
between	O
the	O
lecture	O
and	O
game	O
group	O
in	O
ability	O
to	O
maintain	O
interest	O
(	O
P	O
=	O
0.187	O
)	O
.	O

In	O
comparison	O
to	O
pre-survey	O
results	O
,	O
there	O
was	O
a	O
statistically	O
significant	O
decrease	O
in	O
interest	O
for	O
further	O
digital	O
interactive	O
materials	O
reported	O
by	O
students	O
in	O
the	O
game	O
group	O
(	O
P	O
=	O
0.146	O
)	O
.	O

Our	O
experience	O
supported	O
the	O
use	O
of	O
a	O
traditional	O
lecture	O
over	O
a	O
digital	O
game	O
module	O
.	O

While	O
these	O
results	O
might	O
be	O
affected	O
by	O
the	O
specific	O
lecture	O
and	O
digital	O
content	O
in	O
any	O
given	O
comparison	O
,	O
a	O
digital	O
module	O
is	O
not	O
always	O
the	O
superior	O
option	O
.	O

Negative	O
Psychological	O
Consequences	O
of	O
Breast	O
Cancer	O
among	O
Recently	O
Diagnosed	O
Ethnically	O
Diverse	O
Women	O
.	O

Breast	O
cancer	O
has	O
psychological	O
consequences	O
that	O
impact	O
quality	O
of	O
life	O
(	O
QOL	O
)	O
.	O

We	O
examined	O
factors	O
associated	O
with	O
negative	O
psychological	O
consequences	O
of	O
a	O
breast	O
cancer	O
diagnosis	O
,	O
in	O
a	O
diverse	O
sample	O
of	O
910	O
recently	O
diagnosed	O
patients	O
(	O
378	O
African-American	O
,	O
372	O
White	O
,	O
and	O
160	O
Latina	O
)	O
.	O

Patients	O
completed	O
an	O
in-person	O
interview	O
as	O
part	O
of	O
the	O
Breast	O
Cancer	O
Care	O
in	O
Chicago	O
study	O
within	O
an	O
average	O
of	O
four	O
months	O
from	O
diagnosis	O
.	O

The	O
Cockburn	O
negative	O
psychological	O
consequences	O
of	O
breast	B-P
cancer	I-P
screening	I-P
scale	O
was	O
revised	O
to	O
focus	O
on	O
a	O
breast	O
cancer	O
diagnosis	O
.	O

Path	O
analysis	O
assessed	O
predictors	O
of	O
psychological	O
consequences	O
and	O
potential	O
mediators	O
between	O
race	O
/	O
ethnicity	O
and	O
psychological	O
consequences	O
.	O

Compared	O
to	O
White	O
counterparts	O
,	O
bivariate	O
analysis	O
showed	O
African-American	O
(	O
β	O
=	O
1.4	O
,	O
p	O
<	O
0.05	O
)	O
and	O
Latina	O
(	O
β	O
=	O
3.6	O
,	O
p	O
<	O
0.001	O
)	O
women	O
reported	O
greater	O
psychological	O
consequences	O
.	O

Strongest	O
predictors	O
(	O
P	O
<	O
0.05	O
for	O
all	O
)	O
included	O
unmet	O
social	O
support	O
(	O
β	O
=	O
0.38	O
)	O
,	O
and	O
provider	O
trust	O
(	O
β	O
=	O
0.12	O
)	O
,	O
followed	O
by	O
stage	O
at	O
diagnosis	O
(	O
β	O
=	O
0.10	O
)	O
and	O
perceived	O
neighborhood	O
social	O
disorder	O
(	O
β	O
=	O
0.09	O
)	O
.The	O
strongest	O
mediator	O
between	O
race	O
/	O
ethnicity	O
and	O
psychological	O
consequences	O
was	O
unmet	O
social	O
support	O
.	O

African-American	O
and	O
Latina	O
women	O
reported	O
greater	O
psychological	O
consequences	O
related	O
to	O
their	O
breast	O
cancer	O
diagnosis	O
;	O
this	O
disparity	O
was	O
mediated	O
by	O
differences	O
in	O
unmet	O
social	O
support	O
.	O

Social	O
support	O
represents	O
a	O
promising	O
point	O
of	O
intervention	O
.	O

A	O
rare	O
cause	O
of	O
gastric	O
obstruction	O
:	O
Lighters	O
swallowing	O
.	O

The	O
majority	O
of	O
swallowed	O
foreign	O
bodies	O
are	O
thrown	O
spontaneously	O
without	O
causing	O
complications	O
in	O
the	O
digestive	O
system	O
.	O

Multiple	O
number	O
of	O
foreign	O
bodies	O
may	O
be	O
swallowed	O
by	O
psychiatric	O
patients	O
which	O
delay	O
diagnosis	O
and	O
increase	O
the	O
complication	O
rate	O
.	O

Long	O
and	O
hard	O
objects	O
can	O
not	O
pass	O
through	O
the	O
pylorus	O
,	O
and	O
may	O
cause	O
obstruction	O
,	O
ulceration	O
,	O
bleeding	O
and	O
perforation	O
.	O

Endoscopy	B-P
is	O
used	O
as	O
an	O
effective	O
method	O
in	O
such	O
cases	O
.	O

An	O
exploratory	B-P
laparatomy	I-P
was	O
performed	O
after	O
unsuccessful	O
endoscopic	O
foreign	O
object	O
removal	O
in	O
a	O
28-year-old	O
schizophrenic	O
patient	O
with	O
gastric	O
outlet	O
obstruction	O
due	O
to	O
multiple	O
cigarette	O
lighter	O
swallowing	O
.	O

Ten	O
lighters	O
were	O
removed	O
from	O
the	O
stomach	O
through	O
gastrotomy	O
and	O
one	O
more	O
lighter	O
was	O
removed	O
from	O
the	O
descending	O
colon	O
by	O
milking	O
through	O
the	O
anus	O
.	O

The	O
aim	O
of	O
this	O
paper	O
is	O
to	O
discuss	O
encountered	O
difficulties	O
in	O
psychiatric	O
patients	O
who	O
underwent	O
surgery	O
due	O
to	O
intake	O
of	O
foreign	O
bodies	O
.	O

Increase	O
in	O
average	O
foveal	O
thickness	O
after	O
internal	O
limiting	O
membrane	O
peeling	O
.	O

To	O
report	O
the	O
findings	O
in	O
three	O
cases	O
in	O
which	O
the	O
average	O
foveal	O
thickness	O
was	O
increased	O
after	O
a	O
thin	O
epiretinal	O
membrane	O
(	O
ERM	O
)	O
was	O
removed	O
by	O
vitrectomy	O
with	O
internal	O
limiting	O
membrane	O
(	O
ILM	O
)	O
peeling	O
.	O

The	O
foveal	O
contour	O
was	O
normal	O
preoperatively	O
in	O
all	O
eyes	O
.	O

All	O
cases	O
underwent	O
successful	O
phacovitrectomy	O
with	O
ILM	O
peeling	O
for	O
a	O
thin	O
ERM	O
.	O

The	O
optical	B-P
coherence	I-P
tomography	I-P
(	O
OCT	B-P
)	O
images	O
were	O
examined	O
before	O
and	O
after	O
the	O
surgery	O
.	O

The	O
changes	O
in	O
the	O
average	O
foveal	O
(	O
1	O
mm	O
)	O
thickness	O
and	O
the	O
foveal	O
areas	O
within	O
500	O
μm	O
from	O
the	O
foveal	O
center	O
were	O
measured	O
.	O

The	O
postoperative	O
changes	O
in	O
the	O
inner	O
and	O
outer	O
retinal	O
areas	O
determined	O
from	O
the	O
cross-sectional	O
OCT	B-P
images	O
were	O
analyzed	O
.	O

The	O
average	O
foveal	O
thickness	O
and	O
the	O
inner	O
and	O
outer	O
foveal	O
areas	O
increased	O
significantly	O
after	O
the	O
surgery	O
in	O
each	O
of	O
the	O
three	O
cases	O
.	O

The	O
percentage	O
increase	O
in	O
the	O
average	O
foveal	O
thickness	O
relative	O
to	O
the	O
baseline	O
thickness	O
was	O
26	O
%	O
in	O
Case	O
1	O
,	O
29	O
%	O
in	O
Case	O
2	O
,	O
and	O
31	O
%	O
in	O
Case	O
3	O
.	O

The	O
percentage	O
increase	O
in	O
the	O
foveal	O
inner	O
retinal	O
area	O
was	O
71	O
%	O
in	O
Case	O
1	O
,	O
113	O
%	O
in	O
Case	O
2	O
,	O
and	O
110	O
%	O
in	O
Case	O
3	O
,	O
and	O
the	O
percentage	O
increase	O
in	O
foveal	O
outer	O
retinal	O
area	O
was	O
8	O
%	O
in	O
Case	O
1	O
,	O
13	O
%	O
in	O
Case	O
2	O
,	O
and	O
18	O
%	O
in	O
Case	O
3	O
.	O

The	O
increase	O
in	O
the	O
average	O
foveal	O
thickness	O
and	O
the	O
inner	O
and	O
outer	O
foveal	O
areas	O
suggests	O
that	O
a	O
centripetal	O
movement	O
of	O
the	O
inner	O
and	O
outer	O
retinal	O
layers	O
toward	O
the	O
foveal	O
center	O
probably	O
occurred	O
due	O
to	O
the	O
ILM	O
peeling	O
.	O

Family	O
Psychosocial	O
Risk	O
Screening	O
in	O
Infants	O
and	O
Older	O
Children	O
in	O
the	O
Acute	O
Pediatric	O
Hospital	O
Setting	O
Using	O
the	O
Psychosocial	O
Assessment	O
Tool	O
.	O

To	O
examine	O
the	O
validity	O
of	O
the	O
Psychosocial	O
Assessment	O
Tool	O
(	O
PAT	O
)	O
with	O
families	O
of	O
infants	O
(	O
<	O
2	O
years	O
)	O
and	O
children	O
admitted	O
to	O
hospital	O
with	O
acute	O
life-threatening	O
illnesses	O
.	O

METHODS	O
:	O
A	O
total	O
of	O
235	O
parents	O
of	O
177	O
children	O
admitted	O
to	O
oncology	O
,	O
cardiology	O
,	O
or	O
pediatric	O
intensive	O
care	O
completed	O
the	O
PAT	O
and	O
measures	O
of	O
acute	O
stress	O
,	O
trait	O
anxiety	O
,	O
family	O
functioning	O
,	O
and	O
quality	O
of	O
life	O
,	O
a	O
mean	O
3.7	O
weeks	O
following	O
diagnosis	O
.	O

A	O
modified	O
PAT	O
was	O
used	O
for	O
families	O
of	O
infants	O
,	O
rendering	O
two	O
forms	O
,	O
PAT	O
(	O
<	O
2	O
)	O
and	O
PAT	O
(	O
2+	O
)	O
.	O

RESULTS	O
:	O
Psychometrics	B-P
for	O
PAT	O
(	O
<	O
2	O
)	O
and	O
PAT	O
(	O
2+	O
)	O
were	O
acceptable	O
.	O

PAT	O
Total	O
and	O
Subscale	O
scores	O
for	O
each	O
version	O
were	O
significantly	O
correlated	O
with	O
validation	O
measures	O
.	O

Internal	O
consistency	O
for	O
PAT	O
subscales	O
was	O
variable	O
.	O

Receiver	O
Operating	O
Characteristics	O
provided	O
some	O
support	O
for	O
PAT	O
cutoffs	O
.	O

PAT	O
scores	O
across	O
illness	O
groups	O
were	O
comparable	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
provides	O
promising	O
support	O
for	O
the	O
PAT	O
as	O
a	O
psychosocial	O
screener	O
for	O
families	O
of	O
infants	O
and	O
older	O
children	O
across	O
illness	O
conditions	O
.	O

Sorting	O
nexin-4	O
regulates	O
β-amyloid	O
production	O
by	O
modulating	O
β-site-activating	O
cleavage	O
enzyme-1	O
.	O

Amyloid	O
precursor	O
protein	O
(	O
APP	O
)	O
is	O
cleaved	O
by	O
β-site	O
amyloid	O
precursor	O
protein-cleaving	O
enzyme	O
1	O
(	O
BACE1	O
)	O
to	O
produce	O
β-amyloid	O
(	O
Aβ	O
)	O
,	O
a	O
critical	O
pathogenic	O
peptide	O
in	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
.	O

Aβ	O
generation	O
can	O
be	O
affected	O
by	O
the	O
intracellular	O
trafficking	O
of	O
APP	O
or	O
its	O
related	O
secretases	O
,	O
which	O
is	O
thus	O
important	O
to	O
understanding	O
its	O
pathological	O
alterations	O
.	O

Although	O
sorting	O
nexin	O
(	O
SNX	O
)	O
family	O
proteins	O
regulate	O
this	O
trafficking	O
,	O
the	O
relevance	O
and	O
role	O
of	O
sorting	O
nexin-4	O
(	O
SNX4	O
)	O
regarding	O
AD	O
has	O
not	O
been	O
studied	O
yet	O
.	O

In	O
this	O
study	O
,	O
human	O
brain	O
tissue	O
and	O
APP	O
/	O
PS1	O
mouse	O
brain	O
tissue	O
were	O
used	O
to	O
check	O
the	O
disease	O
relevance	O
of	O
SNX4	O
.	O

To	O
investigate	O
the	O
role	O
of	O
SNX4	O
in	O
AD	O
pathogenesis	O
,	O
several	O
experiments	O
were	O
done	O
,	O
such	O
as	O
coimmunoprecipitation	O
,	O
Western	O
blotting	O
,	O
immunohistochemistry	B-P
,	O
and	O
gradient	O
fractionation	O
.	O

We	O
found	O
that	O
SNX4	O
protein	O
levels	O
changed	O
in	O
the	O
brains	O
of	O
patients	O
with	O
AD	O
and	O
of	O
AD	O
model	O
mice	O
.	O

Overexpression	O
of	O
SNX4	O
significantly	O
increased	O
the	O
levels	O
of	O
BACE1	O
and	O
Aβ	O
.	O

Downregulation	O
of	O
SNX4	O
had	O
the	O
opposite	O
effect	O
.	O

SNX4	O
interacts	O
with	O
BACE1	O
and	O
prevents	O
BACE1	O
trafficking	O
to	O
the	O
lysosomal	O
degradation	O
system	O
,	O
resulting	O
in	O
an	O
increased	O
half-life	O
of	O
BACE1	O
and	O
increased	O
production	O
of	O
Aβ	O
.	O

We	O
show	O
that	O
SNX4	O
regulates	O
BACE1	O
trafficking	O
.	O

Our	O
findings	O
suggest	O
novel	O
therapeutic	O
implications	O
of	O
modulating	O
SNX4	O
to	O
regulate	O
BACE1	O
-mediated	O
β-processing	O
of	O
APP	O
and	O
subsequent	O
Aβ	O
generation	O
.	O

Ictal	O
unilateral	O
blinking	O
is	O
an	O
unreliable	O
lateralizing	O
sign	O
in	O
tuberous	O
sclerosis	O
complex	O
.	O

Ictal	O
unilateral	O
blinking	O
is	O
an	O
uncommon	O
but	O
reportedly	O
reliable	O
lateralizing	O
sign	O
,	O
indicating	O
an	O
ipsilateral	O
seizure	O
focus	O
.	O

We	O
aimed	O
to	O
determine	O
its	O
lateralizing	O
utility	O
in	O
patients	O
with	O
tuberous	O
sclerosis	O
complex	O
(	O
TSC	O
)	O
.	O

We	O
reviewed	O
the	O
video-EEGs	B-P
of	O
92	O
children	O
with	O
TSC	O
and	O
drug-resistant	O
epilepsy	O
.	O

Eleven	O
(	O
12	O
%	O
)	O
had	O
seizures	O
with	O
unilateral	O
blinking	O
,	O
of	O
which	O
10	O
underwent	O
epilepsy	O
surgery	O
.	O

Lateralization	O
of	O
seizures	O
was	O
inferred	O
from	O
other	O
semiology	O
,	O
ictal	O
scalp	B-P
EEG	I-P
and	O
outcome	O
following	O
tuberectomy	O
.	O

Seizures	O
manifesting	O
with	O
unilateral	O
blinking	O
were	O
focal	O
motor	O
in	O
four	O
patients	O
,	O
focal	O
motor	O
evolving	O
into	O
epileptic	O
spasms	O
in	O
six	O
,	O
and	O
epileptic	O
spasms	O
with	O
focal	O
features	O
in	O
one	O
.	O

Associated	O
unilateral	O
facial	O
contraction	O
was	O
seen	O
in	O
five	O
patients	O
and	O
arm	O
jerking	O
in	O
four	O
.	O

Lateralized	O
scalp	O
ictal	O
rhythms	O
were	O
seen	O
in	O
seven	O
patients	O
.	O

Following	O
tuberectomies	O
,	O
seven	O
patients	O
are	O
seizure	O
free	O
and	O
two	O
had	O
>	O
90	O
%	O
reduction	O
.	O

Overall	O
lateralization	O
of	O
seizures	O
with	O
unilateral	O
blinking	O
was	O
contralateral	O
in	O
six	O
patients	O
and	O
ipsilateral	O
in	O
four	O
.	O

When	O
unilateral	O
blinking	O
was	O
early	O
in	O
seizures	O
,	O
overall	O
lateralization	O
was	O
more	O
often	O
contralateral	O
(	O
6/7	O
patients	O
,	O
PPV	O
85	O
%	O
)	O
.	O

Ictal	O
unilateral	O
blinking	O
is	O
not	O
infrequent	O
but	O
unreliable	O
in	O
lateralizing	O
seizures	O
in	O
TSC	O
.	O

Unrecognized	O
seizure	O
propagation	O
to	O
contralateral	O
symptomatogenic	O
regions	O
and	O
potentially	O
different	O
mechanisms	O
may	O
account	O
for	O
the	O
variable	O
lateralization	O
.	O

Signs	O
of	O
dysarthria	O
in	O
adults	O
with	O
22q11.2	O
deletion	O
syndrome	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
how	O
adults	O
with	O
22q11.2	O
deletion	O
syndrome	O
(	O
22q11DS	O
)	O
performed	O
on	O
dysarthria	O
and	O
intelligibility	O
tests	B-P
compared	O
with	O
a	O
control	O
group	O
.	O

Ten	O
participants	O
with	O
confirmed	O
22q11.2	O
deletion	O
,	O
five	O
males	O
and	O
five	O
females	O
with	O
a	O
mean	O
age	O
of	O
31	O
years	O
(	O
range	O
:	O
19-49	O
)	O
,	O
were	O
compared	O
with	O
a	O
control	O
group	O
matched	O
for	O
gender	O
and	O
age	O
(	O
five	O
males	O
and	O
five	O
females	O
,	O
mean	O
age	O
:	O
32	O
years	O
,	O
range	O
:	O
19-49	O
)	O
.	O

Assessment	O
of	O
non-verbal	B-P
and	I-P
verbal	I-P
tasks	I-P
reflecting	O
respiration	O
,	O
phonation	O
,	O
oral	O
motor	O
function	O
,	O
velopharyngeal	O
function	O
,	O
articulation	O
,	O
and	O
prosody	O
was	O
performed	O
as	O
well	O
as	O
the	O
Swedish	O
Test	O
of	O
Intelligibility	O
(	O
STI	O
)	O
.	O

All	O
assessments	O
were	O
made	O
by	O
two	O
raters	O
;	O
inter-rater	O
and	O
intra-rater	O
reliability	O
was	O
acceptable	O
.	O

The	O
participants	O
with	O
22q11DS	O
had	O
significantly	O
more	O
problems	O
than	O
the	O
control	O
group	O
on	O
all	O
investigated	O
dimensions	O
except	O
the	O
STI	O
.	O

Overall	O
,	O
the	O
severity	O
of	O
their	O
speech	O
deviation	O
was	O
rated	O
as	O
mild	O
to	O
moderate	O
.	O

The	O
largest	O
difficulties	O
were	O
found	O
regarding	O
speech	O
respiration	O
,	O
phonation	O
,	O
oral	O
motor	O
function	O
,	O
and	O
velopharyngeal	O
function	O
.	O

The	O
results	O
of	O
the	O
present	O
study	O
suggest	O
that	O
a	O
neurological	O
etiology	O
could	O
be	O
added	O
to	O
the	O
previously	O
described	O
structural	O
etiology	O
explaining	O
the	O
speech	O
difficulties	O
found	O
in	O
22q11DS	O
.	O

Signs	O
of	O
difficulties	O
in	O
both	O
speech	O
motor	O
planning	O
and	O
speech	O
motor	O
programming	O
were	O
found	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
confirm	O
the	O
results	O
,	O
as	O
are	O
studies	O
of	O
the	O
association	O
between	O
structural	O
brain	O
abnormalities	O
and	O
neurological	O
speech	O
symptoms	O
.	O

For	O
clinical	O
purposes	O
,	O
it	O
is	O
important	O
that	O
clinicians	O
have	O
knowledge	O
about	O
the	O
variable	O
speech	O
symptoms	O
that	O
may	O
occur	O
in	O
individuals	O
with	O
22q11DS	O
and	O
that	O
they	O
be	O
aware	O
of	O
the	O
complexity	O
of	O
the	O
etiology	O
of	O
such	O
speech	O
symptoms	O
.	O

©	O
2017	O
Wiley	O
Periodicals	O
,	O
Inc	O
.	O

Farnesylthiosalicylic	O
acid	O
-loaded	O
lipid-polyethylene	O
glycol-polymer	O
hybrid	O
nanoparticles	O
for	O
treatment	O
of	O
glioblastoma	O
.	O

We	O
aimed	O
to	O
develop	O
lipid-polyethylene	O
glycol	O
(	O
PEG	O
)	O
-polymer	O
hybrid	O
nanoparticles	O
,	O
which	O
have	O
high	O
affinity	O
to	O
tumour	O
tissue	O
with	O
active	O
ingredient	O
,	O
a	O
new	O
generation	O
antineoplastic	O
drug	O
,	O
farnesylthiosalicylic	O
acid	O
(	O
FTA	O
)	O
for	O
treatment	O
of	O
glioblastoma	O
.	O

Farnesylthiosalicylic	O
acid	O
-loaded	O
poly	O
(	O
lactic-co-glycolic	O
acid	O
)	O
-1,2	O
distearoyl-glycerol-3-phospho-ethanolamine-N	O
[	O
methoxy	O
(	O
PEG	O
)	O
-2000	O
]	O
ammonium	O
salt	O
(	O
PLGA-DSPE-PEG	O
)	O
with	O
or	O
without	O
1,2-dioleoyl-3-trimethylammonium-propane	O
(	O
DOTAP	O
)	O
hybrid	O
nanoparticles	O
has	O
been	O
prepared	O
and	O
evaluated	O
for	O
in-vitro	O
characterization	O
.	O

Cytotoxicity	O
of	O
FTA-loaded	O
nanoparticles	O
along	O
with	O
its	O
efficacy	O
on	O
rat	O
glioma-2	O
(	O
RG2	O
)	O
cells	O
was	O
also	O
evaluated	O
both	O
in	O
vitro	O
(	O
in	O
comparison	O
with	O
non-malignant	O
cell	O
line	O
,	O
L929	O
)	O
and	O
in	O
vivo	O
.	O

Scanning	O
electron	O
microscopy	O
studies	O
showed	O
that	O
all	O
formulations	O
prepared	O
had	O
smooth	O
surface	O
and	O
spherical	O
in	O
shape	O
.	O

FTA	O
and	O
FTA-loaded	O
nanoparticles	O
have	O
cytotoxic	O
activity	O
against	O
RG2	O
glioma	O
cell	O
lines	O
in	O
cell	O
culture	O
studies	O
,	O
which	O
further	O
increases	O
with	O
addition	O
of	O
DOTAP	O
.	O

Magnetic	B-P
resonance	I-P
imaging	I-P
and	O
histopathologic	O
evaluation	O
on	O
RG2	O
tumour	O
cells	O
in	O
rat	O
glioma	O
model	O
(	O
49	O
female	O
Wistar	O
rats	O
,	O
250-300	O
g	O
)	O
comparing	O
intravenous	O
and	O
intratumoral	O
injections	O
of	O
the	O
drug	O
have	O
been	O
performed	O
and	O
FTA-loaded	O
nanoparticles	O
reduced	O
tumour	O
size	O
significantly	O
in	O
in-vivo	O
studies	O
,	O
with	O
higher	O
efficiency	O
of	O
intratumoral	O
administration	O
than	O
intravenous	O
route	O
.	O

Farnesylthiosalicylic	O
acid	O
-loaded	O
PLGA-DSPE-PEG-DOTAP	O
hybrid	O
nanoparticles	O
are	O
proven	O
to	O
be	O
effective	O
against	O
glioblastoma	O
in	O
both	O
in-vitro	O
and	O
in-vivo	O
experiments	O
.	O

The	O
Usefulness	O
of	O
Employing	O
an	O
Electronic	O
Traction	O
Table	O
to	O
Determine	O
Flexibility	O
in	O
Adolescent	O
Idiopathic	O
Scoliosis	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
develop	O
new	O
equipment	O
for	O
the	O
assessment	O
of	O
the	O
flexibility	O
of	O
the	O
spine	O
with	O
different	O
forces	O
.	O

This	O
new	O
system	O
should	O
provide	O
a	O
different	O
perspective	O
to	O
adolescent	O
idiopathic	O
scoliosis	O
(	O
AIS	O
)	O
for	O
the	O
selection	O
of	O
fusion	O
levels	O
and	O
surgical	O
success	O
.	O

Eighteen	O
patients	O
suffering	O
from	O
AIS	O
who	O
were	O
scheduled	O
to	O
undergo	O
posterior	O
instrumented	O
spinal	O
fusion	O
in	O
our	O
clinic	O
were	O
recruited	O
in	O
this	O
study	O
.	O

The	O
Electronic	O
Traction	O
Table	O
(	O
ETT	O
)	O
that	O
was	O
designed	O
in	O
our	O
clinic	O
was	O
used	O
to	O
evaluate	O
the	O
radiogical	O
and	O
clinical	O
parameters	O
of	O
the	O
spine	O
.	O

The	O
significant	O
prescriptive	O
angle	O
of	O
major	O
Cobb	O
angles	O
between	O
postoperative	O
angles	O
were	O
longitudinal	O
traction	O
and	O
lateral	O
pushing	O
Cobb	O
angles	O
.	O

Longitudinal	O
traction	O
and	O
lateral	O
pushing	O
angles	O
were	O
more	O
correlated	O
with	O
correction	O
ratios	O
.	O

There	O
was	O
a	O
significant	O
difference	O
between	O
longitudinal	O
traction	O
minor	O
Cobb	O
angle	O
,	O
longitudinal	O
traction	O
lateral	O
pushing	O
minor	O
Cobb	O
angle	O
and	O
postoperative	O
minor	O
Cobb	O
angles	O
.	O

The	O
deformity	O
is	O
needed	O
to	O
balance	O
both	O
tractional	O
and	O
rotational	O
forces	O
and	O
useful	O
technique	O
to	O
evaluate	O
curve	O
flexibility	O
before	O
the	O
operation	O
.	O

Electronic	O
traction	O
table	O
is	O
a	O
new	O
device	O
for	O
determining	O
preoperative	O
flexibility	O
with	O
longitudinal	O
traction	O
and	O
lateral	B-P
pushing	I-P
radiographs	I-P
.	O

It	O
can	O
be	O
useful	O
for	O
choosing	O
selective	O
fusion	O
levels	O
at	O
the	O
proximal	O
and	O
distal	O
end	O
of	O
the	O
vertebral	O
column	O
.	O

2,3,5,4'-Tetrahydroxystilbene-2-O-β-D-Glucoside	O
Attenuates	O
Ischemia	O
/	O
Reperfusion-Induced	O
Brain	O
Injury	O
in	O
Rats	O
by	O
Promoting	O
Angiogenesis	O
.	O

cerebral	O
ischemia	O
can	O
cause	O
brain	O
infarcts	O
,	O
which	O
are	O
difficult	O
to	O
recover	O
due	O
to	O
poor	O
angiogenesis	O
.	O

2,3,5,4'-Tetrahydroxystilbene-2-O-β-D-glucoside	O
is	O
a	O
natural	O
polyphenol	O
,	O
has	O
antioxidant	O
and	O
anti-inflammatory	O
activity	O
,	O
and	O
can	O
protect	O
from	O
ischemic	O
neuronal	O
injury	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
effect	O
of	O
2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside	O
on	O
brain	O
microcirculation	O
after	O
stroke	O
.	O

This	O
study	O
aimed	O
at	O
investigating	O
the	O
influence	O
of	O
2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside	O
on	O
brain	O
lesions	O
and	O
angiogenesis	O
after	O
stroke	O
.	O

Sprague-Dawley	O
rats	O
were	O
subjected	O
to	O
right	O
middle	O
cerebral	O
artery	O
occlusion	O
and	O
treated	O
with	O
vehicle	O
,	O
nimodipine	O
,	O
or	O
different	O
doses	O
of	O
2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside	O
daily	O
beginning	O
at	O
6	O
h	O
post-middle	O
cerebral	O
artery	O
occlusion	O
for	O
14	O
days	O
.	O

The	O
volume	O
of	O
cerebral	O
infarcts	O
,	O
degree	O
of	O
neurological	O
dysfunction	O
,	O
and	O
level	O
of	O
microvessel	O
density	O
were	O
determined	O
longitudinally	O
.	O

The	O
levels	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
,	O
angiopoietin	O
1	O
,	O
and	O
angiopoietin	O
receptor-2	O
expression	O
in	O
the	O
brain	O
lesions	O
were	O
characterized	O
by	O
immunohistochemistry	B-P
and	O
Western	O
blot	O
assays	O
at	O
14	O
days	O
post-middle	O
cerebral	O
artery	O
occlusion	O
.	O

We	O
found	O
that	O
2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside	O
significantly	O
promoted	O
postoperative	O
recovery	O
in	O
rats	O
by	O
minimizing	O
the	O
volume	O
of	O
cerebral	O
infarcts	O
and	O
improving	O
neurological	O
dysfunction	O
in	O
a	O
dose	O
-	O
and	O
time-dependent	O
manner	O
.	O

Additionally	O
,	O
2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside	O
significantly	O
increased	O
the	O
microvessel	O
density	O
in	O
the	O
brain	O
and	O
upregulated	O
CD31	O
expression	O
in	O
ischemic	O
penumbra	O
,	O
relative	O
to	O
that	O
in	O
the	O
control	O
.	O

Finally	O
,	O
treatment	O
with	O
2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside	O
significantly	O
upregulated	O
the	O
relative	O
levels	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
,	O
angiopoietin	O
1	O
,	O
and	O
angiopoietin	O
receptor-2	O
expression	O
in	O
the	O
brain	O
lesions	O
of	O
rats	O
.	O

Therefore	O
,	O
these	O
data	O
indicated	O
that	O
2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside	O
treatment	O
promoted	O
angiogenesis	O
and	O
recovery	O
from	O
ischemia/reperfusion	O
-induced	O
brain	O
injury	O
in	O
rats	O
.	O

Altered	O
interregional	O
correlations	O
between	O
serotonin	O
transporter	O
availability	O
and	O
cerebral	O
glucose	O
metabolism	O
in	O
schizophrenia	O
:	O
A	O
high-resolution	B-P
PET	I-P
study	O
using	O
[	O
(	O
11	O
)	O
C	O
]	O
DASB	O
and	O
[	O
(	O
18	O
)	O
F	O
]	O
FDG	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
patterns	O
of	O
interregional	O
correlations	O
of	O
serotonin	O
transporter	O
(	O
SERT	O
)	O
availability	O
with	O
glucose	O
metabolism	O
using	O
7-Tesla	B-P
magnetic	I-P
resonance	I-P
imaging	I-P
(	O
MRI	B-P
)	O
and	O
high-resolution	B-P
positron	I-P
emission	I-P
tomography	I-P
(	O
PET	B-P
)	O
with	O
(	O
11	O
)	O
C-3-amino-4-	O
(	O
2-dimethylaminomethylphenylthio	O
)	O
benzonitrile	O
(	O
[	O
(	O
11	O
)	O
C	O
]	O
DASB	O
)	O
and	O
[	O
(	O
18	O
)	O
F	O
]	O
fluorodeoxyglucose	O
(	O
[	O
(	O
18	O
)	O
F	O
]	O
FDG	O
)	O
in	O
antipsychotic-free	O
patients	O
with	O
schizophrenia	O
in	O
order	O
to	O
shed	O
new	O
light	O
on	O
the	O
disrupted	O
functional	O
connectivity	O
in	O
schizophrenia	O
.	O

Nineteen	O
patients	O
with	O
schizophrenia	O
and	O
18	O
healthy	O
controls	O
underwent	O
high-resolution	B-P
PET	I-P
and	O
MRI	B-P
.	O

The	O
binding	O
potential	O
(	O
BPND	O
)	O
of	O
[	O
(	O
11	O
)	O
C	O
]	O
DASB	O
and	O
standardized	O
uptake	O
value	O
ratio	O
(	O
SUVR	O
)	O
of	O
[	O
(	O
18	O
)	O
F	O
]	O
FDG	O
were	O
obtained	O
.	O

In	O
SERT	O
availability	O
,	O
the	O
region	O
of	O
interest	O
(	O
ROI	O
)	O
-based	O
analyses	O
showed	O
no	O
significant	O
group	O
differences	O
in	O
any	O
region	O
,	O
except	O
for	O
the	O
anterior	O
hippocampus	O
where	O
the	O
SERT	O
availability	O
was	O
lower	O
in	O
patients	O
with	O
schizophrenia	O
than	O
in	O
controls	O
.	O

The	O
ROI	O
-	O
and	O
voxel	O
-based	O
analyses	O
revealed	O
that	O
the	O
[	O
(	O
18	O
)	O
F	O
]	O
FDG	O
SUVR	O
values	O
were	O
significantly	O
lower	O
in	O
patients	O
than	O
in	O
controls	O
in	O
the	O
right	O
superior	O
frontal	O
gyrus	O
and	O
medial	O
part	O
of	O
the	O
left	O
superior	O
frontal	O
gyrus	O
.	O

Regarding	O
the	O
interregional	O
correlations	O
of	O
[	O
(	O
11	O
)	O
C	O
]	O
DASB	O
BPND	O
with	O
[	O
(	O
18	O
)	O
F	O
]	O
FDG	O
SUVR	O
,	O
more	O
widespread	O
positive	O
correlations	O
across	O
the	O
brain	O
regions	O
were	O
observed	O
in	O
control	O
subjects	O
than	O
in	O
patients	O
with	O
schizophrenia	O
.	O

Notably	O
,	O
the	O
patients	O
and	O
control	O
subjects	O
showed	O
statistically	O
significant	O
differences	O
in	O
correlations	O
between	O
the	O
SERT	O
availability	O
in	O
the	O
parietal	O
and	O
temporal	O
cortices	O
and	O
the	O
glucose	O
metabolism	O
in	O
the	O
posterior	O
cingulate	O
cortex	O
.	O

These	O
results	O
suggest	O
abnormal	O
functional	O
connectivity	O
between	O
the	O
higher-order	O
cortical	O
regions	O
in	O
schizophrenia	O
and	O
a	O
possible	O
important	O
role	O
of	O
the	O
posterior	O
cingulate	O
gyrus	O
and	O
its	O
related	O
circuitry	O
in	O
the	O
pathophysiology	O
of	O
schizophrenia	O
.	O

Tips	O
and	O
Pitfalls	O
in	O
Direct	O
Ligation	O
of	O
Large	O
Spontaneous	O
Splenorenal	O
Shunt	O
during	O
Liver	O
Transplantation	O
.	O

Patients	O
with	O
large	O
spontaneous	O
splenorenal	O
shunt	O
(	O
SRS	O
)	O
prove	O
challenging	O
during	O
liver	O
transplantation	O
(	O
LT	O
)	O
,	O
irrespective	O
of	O
organizing	O
portal	O
vein	O
(	O
PV	O
)	O
thrombosis	O
.	O

Here	O
,	O
we	O
detail	O
the	O
clinical	O
outcomes	O
of	O
26	O
patients	O
who	O
underwent	O
direct	O
ligation	O
of	O
large	O
SRS	O
during	O
LT	O
.	O

Direct	O
ligation	O
of	O
large	O
SRS	O
was	O
applied	O
in	O
poor	O
portal	O
flow	O
during	O
LT.	O
We	O
performed	O
temporary	O
test	O
clamping	O
of	O
the	O
SRS	O
before	O
direct	O
ligation	O
and	O
applied	O
PV	O
pressure	O
monitoring	O
in	O
patients	O
who	O
showed	O
signs	O
of	O
portal	O
hypertension	O
,	O
such	O
as	O
bowel	O
edema	O
.	O

We	O
retrospectively	O
reviewed	O
and	O
evaluated	O
their	O
clinical	O
outcomes	O
.	O

Among	O
843	O
patients	O
who	O
underwent	O
LT	O
between	O
2010	O
and	O
2015	O
,	O
26	O
(	O
3.9	O
%	O
)	O
underwent	O
direct	O
ligation	O
of	O
SRS	O
without	O
any	O
intraoperative	O
event	O
.	O

Mean	O
preoperative	O
MELD	O
score	O
was	O
16.7±9.0	O
.	O

The	O
main	O
PV	O
diameter	O
on	O
preoperative	O
computed	B-P
tomography	I-P
was	O
8.3±3.4	O
mm	O
(	O
range	O
,	O
3.0-14.0	O
mm	O
)	O
.	O

SRS	O
was	O
easily	O
identified	O
at	O
just	O
below	O
the	O
distal	O
pancreas	O
and	O
beside	O
the	O
inferior	O
mesenteric	O
vein	O
in	O
all	O
patients	O
.	O

Accompanying	O
PV	O
thrombectomy	O
was	O
done	O
in	O
42.3	O
%	O
of	O
patients	O
.	O

Among	O
26	O
patients	O
,	O
massive	O
and	O
prolonged	O
ascites	O
was	O
evident	O
in	O
15.4	O
%	O
(	O
n	O
=	O
4	O
)	O
postoperatively	O
.	O

They	O
were	O
all	O
living	O
donor	O
LT	O
recipients	O
with	O
a	O
small	O
PV	O
diameter	O
(	O
4.0-6.7	O
mm	O
)	O
.	O

Except	O
for	O
one	O
patient	O
who	O
underwent	O
splenic	O
artery	O
embolization	O
,	O
ascites	O
was	O
tolerable	O
and	O
well	O
controlled	O
by	O
conservative	O
management	O
.	O

There	O
was	O
a	O
7.7	O
%	O
rate	O
of	O
major	O
complications	O
related	O
to	O
direct	O
ligation	O
,	O
including	O
reoperation	O
due	O
to	O
combined	O
ligation	O
of	O
SRS	O
along	O
with	O
a	O
left	O
renal	O
vein	O
at	O
the	O
confluence	O
.	O

Except	O
for	O
one	O
hospital	O
mortality	O
due	O
to	O
sepsis	O
,	O
25	O
patients	O
(	O
96.2	O
%	O
)	O
are	O
alive	O
with	O
no	O
evidence	O
of	O
further	O
PV	O
complications	O
.	O

In	O
conclusion	O
,	O
direct	O
ligation	O
of	O
large	O
SRS	O
during	O
LT	O
is	O
a	O
safe	O
and	O
feasible	O
method	O
to	O
overcome	O
the	O
effects	O
of	O
a	O
large	O
SRS	O
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

Assessment	O
of	O
Residual	O
Disease	O
With	O
Molecular	B-P
Breast	I-P
Imaging	I-P
in	O
Patients	O
Undergoing	O
Neoadjuvant	O
Therapy	O
:	O
Association	O
With	O
Molecular	O
Subtypes	O
.	O

Assessment	O
of	O
residual	O
disease	O
after	O
neoadjuvant	O
therapy	O
for	O
breast	O
cancer	O
is	O
an	O
ongoing	O
challenge	O
of	O
breast	O
imaging	B-P
.	O

This	O
study	O
evaluates	O
the	O
accuracy	O
of	O
a	O
novel	O
dedicated	O
system	O
for	O
molecular	B-P
breast	I-P
imaging	I-P
(	O
MBI	B-P
)	O
composed	O
of	O
the	O
new	O
generation	O
of	O
cadmium	O
zinc	O
telluride	O
detectors	O
in	O
assessing	O
residual	O
disease	O
after	O
neoadjuvant	O
therapy	O
in	O
patients	O
with	O
breast	O
cancer	O
.	O

Clinical	O
data	O
,	O
imaging	B-P
,	O
surgical	O
,	O
and	O
pathological	O
findings	O
of	O
51	O
women	O
with	O
breast	O
cancer	O
undergoing	O
neoadjuvant	O
therapy	O
were	O
recorded	O
.	O

MBI	B-P
findings	O
were	O
correlated	O
with	O
surgical	O
pathology	O
results	O
.	O

Accuracy	O
of	O
MBI	B-P
in	O
predicting	O
complete	O
pathological	O
response	O
and	O
size	O
of	O
residual	O
disease	O
was	O
assessed	O
according	O
to	O
molecular	O
subtypes	O
.	O

The	O
size	O
of	O
the	O
largest	O
focus	O
of	O
uptake	O
on	O
MBI	B-P
correlated	O
with	O
the	O
largest	O
dimension	O
measured	O
on	O
pathology	O
(	O
r	O
=	O
0.55	O
;	O
P	O
<	O
.001	O
)	O
.	O

This	O
correlation	O
was	O
stronger	O
for	O
triple	O
negative	O
and	O
HER2/neu	O
positive	O
subtypes	O
(	O
r	O
=	O
0.92	O
and	O
0.62	O
,	O
respectively	O
)	O
.	O

Sixteen	O
patients	O
(	O
31	O
%	O
)	O
had	O
complete	O
pathological	O
response	O
.	O

The	O
sensitivity	O
and	O
specificity	O
of	O
MBI	B-P
for	O
detecting	O
residual	O
disease	O
were	O
83	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
66-93	O
)	O
and	O
69	O
%	O
(	O
95	O
%	O
CI	O
,	O
42-88	O
)	O
,	O
respectively	O
.	O

For	O
triple	O
negative	O
or	O
HER2/neu	O
positive	O
disease	O
the	O
sensitivity	O
and	O
specificity	O
were	O
88	O
%	O
(	O
95	O
%	O
CI	O
,	O
62-98	O
)	O
and	O
75	O
%	O
(	O
95	O
%	O
CI	O
,	O
43-93	O
)	O
,	O
respectively	O
.	O

The	O
accuracy	O
of	O
MBI	B-P
in	O
assessing	O
residual	O
disease	O
after	O
neoadjuvant	O
treatment	O
might	O
be	O
related	O
to	O
the	O
molecular	O
subtype	O
.	O

Accuracy	O
is	O
highest	O
in	O
the	O
triple	O
negative	O
and	O
HER2/neu	O
positive	O
subtypes	O
.	O

Pyoderma	O
gangrenosum	O
:	O
A	O
clinician	O
's	O
nightmare	O
.	O

Pyoderma	O
gangrenosum	O
(	O
PG	O
)	O
is	O
a	O
rare	O
disease	O
and	O
that	O
affecting	O
specifically	O
the	O
sole	O
of	O
the	O
foot	O
,	O
is	O
even	O
rarer	O
.	O

Here	O
,	O
we	O
report	O
the	O
case	O
of	O
a	O
54-year-	O
old	O
female	O
admitted	O
with	O
a	O
painful	O
ulcer	O
on	O
the	O
sole	O
of	O
the	O
right	O
foot	O
which	O
was	O
initially	O
treated	O
with	O
empirical	O
antibiotics	O
and	O
debridement	O
.	O

The	O
disease	O
was	O
found	O
to	O
spread	O
rapidly	O
after	O
each	O
debridement	O
.	O

The	O
culture	O
reports	O
were	O
negative	O
;	O
rheumatology	O
workup	B-P
and	O
Doppler	B-P
study	I-P
were	O
within	O
normal	O
limits	O
.	O

A	O
clinical	O
suspicion	O
of	O
PG	O
was	O
made	O
and	O
was	O
confirmed	O
with	O
tissue	B-P
biopsy	I-P
.	O

She	O
was	O
started	O
on	O
oral	O
steroids	O
following	O
which	O
she	O
dramatically	O
improved	O
.	O

Thus	O
,	O
when	O
a	O
patient	O
presents	O
with	O
a	O
rapidly	O
expanding	O
painful	O
ulcer	O
in	O
a	O
vascular	O
limb	O
that	O
is	O
refractory	O
to	O
antibiotic	O
treatment	O
and	O
exacerbating	O
on	O
debridement	O
,	O
it	O
is	O
imperative	O
to	O
consider	O
the	O
possibility	O
of	O
PG	O
.	O

Simvastatin	O
enhances	O
the	O
hippocampal	O
klotho	O
in	O
a	O
rat	O
model	O
of	O
streptozotocin	O
-	O
induced	O
cognitive	O
decline	O
.	O

Brain	O
oxidative	O
status	O
is	O
a	O
crucial	O
factor	O
in	O
the	O
development	O
of	O
sporadic	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
.	O

Klotho	O
,	O
an	O
anti-aging	O
protein	O
,	O
diminishes	O
oxidative	O
stress	O
by	O
the	O
induction	O
of	O
manganese	O
superoxide	O
dismutase	O
(	O
MnSOD	O
)	O
.	O

Thus	O
,	O
the	O
substances	O
that	O
increase	O
klotho	O
expression	O
could	O
be	O
considered	O
as	O
a	O
potential	O
treatment	O
for	O
Alzheimer	O
's	O
disease	O
when	O
the	O
oxidative	O
imbalance	O
is	O
present	O
.	O

Statins	O
are	O
suggested	O
to	O
up-regulate	O
klotho	O
expression	O
.	O

We	O
examined	O
the	O
effect	O
of	O
simvastatin	O
(	O
5mg/kg	O
,	O
daily	O
for	O
3	O
weeks	O
)	O
on	O
hippocampal	O
klotho	O
and	O
MnSOD	O
expression	O
in	O
the	O
cognitive	O
declined	O
animal	O
model	O
induced	O
by	O
intracerebroventricular	O
(	O
ICV	O
)	O
-	O
streptozotocin	O
(	O
STZ	O
)	O
administration	O
.	O

Cognitive	B-P
assessment	I-P
was	O
performed	O
by	O
the	O
Morris	O
Water	O
Maze	O
(	O
MWM	O
)	O
test	O
.	O

The	O
results	O
indicated	O
that	O
mean	O
escape	O
latency	O
and	O
distance	O
were	O
prolonged	O
in	O
the	O
ICV	O
-	O
STZ	O
group	O
compared	O
with	O
the	O
control	O
group	O
.	O

The	O
expression	O
of	O
klotho	O
and	O
MnSOD	O
were	O
also	O
down	O
regulated	O
in	O
the	O
hippocampus	O
.	O

Furthermore	O
,	O
improved	O
spatial	O
performance	O
was	O
observed	O
in	O
simvastatin	O
-	O
treated	O
animals	O
.	O

This	O
effect	O
could	O
be	O
related	O
to	O
increase	O
in	O
oxidative	O
stress	O
tolerance	O
as	O
evidenced	O
by	O
klotho	O
and	O
MnSOD	O
up-regulation	O
.	O

Our	O
current	O
study	O
indicates	O
that	O
klotho	O
upregulation	O
may	O
be	O
a	O
neuroprotective	O
mechanism	O
of	O
simvastatin	O
against	O
cognitive	O
decline	O
in	O
AD	O
.	O

Folate	O
-based	O
single	O
cell	O
screening	O
using	O
surface	O
enhanced	O
Raman	O
microimaging	O
.	O

Recent	O
progress	O
in	O
nanotechnology	O
and	O
its	O
application	O
to	O
biomedical	O
settings	O
have	O
generated	O
great	O
advantages	O
in	O
dealing	O
with	O
early	B-P
cancer	I-P
diagnosis	I-P
.	O

The	O
identification	O
of	O
the	O
specific	O
properties	O
of	O
cancer	O
cells	O
,	O
such	O
as	O
the	O
expression	O
of	O
particular	O
plasma	O
membrane	O
molecular	O
receptors	O
,	O
has	O
become	O
crucial	O
in	O
revealing	O
the	O
presence	O
and	O
in	O
assessing	O
the	O
stage	O
of	O
development	O
of	O
the	O
disease	O
.	O

Here	O
we	O
report	O
a	O
single	O
cell	O
screening	O
approach	O
based	O
on	O
Surface	O
Enhanced	O
Raman	O
Scattering	O
(	O
SERS	O
)	O
microimaging	O
.	O

We	O
fabricated	O
a	O
SERS-labelled	O
nanovector	O
based	O
on	O
the	O
biofunctionalization	O
of	O
gold	O
nanoparticles	O
with	O
folic	O
acid	O
.	O

After	O
treating	O
the	O
cells	O
with	O
the	O
nanovector	O
,	O
we	O
were	O
able	O
to	O
distinguish	O
three	O
different	O
cell	O
populations	O
from	O
different	O
cell	O
lines	O
(	O
cancer	O
HeLa	O
and	O
PC-3	O
,	O
and	O
normal	O
HaCaT	O
lines	O
)	O
,	O
suitably	O
chosen	O
for	O
their	O
different	O
expressions	O
of	O
folate	O
binding	O
proteins	O
.	O

The	O
nanovector	O
,	O
indeed	O
,	O
binds	O
much	O
more	O
efficiently	O
on	O
cancer	O
cell	O
lines	O
than	O
on	O
normal	O
ones	O
,	O
resulting	O
in	O
a	O
higher	O
SERS	O
signal	O
measured	O
on	O
cancer	O
cells	O
.	O

These	O
results	O
pave	O
the	O
way	O
for	O
applications	O
in	O
single	O
cell	O
diagnostics	O
and	O
,	O
potentially	O
,	O
in	O
theranostics	O
.	O

Covalent	O
Modulators	O
of	O
the	O
Vacuolar	O
ATPase	O
.	O

The	O
vacuolar	O
H	O
(	O
+	O
)	O
ATPase	O
(	O
V-ATPase	O
)	O
is	O
a	O
complex	O
multisubunit	O
machine	O
that	O
regulates	O
important	O
cellular	O
processes	O
through	O
controlling	O
acidity	O
of	O
intracellular	O
compartments	O
in	O
eukaryotes	O
.	O

Existing	O
small-molecule	O
modulators	O
of	O
V-ATPase	O
either	O
are	O
restricted	O
to	O
targeting	O
one	O
membranous	O
subunit	O
of	O
V-ATPase	O
or	O
have	O
poorly	O
understood	O
mechanisms	O
of	O
action	O
.	O

Small	O
molecules	O
with	O
novel	O
and	O
defined	O
mechanisms	O
of	O
inhibition	O
are	O
thus	O
needed	O
to	O
functionally	O
characterize	O
V-ATPase	O
and	O
to	O
fully	O
evaluate	O
the	O
therapeutic	O
relevance	O
of	O
V-ATPase	O
in	O
human	O
diseases	O
.	O

We	O
have	O
discovered	O
electrophilic	O
quinazolines	O
that	O
covalently	O
modify	O
a	O
soluble	O
catalytic	O
subunit	O
of	O
V-ATPase	O
with	O
high	O
potency	O
and	O
exquisite	O
proteomic	O
selectivity	O
as	O
revealed	O
by	O
fluorescence	B-P
imaging	I-P
and	O
chemical	O
proteomic	O
activity-based	O
profiling	O
.	O

The	O
site	O
of	O
covalent	O
modification	O
was	O
mapped	O
to	O
a	O
cysteine	O
residue	O
located	O
in	O
a	O
region	O
of	O
V-ATPase	O
subunit	O
A	O
that	O
is	O
thought	O
to	O
regulate	O
the	O
dissociation	O
of	O
V-ATPase	O
.	O

We	O
further	O
demonstrate	O
that	O
a	O
previously	O
reported	O
V-ATPase	O
inhibitor	O
,	O
3-bromopyruvate	O
,	O
also	O
targets	O
the	O
same	O
cysteine	O
residue	O
and	O
that	O
our	O
electrophilic	O
quinazolines	O
modulate	O
the	O
function	O
of	O
V-ATPase	O
in	O
cells	O
.	O

With	O
their	O
well-defined	O
mechanism	O
of	O
action	O
and	O
high	O
proteomic	O
specificity	O
,	O
the	O
described	O
quinazolines	O
offer	O
a	O
powerful	O
set	O
of	O
chemical	O
probes	O
to	O
investigate	O
the	O
physiological	O
and	O
pathological	O
roles	O
of	O
V-ATPase	O
.	O

The	O
effect	O
of	O
total	O
hip	O
arthroplasty	O
on	O
sagittal	O
spinal	O
-	O
pelvic-leg	O
alignment	O
and	O
low	O
back	O
pain	O
in	O
patients	O
with	O
severe	O
hip	O
osteoarthritis	O
.	O

Sagittal	O
spinopelvic	O
malalignment	O
has	O
been	O
reported	O
in	O
spinal	O
disorders	O
such	O
as	O
low	O
back	O
pain	O
(	O
LBP	O
)	O
,	O
and	O
restoration	O
of	O
normal	O
alignment	O
is	O
targeted	O
when	O
treating	O
these	O
disorders	O
.	O

Abnormal	O
sagittal	O
spinal	O
-	O
pelvic-leg	O
alignment	O
has	O
been	O
reported	O
in	O
patients	O
with	O
severe	O
hip	O
osteoarthritis	O
(	O
OA	O
)	O
,	O
who	O
have	O
a	O
high	O
prevalence	O
of	O
associated	O
LBP	O
.	O

This	O
prospective	O
longitudinal	O
study	O
aimed	O
to	O
investigate	O
changes	O
in	O
sagittal	O
spinal	O
-	O
pelvic-leg	O
alignment	O
after	O
total	O
hip	O
arthroplasty	O
(	O
THA	O
)	O
in	O
patients	O
with	O
severe	O
hip	O
OA	O
,	O
and	O
whether	O
these	O
changes	O
contribute	O
to	O
LBP	O
relief	O
.	O

Patients	O
undergoing	O
primary	O
THA	O
due	O
to	O
severe	O
unilateral	O
hip	O
OA	O
were	O
recruited	O
.	O

Physical	O
examination	O
and	O
X-ray	O
films	O
were	O
taken	O
to	O
rule	O
out	O
any	O
spinal	O
disorder	O
.	O

Sagittal	O
alignment	O
of	O
pelvis	O
,	O
hip	O
,	O
and	O
spine	O
was	O
analyzed	O
on	O
lateral	B-P
radiographs	I-P
taken	O
before	O
(	O
baseline	O
)	O
and	O
1	O
year	O
after	O
(	O
follow-up	O
)	O
THA	O
.	O

Functional	O
instruments	O
were	O
completed	O
by	O
patients	O
including	O
:	O
visual	B-P
analog	I-P
scale	I-P
(	O
VAS	B-P
)	O
for	O
LBP	O
,	O
Roland-Morris	O
Disability	O
Questionnaire	O
(	O
RMDQ	O
)	O
,	O
and	O
Harris	O
Hip	O
Score	O
(	O
HHS	O
)	O
.	O

Comparisons	O
were	O
carried	O
out	O
at	O
baseline	O
and	O
follow-up	O
,	O
and	O
between	O
patients	O
with	O
and	O
without	O
LBP	O
.	O

The	O
recruited	O
69	O
patients	O
showed	O
significantly	O
reduced	O
hip	O
flexion	O
and	O
improved	O
global	O
spinal	O
balance	O
at	O
follow-up	O
compared	O
with	O
baseline	O
.	O

LBP	O
was	O
reported	O
by	O
39	O
patients	O
(	O
56.5	O
%	O
)	O
before	O
surgery	O
;	O
at	O
follow-up	O
,	O
17	O
reported	O
complete	O
resolution	O
,	O
while	O
22	O
reported	O
significant	O
relief	O
.	O

Significant	O
decreases	O
in	O
VAS	O
and	O
RMDQ	O
scores	O
in	O
lumbar	O
spine	O
and	O
increase	O
in	O
hip	O
HHS	O
were	O
observed	O
.	O

THA	O
in	O
patients	O
with	O
severe	O
hip	O
OA	O
could	O
help	O
correct	O
abnormal	O
sagittal	O
spinal	O
-	O
pelvic-leg	O
alignment	O
and	O
relieve	O
comorbid	O
LBP	O
.	O

Improvements	O
in	O
hip	O
flexion	O
and	O
global	O
spinal	O
balance	O
might	O
be	O
involved	O
in	O
the	O
mechanism	O
of	O
LBP	O
relief	O
.	O

Bi-layered	O
constructs	O
of	O
poly	O
(	O
glycerol-sebacate	O
)	O
-	O
β-tricalcium	O
phosphate	O
for	O
bone-soft	O
tissue	O
interface	O
applications	O
.	O

This	O
study	O
aims	O
to	O
establish	O
a	O
facile	O
protocol	O
for	O
the	O
preparation	O
of	O
a	O
bi-layered	O
poly	O
(	O
glycerol-sebacate	O
)	O
(	O
PGS	O
)	O
/	O
β-tricalcium	O
phosphate	O
(	O
β-TCP	O
)	O
construct	O
and	O
to	O
investigate	O
its	O
potential	O
for	O
bone-soft	O
tissue	O
engineering	O
applications	O
.	O

The	O
layered	O
structure	O
was	O
prepared	O
by	O
distributing	O
the	O
ceramic	O
particles	O
within	O
a	O
prepolymer	O
synthesized	O
in	O
a	O
microwave	O
reactor	O
followed	O
by	O
a	O
cross-linking	O
of	O
the	O
final	O
construct	O
in	O
vacuum	O
(	O
<	O
10mbar	O
)	O
.	O

The	O
vacuum	O
stage	O
led	O
to	O
the	O
separation	O
of	O
cross-linked	O
elastomer	O
(	O
top	O
)	O
and	O
ceramic	O
(	O
bottom	O
)	O
phases	O
.	O

Results	O
showed	O
that	O
addition	O
of	O
β-TCP	O
particles	O
to	O
the	O
elastomer	O
matrix	O
after	O
the	O
polymerization	O
led	O
to	O
an	O
increase	O
in	O
compression	O
strength	O
(	O
up	O
to	O
14±2.3MPa	O
)	O
.	O

Tensile	O
strength	O
(	O
σ	O
)	O
,	O
Young	O
's	O
modulus	O
(	O
E	O
)	O
,	O
and	O
elongation	O
at	O
break	O
(	O
%	O
)	O
values	O
were	O
calculated	O
as	O
0.29±0.03MPa	O
and	O
0.21±0.03	O
;	O
0.38±0.02	O
and	O
1.95±0.4	O
;	O
and	O
240±50	O
%	O
and	O
24±2	O
%	O
for	O
PGS	O
and	O
PGS	O
/	O
β-TCP	O
bi-layered	O
constructs	O
,	O
respectively	O
.	O

Morphology	O
was	O
characterized	O
by	O
using	O
Scanning	O
Electron	O
Microscopy	O
(	O
SEM	O
)	O
and	O
micro-computed	B-P
tomography	I-P
(	O
μ-CT	B-P
)	O
.	O

Tomography	B-P
data	O
revealed	O
an	O
open	O
porosity	O
of	O
35	O
%	O
for	O
the	O
construct	O
,	O
mostly	O
contributed	O
from	O
the	O
ceramic	O
phase	O
since	O
the	O
elastomer	O
side	O
has	O
no	O
pore	O
.	O

Homogeneous	O
β-TCP	O
distribution	O
within	O
the	O
elastomeric	O
structure	O
was	O
observed	O
.	O

Cell	O
culture	O
studies	O
confirmed	O
biocompatibility	O
with	O
poor	O
elastomer	O
-	O
side	O
and	O
good	O
bone	O
-	O
side	O
cell	O
attachment	O
.	O

In	O
a	O
further	O
study	O
to	O
investigate	O
the	O
osteogenic	O
properties	O
,	O
the	O
construct	O
were	O
loaded	O
with	O
BMP-2	O
and/or	O
TGF-β1	O
.	O

The	O
PGS	O
/	O
β-TCP	O
bi-layered	O
constructs	O
with	O
improved	O
mechanical	O
and	O
biological	O
properties	O
have	O
the	O
potential	O
to	O
be	O
used	O
in	O
bone-soft	O
tissue	O
interface	O
applications	O
where	O
soft	O
tissue	O
penetration	O
is	O
a	O
problem	O
.	O

Multiparametric	O
estimation	O
of	O
brain	O
hemodynamics	O
with	O
MR	B-P
fingerprinting	I-P
ASL	I-P
.	O

Assessment	O
of	O
brain	O
hemodynamics	O
without	O
exogenous	O
contrast	O
agents	O
is	O
of	O
increasing	O
importance	O
in	O
clinical	O
applications	O
.	O

This	O
study	O
aims	O
to	O
develop	O
an	O
MR	B-P
perfusion	I-P
technique	I-P
that	O
can	O
provide	O
noncontrast	O
and	O
multiparametric	O
estimation	O
of	O
hemodynamic	O
markers	O
.	O

We	O
devised	O
an	O
arterial	B-P
spin	I-P
labeling	I-P
(	O
ASL	B-P
)	O
method	O
based	O
on	O
the	O
principle	O
of	O
MR	B-P
fingerprinting	I-P
(	O
MRF	B-P
)	O
,	O
referred	O
to	O
as	O
MRF-ASL	B-P
.	O

By	O
taking	O
advantage	O
of	O
the	O
rich	O
information	O
contained	O
in	O
MRF	B-P
sequence	I-P
,	O
up	O
to	O
seven	O
hemodynamic	O
parameters	O
can	O
be	O
estimated	O
concomitantly	O
.	O

Feasibility	O
demonstration	O
,	O
flip	O
angle	O
optimization	O
,	O
comparison	O
with	O
Look-Locker	B-P
ASL	I-P
,	O
reproducibility	O
test	O
,	O
sensitivity	O
to	O
hypercapnia	O
challenge	O
,	O
and	O
initial	O
clinical	O
application	O
in	O
an	O
intracranial	O
steno-occlusive	O
process	O
,	O
Moyamoya	O
disease	O
,	O
were	O
performed	O
to	O
evaluate	O
this	O
technique	O
.	O

Magnetic	B-P
resonance	I-P
fingerprinting	I-P
ASL	I-P
provided	O
estimation	O
of	O
up	O
to	O
seven	O
parameters	O
,	O
including	O
B1+	O
,	O
tissue	O
T1	O
,	O
cerebral	O
blood	O
flow	O
(	O
CBF	O
)	O
,	O
tissue	O
bolus	O
arrival	O
time	O
(	O
BAT	O
)	O
,	O
pass-through	O
arterial	O
BAT	O
,	O
pass-through	O
blood	O
volume	O
,	O
and	O
pass-through	O
blood	B-P
travel	I-P
time	I-P
.	O

Coefficients	O
of	O
variation	O
of	O
the	O
estimated	O
parameters	O
ranged	O
from	O
0.2	O
to	O
9.6	O
%	O
.	O

Hypercapnia	O
resulted	O
in	O
an	O
increase	O
in	O
CBF	O
by	O
57.7	O
%	O
,	O
and	O
a	O
decrease	O
in	O
BAT	O
by	O
13.7	O
and	O
24.8	O
%	O
in	O
tissue	O
and	O
vessels	O
,	O
respectively	O
.	O

Patients	O
with	O
Moyamoya	O
disease	O
showed	O
diminished	O
CBF	O
and	O
lengthened	O
BAT	O
that	O
could	O
not	O
be	O
detected	O
with	O
regular	O
ASL	B-P
.	O

Magnetic	B-P
resonance	I-P
fingerprinting	I-P
ASL	I-P
is	O
a	O
promising	O
technique	O
for	O
noncontrast	O
,	O
multiparametric	O
perfusion	O
assessment	O
.	O

Magn	O
Reson	O
Med	O
,	O
2016	O
.	O

©	O
2016	O
International	O
Society	O
for	O
Magnetic	O
Resonance	O
in	O
Medicine	O
.	O

Reduced	O
haemodynamic	O
coupling	O
and	O
exercise	O
are	O
associated	O
with	O
vascular	O
stiffening	O
in	O
pulmonary	O
arterial	O
hypertension	O
.	O

Inadequate	O
right	O
ventricular	O
(	O
RV	O
)	O
and	O
pulmonary	O
arterial	O
(	O
PA	O
)	O
functional	O
responses	O
to	O
exercise	O
are	O
important	O
yet	O
poorly	O
understood	O
features	O
of	O
pulmonary	O
arterial	O
hypertension	O
(	O
PAH	O
)	O
.	O

This	O
study	O
combined	O
invasive	O
catheterisation	O
with	O
echocardiography	B-P
to	O
assess	O
RV	O
afterload	O
,	O
RV	O
function	O
and	O
ventricular	O
-	O
vascular	O
coupling	O
in	O
subjects	O
with	O
PAH	O
.	O

Twenty-six	O
subjects	O
with	O
PAH	O
were	O
prospectively	O
recruited	O
to	O
undergo	O
right	O
heart	O
catheterisation	O
and	O
Doppler	B-P
echocardiography	I-P
at	O
rest	O
and	O
during	O
incremental	O
exercise	O
,	O
and	O
cardiac	B-P
MRI	I-P
at	O
rest	O
.	O

Measurements	O
at	O
rest	O
included	O
basic	O
haemodynamics	O
,	O
RV	O
function	O
and	O
coupling	O
efficiency	O
(	O
η	O
)	O
.	O

Measurements	O
during	O
incremental	O
exercise	O
included	O
pulmonary	O
vascular	O
resistance	O
(	O
Z0	O
)	O
,	O
characteristic	B-P
impedance	I-P
(	O
ZC	B-P
,	O
a	O
measure	O
of	O
proximal	O
PA	O
stiffness	O
)	O
and	O
proximal	O
and	O
distal	O
PA	O
compliance	O
(	O
CPA	O
)	O
.	O

In	O
patients	O
with	O
PAH	O
,	O
the	O
proximal	O
PAs	O
were	O
significantly	O
stiffer	O
at	O
maximum	O
exercise	O
(	O
ZC	B-P
=2.31±0.38	O
vs	O
1.33±0.15	O
WU×m	O
(	O
2	O
)	O
at	O
rest	O
;	O
p=0.003	O
)	O
and	O
PA	O
compliance	O
was	O
decreased	O
(	O
CPA	O
=0.88±0.10	O
vs	O
1.32±0.17	O
mL/mm	O
Hg/m	O
(	O
2	O
)	O
at	O
rest	O
;	O
p=0.0002	O
)	O
.	O

Z0	O
did	O
not	O
change	O
with	O
exercise	O
.	O

As	O
a	O
result	O
,	O
the	O
resistance-compliance	O
(	O
RC	O
)	O
time	O
decreased	O
with	O
exercise	O
(	O
0.67±0.05	O
vs	O
1.00±0.07	O
s	O
at	O
rest	O
;	O
p	O
<	O
10	O
(	O
-6	O
)	O
)	O
.	O

When	O
patients	O
were	O
grouped	O
according	O
to	O
resting	O
coupling	O
efficiency	O
,	O
those	O
with	O
poorer	O
η	O
exhibited	O
stiffer	O
proximal	O
PAs	O
at	O
rest	O
,	O
a	O
lower	O
maximum	O
exercise	O
level	O
,	O
and	O
more	O
limited	O
CPA	O
reduction	O
at	O
maximum	O
exercise	O
.	O

In	O
PAH	O
,	O
exercise	O
causes	O
proximal	O
and	O
distal	O
PA	O
stiffening	O
,	O
which	O
combined	O
with	O
preserved	O
Z0	O
results	O
in	O
decreased	O
RC	O
time	O
with	O
exercise	O
.	O

Stiff	O
PAs	O
at	O
rest	O
may	O
also	O
contribute	O
to	O
poor	O
haemodynamic	O
coupling	O
,	O
reflecting	O
reduced	O
pulmonary	O
vascular	O
reserve	O
that	O
contributes	O
to	O
limit	O
the	O
maximum	O
exercise	O
level	O
tolerated	O
.	O

Evaluation	O
of	O
changes	O
in	O
anthropometric	O
indexes	O
due	O
to	O
intermaxillary	O
fixation	O
following	O
facial	O
fractures	O
.	O

Background	O
.	O

One	O
of	O
the	O
treatment	O
modalities	O
for	O
facial	O
fractures	O
is	O
closed	O
reduction	O
technique	O
,	O
but	O
treatment	O
with	O
intermaxillary	O
fixation	O
(	O
IMF	O
)	O
interferes	O
with	O
normal	O
nutrition	O
,	O
and	O
malnutrition	O
can	O
affect	O
the	O
patient	O
's	O
recovery	O
.	O

Anthropometric	O
measurements	O
such	O
as	O
skinfold	B-P
thickness	I-P
and	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
are	O
universal	O
indexes	O
for	O
diagnosing	O
malnutrition	O
.	O

Therefore	O
,	O
in	O
this	O
study	O
we	O
explain	O
how	O
treatment	O
with	O
IMF	O
changes	O
the	O
anthropometric	O
indexes	O
.	O

Methods	O
.	O

In	O
this	O
study	O
60	O
patients	O
were	O
treated	O
with	O
4	O
weeks	O
of	O
IMF	O
.	O

Skinfold	B-P
thickness	I-P
and	O
BMI	O
of	O
these	O
patients	O
were	O
measured	O
and	O
compared	O
before	O
and	O
after	O
the	O
treatment	O
.	O

Results	O
.	O

Patients	O
'	O
weight	O
,	O
BMI	O
and	O
skinfold	B-P
thickness	I-P
decreased	O
during	O
the	O
IMF	O
period	O
,	O
and	O
this	O
decrease	O
was	O
statistically	O
significant	O
(	O
P	O
<	O
0.01	O
)	O
.	O

Conclusion	O
.	O

Although	O
no	O
severe	O
and	O
acute	O
malnutrition	O
was	O
seen	O
among	O
our	O
patients	O
,	O
IMF	O
led	O
to	O
mild	O
to	O
moderate	O
malnutrition	O
in	O
some	O
cases	O
,	O
making	O
it	O
necessary	O
to	O
use	O
nutritional	O
supplements	O
.	O

Development	O
of	O
the	O
four-item	O
Letter	O
and	O
Shape	O
Drawing	O
test	O
(	O
LSD-4	O
)	O
:	O
A	O
brief	O
bedside	B-P
test	I-P
of	O
visuospatial	O
function	O
.	O

Conventional	O
bedside	B-P
tests	I-P
of	O
visuospatial	O
function	O
such	O
as	O
the	O
Clock	O
Drawing	O
(	O
CDT	O
)	O
and	O
Intersecting	O
Pentagons	O
(	O
IPT	O
)	O
lack	O
consistency	O
in	O
delivery	O
and	O
interpretation	O
.	O

We	O
compared	O
performance	O
on	O
a	O
novel	O
test	O
of	O
visuospatial	O
ability	O
-	O
the	O
LSD	O
-	O
with	O
the	O
IPT	O
,	O
CDT	O
and	O
MMSE	B-P
in	O
180	O
acute	O
elderly	O
medical	O
inpatients	O
[	O
mean	O
age	O
79.7±7.1	O
(	O
range	O
62-96	O
)	O
;	O
91	O
females	O
(	O
50.6	O
%	O
)	O
]	O
.	O

124	O
(	O
69	O
%	O
)	O
scored	O
≤23	O
on	O
the	O
MMSE	B-P
;	O
60	O
with	O
mild	O
(	O
score	O
18-23	O
)	O
and	O
64	O
with	O
severe	O
(	O
score	O
≤17	O
)	O
impairment	O
.	O

78	O
(	O
43	O
%	O
)	O
scored	O
≥6	O
on	O
the	O
CDT	O
,	O
while	O
for	O
the	O
IPT	O
,	O
87	O
(	O
47	O
%	O
)	O
scored	O
≥4	O
.	O

The	O
CDT	O
and	O
IPT	O
agreed	O
on	O
the	O
classification	O
of	O
138	O
patients	O
(	O
77	O
%	O
)	O
with	O
modest-	O
strong	O
agreement	O
with	O
the	O
MMSE	B-P
categories	O
.	O

Correlation	O
between	O
the	O
LSD	O
and	O
visuospatial	O
tests	O
was	O
high	O
.	O

A	O
four-item	O
version	O
of	O
the	O
LSD	O
incorporating	O
items	O
1,10,12,15	O
had	O
high	O
correlation	O
with	O
the	O
LSD-15	O
and	O
strong	O
association	O
with	O
MMSE	B-P
categories	O
.	O

The	O
LSD-4	O
provides	O
a	O
brief	O
and	O
easily	O
interpreted	O
bedside	B-P
test	I-P
of	O
visuospatial	O
function	O
that	O
has	O
high	O
coverage	O
of	O
elderly	O
patients	O
with	O
neurocognitive	O
impairment	O
,	O
good	O
agreement	O
with	O
conventional	O
tests	O
of	O
visuospatial	O
ability	O
and	O
favourable	O
ability	O
to	O
identify	O
significant	O
cognitive	O
impairment	O
.	O

[	O
181	O
words	O
]	O
.	O

